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Abstract 
Introduction 
Hypoxic Ischaemic Encephalopathy (HIE) is a serious complication in the period surrounding 
birth. HIE occurs in 1 to 5 per 1000 live term births in the developed world and can result in 
death in up to 20% of cases and poor long-term outcomes such as cerebral palsy in 25% of 
surviving infants. HIE occurs due to an insufficient supply of oxygenated blood delivery to 
the brain. This initiates an evolving cascade of biochemical events that leads to brain injury. 
One complication of HIE is blood-brain barrier (BBB) -disruption. The BBB plays a vital 
protective role and is essential for maintaining the delicate balance of the brain’s 
microenvironment required for correct neuronal function.  BBB-disruption may contribute to 
neuropathology via extravasation of neurotoxic blood products and peripheral cells, greater 
neuroinflammation, oedema formation, impaired energy delivery, or exacerbation of seizure. 
BBB-disruption is therefore an important part of HI-injury neuropathology; however, it has 
been insufficiently described in neonatal HIE. In addition, there has not been investigation 
into the association between neonatal seizure and BBB-disruption, despite robust evidence 
in other disease states of a relationship. Finally, there has been insufficient investigation on 
the impact of therapeutic hypothermia (the current standard of care for moderate-severely 
injured neonates with HIE) on BBB permeability in neonates. Therefore, this thesis 
investigated BBB permeability over time, the association between BBB and seizure, and the 
effect of hypothermia on BBB permeability using a clinically-relevant, large animal model of 
neonatal HIE. 
Methods 
A newborn piglet model of hypoxia ischaemia was utilised. Piglets (<24h) were 
anaesthetised, ventilated, catheterised, and HI was induced by reduction of inspired O2 from 
21% (air) to ~4% for 30mins. To evaluate the evolution of BBB-disruption over time animals 
were survived to 2, 4, 8, 12, or 24h post-HI and BBB-disruption was assessed at each of the 
time-points (Chapter 3).  To assess the effects of early BBB-disruption on outcome and an 
association between BBB-disruption and seizures, animals were recovered to a time-point 
that allowed longer term neurobehavioural assessment (72h) following HI and animals with 
and without seizures were compared (Chapter 4). To assess the impact of therapeutic 
hypothermia on BBB-disruption, animals were treated with hypothermia (5°C decrease in 
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core body temperature) for a period of 24h under anaesthesia, followed by 10h of rewarming 
and recovered to 72h post-HI (Chapter 5). BBB-disruption was assessed by evaluating 
differences in BBB permeability primarily to immunoglobulin G (IgG) (Chapters 3, 4, & 5) 
and sodium fluorescein (Chapter 3). In addition, protein and mRNA changes to three tight 
junction proteins (claudin 5, occludin, and zonula occludens 1) were assessed. Changes to 
several inflammatory genes such as tumour necrosis factor alpha, transforming growth 
factor beta, and the interleukins were also evaluated due to their roles in neonatal HIE brain 
injury and BBB-disruption. 
Results 
Results from chapter 3 indicate that permeability of the BBB is increased in the first 24h after 
HI, but to a variable extent. Permeability to IgG increases over time, whereas there was no 
difference in sodium fluorescein extravasation into brain tissue. Tight junctions were altered 
at both the mRNA and protein level, with a particular vulnerability at 8h post-HI. mRNA 
expression of the inflammatory mediators was substantially elevated by HI from very early 
time-points and either sustained or upregulated further at 12 and 24h post-HI. Further 
investigation of BBB-disruption following neonatal HI was performed in Chapter 4 by 
assessing disruption at a later time-point. This allowed investigation into the relationship 
between BBB-disruption and outcome with neurobehavioural testing, histopathology 
scoring, and electroencephalography (EEG) analysis. In-depth analysis of seizure was also 
performed and the relationship between seizure and BBB-disruption was assessed. BBB-
disruption in the form of IgG extravasation was significantly associated with both seizure 
burden and short term outcome. mRNA expression of inflammatory genes was upregulated 
in animals with seizure. In Chapter 5 BBB-disruption was assessed in animals treated with 
by the current standard of care for neonatal HIE – therapeutic hypothermia. Hypothermia in 
this study did not significantly improve either short term outcome, seizure burden, or BBB-
disruption. However, the data did trend towards improvements in seizure burden and BBB-
disruption. In addition, hypothermia appeared to alter pro-inflammatory cytokines in the 
brain, but did not uniformly decrease them. In some instances, hypothermia had the effect 
of increasing pro-inflammatory cytokines – particularly cyclooxygenase 2 and interleukin 1 
beta. 
Conclusions 
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In summary, this thesis has addressed several knowledge gaps regarding the evolution of 
BBB-disruption following neonatal HI, how BBB-disruption is related to seizures in this 
syndrome, and if the current standard of care (hypothermia) is attenuating BBB-disruption 
all in a clinically relevant model of neonatal HIE. Increasing our understanding of the 
pathological processes that occur following neonatal HI is essential in developing new 
treatments to improve the outcomes of our vulnerable newborns. Investigating the BBB is a 
major untapped area of research and a potential avenue for novel treatments. 
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CHAPTER 1 - INTRODUCTION 
The most exciting phrase to hear in science, the one that heralds the most discoveries is 
not “Eureka” but “that’s funny…” – Isaac Asimov. 
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1.1 Hypoxic Ischaemic Encephalopathy  
Hypoxia ischaemia (HI) is a serious birth complication arising from insufficient oxygen and 
blood flow. In severe cases, HI can result in the clinical syndrome: hypoxic ischaemic 
encephalopathy (HIE). The incidence of HIE is 1-5 per 1000 live, term births in the developed 
world, including Australia (Graham et al. 2008, Kurinczuk et al. 2010, Byford et al. 2014). 
While HIE can occur in the pre, peri, or postnatal period, the most common cause of HIE in 
term infants is birth asphyxia. Possible complications that can lead to birth asphyxia include 
cord occlusion, placental abruption, or intra-uterine rupture. Moderate to severe HIE can 
result in death or serious long-term disability (Pierrat et al. 2005, de Vries and Jongmans 
2010); Birth asphyxia accounts for approximately 23% of global neonatal deaths (Lawn et 
al. 2005). Approximately 10% of infants with moderate HIE and up to 60% of infants with 
severe HIE die in the neonatal period (Shankaran et al. 2005). In survivors, poor outcomes 
include cerebral palsy, blindness, deafness, epilepsy, cognitive delays, and behavioural 
difficulties. HIE therefore results in substantial social cost for families, and financial burden 
for healthcare systems worldwide (Eunson 2015). 
1.1.1 BRAIN REGIONS DAMAGED FOLLOWING NEONATAL HIE 
Neonatal HI injury does not affect the brain uniformly. The type of brain injury that occurs 
following HIE is dependent on the developmental stage of the neonate (term or preterm) 
and the severity and duration of the HI event. Two major forms of brain injury occur in 
neonates following HI – brain injury with deep grey matter involvement that can extend to 
the cortical regions when severe, or damage to watershed areas with white matter 
involvement that can extend to cortical regions when severe (Barkovich et al. 1995, Miller et 
al. 2005, Volpe 2018). 
In term infants, abrupt total or near total asphyxia results most commonly in a severe form 
of HI brain injury and primarily affects deep grey matter structures – such as the basal 
ganglia, thalamus, or brain stem (Barkovich et al. 1995). In severe acute events, damage 
also occurs in the cortical regions, hippocampus, and white matter (Okereafor et al. 2008). 
Neonates with deep grey matter injury often develop more severe long term cognitive and 
motor deficits than neonates with other forms of HI-induced brain injury (Miller et al. 2005, 
Okereafor et al. 2008).  
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Milder, but prolonged periods of asphyxia cause brain injury in white matter and outer 
cortical areas (Barkovich et al. 1995, Miller et al. 2005). Compensatory mechanisms during 
prolonged oxygen deprivation cause shunting of blood flow toward deep grey matter 
structures and away from white matter and outer cortices. Injury is therefore most commonly 
found in watershed, or parasagittal areas that have poorer arterial blood supply (Chau et al. 
2009, de Vries and Groenendaal 2010). Brain injury in these regions often results in 
cognitive delay in survivors without motor disability, although motor disorders can occur 
(Miller et al. 2005). Watershed-type brain injury is also associated with poorer verbal skills 
in later life (Steinman et al. 2009). 
Animal models of HI can vary substantially in the degree and duration of insult, but patterns 
of brain injury generally correspond with the human observations. Most of the studies using 
animal models of neonatal HIE are in rodents. The Rice-Vannucci method is the most 
commonly utilised model of neonatal HIE in rodents. The original Rice-Vannucci method 
involved unilateral ligation of the common carotid artery in P7 (postnatal day 7) rats, followed 
by reduced inspired oxygen to 8% for 3.5h (Rice et al. 1981). This method results in variable 
cerebral infarct (~56% of animals) with cortical, striatum, white matter, and hippocampal 
damage. The Rice-Vannucci method is advantageous because it is widely utilised and 
therefore well characterised and it allows for use of transgenic models. However, a number 
of limitations in the use of the rodent model of neonatal HI have been raised, including 
differences in the overall structure and complexity of the brain between the rodent and the 
human, as well as differences in the maturation state of the brain at birth (Rumajogee et al. 
2016). Additionally, due arterial occlusion, the Rice-Vannucci method produces regional 
ischaemic damage and better mimics a stroke or global ischaemic event which are rare in 
human newborns: the incidence for perinatal stroke in western countries ranges between 1 
per 2200 to 1 per 7700 live births (Armstrong-Wells et al. 2009, Grunt et al. 2015, Cole et 
al. 2017). 
Large animal models of neonatal HIE have been developed to provide better clinical 
relevance as they more closely mimic the brain structure and characteristics of the human. 
For example, monkeys with severe, near-total asphyxia display extensive cortical and basal 
ganglia damage, with thalamic and brain stem involvement (Myers 1975, McAdams et al. 
2017). Another large animal model of neonatal HIE is the sheep, which undergoes cord 
occlusion in order to mimic a global HI injury (Gunn et al. 1992, Williams et al. 1992). 
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Histopathological injury in sheep is similar to the human – including cortical, thalamic, basal 
ganglia, and white matter lesions (Gunn et al. 1992). However, sheep brain development is 
precocial and therefore are best suited as an in utero model of HIE in order to mimic the 
developmental age of the human brain. Sheep are not commonly recovered to the neonatal 
stage and are thus poorly suited to long term follow-up and neurobehavioural testing. 
Piglets are a particularly useful animal model of neonatal HIE as they have similarities to the 
human newborn – including size, metabolism, brain circulation, and organ and brain 
development timing (Dickerson and Dobbing 1967, Dobbing and Sands 1979, Conrad and 
Johnson 2015). Piglets have an equivalently-timed brain growth spurt to humans at birth 
(Dobbing and Sands 1979, Pond et al. 2000), and are similar to humans in regards to the 
gyrencephalic nature of the brain, grey and white matter distribution, and overall size 
(Conrad and Johnson 2015). As they are a postnatal model, piglets can also be used to 
address neurobehavioural outcome, which is not possible in the fetal sheep model. 
Histological damage in piglets following global hypoxia with ischaemia induced by low blood 
pressure is similar to the human; piglets develop damage to cortex, cerebellum, 
hippocampus, basal ganglia, and thalamus (Foster et al. 2001, Bjorkman et al. 2006, Kyng 
et al. 2015). Additionally, piglets are of a size that is large enough to allow instrumentation 
(electroencephalography (EEG), electrocardiography (ECG), blood pressure, etc.) and allow 
multiple sampling time points, and MRI evaluation of injury. Therefore the piglet model is 
clinically relevant, consistently produces clinically relevant brain injury, and is appropriate in 
terms of brain development (Foster et al. 2001). 
1.1.3 THERAPEUTIC HYPOTHERMIA 
The only routinely utilised treatment for neonates with moderate to severe HIE is therapeutic 
hypothermia (HT). HT is applied as either selective head cooling, or whole body cooling to 
a target temperature of 33.5°C for a period of 72h. There have been a number of trials 
investigating the short and long term outcomes of neonates treated with HT. Major outcomes 
of death and disability at first were not thought to be improved by HT (Gluckman et al. 2005), 
however a number of trials since have demonstrated improved combined death or disability 
outcome (Eicher et al. 2005, Shankaran et al. 2005, Simbruner et al. 2010, Jacobs et al. 
2011, Bharadwaj and Bhat 2012). Improved cognitive scores (Azzopardi et al. 2009), 
psychodevelopmental index (Eicher et al. 2005), sensorineural outcome (Jacobs et al. 
2011), neurobehavioural assessment (Lin et al. 2006, Azzopardi et al. 2009), and fewer 
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clinical seizures (Simbruner et al. 2010) have all been shown after HT between 9 months 
and 2 years post-birth. Due to the evidence that therapeutic HT is safe and effective, this 
treatment has become standard in clinical practice. However, there is still work to be done. 
HT has been shown to be most effective in moderately brain injured neonates, and there is 
still significant risk of death and disability (Gluckman et al. 2015). In order to prevent one 
case of death or major disability in neonates with HIE, 5-10 babies need to be treated with 
HT (Azzopardi et al. 2009, Jacobs et al. 2013). As such, current investigation has focused 
on developing synergistic therapies that will complement the neuroprotective effects of HT. 
To identify potential therapeutics we need to better understand the exact mechanisms of 
brain injury in neonatal HIE, which as yet as incompletely understood. Understanding how 
brain injury is occurring, the interaction of pathological processes, and how these are 
affected by HT could lead to a more targeted approach to developing therapeutics with the 
highest chance of success. 
1.1.3 EVOLUTION OF HYPOXIC ISCHAEMIC INJURY  
One of the defining characteristics of HIE is that brain injury evolves over time. In the hours, 
days, and up to months following the initial HI event, brain injury can worsen and spread. HI 
injury occurs in distinct phases; the primary energy failure phase begins as a result of 
interrupted oxygenated blood flow. This causes a decrease in adenosine triphosphate (ATP) 
and increase in lactic acid due to a switch to anaerobic metabolism (Vannucci and Duffy 
1977, Michiels 2004, Lumb 2017). This energy reduction in turn results in a build-up of 
calcium, sodium, and water which initiates the excitotoxic pathology cascade component of 
HIE (Goldberg and Choi 1993, Rungta et al. 2015). In severe cases, the primary energy 
failure phase can result in necrosis and initiation of apoptotic cascades (Northington et al. 
2011). The primary phase of HI is recognised in the clinic by alterations to fetal heart 
parameters, arterial blood gas parameters (pH < 7.0, or base deficit >12mmol/L), low apgar 
scores, meconium stained fluids, and the need for resuscitation or respiratory support 
(Queensland Clinical Guidelines, 2016). 
The restoration of oxygenated blood to the neonate results in a partial recovery, and the 
start of the latent phase of HI injury between one- and six-hours post-insult. Brain 
metabolites as assessed by magnetic resonance spectroscopy in fetal lambs were found to 
be restored rapidly following the restoration of oxygen (Hope et al. 1987). The more severe 
the initial HI insult was, generally the shorter the latent period and more severe the following 
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secondary energy failure phase (Iwata et al. 2007). Inflammatory processes and oxidative 
metabolism are initiated in the latent phase and apoptotic cascades are worsened (Ivacko 
et al. 1996, Nakajima et al. 2000, Algra et al. 2013). The injury evolves further into a 
secondary energy failure between six and 72h post-HI (Hope et al. 1987, Lorek et al. 1994). 
Excitotoxicity, cytotoxic oedema, mitochondrial failure, and seizures generally occur in this 
period and result in substantial cell death (Vannucci et al. 1993, Lynch et al. 2012). A tertiary 
phase occurs in the following months, and is believed to involve cell remodelling and repair, 
however, injury may continue through processes such as astrocyte and microglial activation, 
and epigenetic dysfunction (Fleiss and Gressens 2012). The key injurious processes that 
occur following HI are shown in Figure 1.1. 
HT is most neuroprotective when begun within 6h of the HI injury – during the latent phase 
of the HI injury cascade. Whilst HT is known to alter multiple disease pathways in HIE, exact 
mechanisms of neuroprotection are still being investigated (Perlman 2006, Drury et al. 
2014). HT reduces cerebral metabolism by 5% per degree of temperature reduction 
(Laptook et al. 1995) which may ameliorate secondary energy failure. However, reduced 
metabolism is not the sole mechanism of HT-induced neuroprotection. HT is thought to 
reduce secondary injury by acting on pathways such as inflammation, excitotoxicity, and 
oxygen metabolism to improve long term developmental outcomes (Ma et al. 2012). HT has 
been shown to reduce the accumulation of excitatory amino acids via a delay in 
depolarisation and rate of release following depolarisation (Nakashima and Todd 1996, 
Nakashima and Todd 1996). Additionally, HT has been shown to improve oxidative stress 
via a reduction in release of nitric oxide following hypoxia in piglets (Thoresen et al. 1997). 
Whereas HT has been shown to attenuate the upregulation pro-inflammatory cytokines in 
an adult pig cardiopulmonary resuscitation model (Meybohm et al. 2010) and modulate the 
pro/anti-inflammatory cytokine ratio across time in a piglet model of neonatal HI (Rocha-
Ferreira et al. 2017). 
However, despite the application of HT, neonates with HIE still often suffer significant 
neuropathology, and poorer eventual outcome. Our understanding of the evolution of HI 
injury is incomplete - particularly in neonates. Each of the pathological processes such as 
inflammation or oxidative stress, can result in substantial cell damage. Additionally, these 
processes can exacerbate other injurious processes. For example, inflammation is 
considered to play a major role in initiating, or sustaining seizures in a variety of 
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neurodegenerative diseases (Riazi et al. 2010, Librizzi et al. 2012). It is vital we understand 
the evolving mechanisms of injury in order to develop novel, effective therapies for this 
vulnerable population. One pathological cascade that occurs following neonatal HI injury 
that is poorly understood is damage to the blood-brain barrier (BBB).  
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Figure 1.1: Phases of hypoxic ischaemic (HI) injury. HI injury evolves over time and can be broken 
down into distinct phases of injury. Primary energy failure is followed by the latent phase with 
restoration of oxygen and blood flow and partial recovery. The latent phase devolves into secondary 
energy failure approximately 6h post-HI depending on the severity of the initial injury. Secondary 
energy failure can last from 6h post HI to several days and is followed by tertiary phase which 
involves repair and brain remodelling. Abbreviations: Adenosine triphosphate (ATP), N-methyl-D-
aspartate (NMDA), oligodendrocyte precursor cell (OPC). 
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1.2 Blood-Brain Barrier  
The BBB plays a major protective and homeostatic role for the brain. As the interface 
between the blood and the brain interstitial fluid the BBB is an integral part of a functioning 
central nervous system (CNS). The BBB has two primary roles – the first is protective by 
restricting invasion of neurotoxic and pathogenic substances into the brain. The second is 
to regulate the movement of ions, metabolites and nutrients in order to maintain the balance 
of the CNS microenvironment. These two actions are essential for the correct metabolic and 
neuronal function of the brain.  
1.2.1 STRUCTURE  
The BBB is comprised of tightly joined endothelial cells of the CNS blood vessels. These 
neurovascular endothelial cells have unique properties of low paracellular permeability and 
high electrical resistance (Ballabh et al. 2004). Neurovascular endothelial cells are 
supported by a number of cell types which interact to maintain the integrity of the barrier. 
Microvessel endothelial cells form cell-to-cell tight and adherens junctions and are supported 
by interactions with adjacent astrocytes, pericytes, microglia, and neurons (Daneman 2012). 
These cells and blood vessels are collectively known as the neurovascular unit and are 
shown in Figure 1.2. Each component of the neurovascular unit and the intricate network of 
crosstalk between each cell is essential for the development of the BBB in the embryo and 
maintenance of integrity of the BBB throughout life. While there are a limited number of 
studies investigating the BBB in the neonate, there is evidence that like the adult, the 
integrity of the BBB is dependent on the structure and function of each component 
(Daneman 2012). 
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Figure 1.2: Representation of the neurovascular unit. Endothelial cells of central nervous system 
blood vessels are joined tightly by tight junctions and supported by surrounding astrocytic end feet, 
pericytes, neurons, and microglia (not shown). 
 
The physical barrier phenotype itself is primarily due to neurovascular endothelial cells. 
These cells have continuous intercellular tight junctions, lack fenestrations, and have very 
low rates of transcytosis (Daneman and Prat 2015). These unique properties limit both trans- 
and paracellular movement between the blood and the brain. Paracellular diffusion is limited 
to lipid soluble molecules, less than ~180Da, with fewer than 10 hydrogen bonds. However, 
there are a number of transcellular transport mechanisms that facilitate entrance of essential 
nutrients such as glucose, fatty acids, and amino acids, along with water and ions (Keaney 
and Campbell 2015). The endothelial cell barrier with its tight junctions limits free diffusion 
of substances into the brain tissue. The integrity of endothelial cells and tight junctions is 
therefore essential for healthy brain function. Endothelial tight junctions are present and 
functional at birth, although a progressive postnatal tightening of the barrier has been 
described (Stewart and Hayakawa 1987, Ek et al. 2003, Ek et al. 2006, Johansson et al. 
2008, Guerra et al. 2011, Saunders et al. 2012). Tight and adherens junctions seal the inter-
endothelial cleft and help form a continuous, semi-permeable barrier. Tight junction proteins 
include occludin, claudins, and junction adhesion molecules, which are anchored into the 
endothelial cell wall with zonula occludens 1 (ZO1) (Liu et al. 2012) (Figure 1.3).  
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Figure 1.3: Schematic diagram of tight junction proteins that seal the inter-endothelial cleft and limit 
free diffusion from the blood to the brain. Abbreviation: ZO – zonula occludens (1, 2, 3). 
Claudins are a large family of proteins that are expressed at the junction points of endothelial 
and epithelial cells. Claudin proteins consist of four membrane spanning domains with two 
extracellular loops and two cytoplasmic loops (Bauer et al. 2014). The predominant isoform 
in the CNS is claudin 5, however claudin 3 and 12 have also been shown to be present 
(Enerson and Drewes 2006). Claudin 5 is a key tight junction protein; its expression is 
sufficient to cause tight junction formation and an associated decrease in paracellular 
permeability in transfected Madin-Darby canine kidney II cells (Wen et al. 2004). Claudin 5 
knockouts in mice are lethal within 10h of life, although the cause of death is unclear (Nitta 
et al. 2003). However, claudin 5 deficient mice exhibited a size selective increase in BBB 
permeability to molecules <800Da which underlies the importance of claudin 5 in limiting 
free movement of substances at the BBB. (Nitta et al. 2003).  
Claudin proteins are not the only tight junction proteins that are important for BBB function. 
Occludin, a ~65kDa protein with four transmembrane regions and two extracellular loops, 
was the first integral tight junction protein identified (Bauer et al. 2014). However, occludin 
knockout mice still form intact tight junctions (Saitou et al. 1998). Although occludin may not 
be essential for tight junction formation, it is nonetheless an integral protein in BBB function. 
Disorganised occludin caused by a loss of angiotensin II is associated with increased BBB 
permeability in mice and in vitro (Wosik et al. 2007). The exact mechanism for how occludin 
supports barrier function is as yet unclear. However, a number of studies have shown that 
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occludin can be altered by post-transcriptional and post-translational modifications which 
may regulate its function at the BBB. This indicates that occludin may contribute to the 
dynamic responses of the BBB to changes in the environment (Blasig et al. 2011, Cummins 
2012). For example, tyrosine phosphorylation of occludin has been shown to alter the 
protein’s ability to interact with other tight junction proteins such as the zonula occludens 
(Kale et al. 2003). 
While junction adhesion molecules (JAMs) are not essential for tight junction formation, 
JAMs may facilitate the assembly of tight junction components, and maintain tight junction 
integrity. JAM loss has previously been associated with BBB permeability increases in a rat 
model of cortical cold injury (Yeung et al. 2008). Whereas adherens junctions, such as 
vascular endothelial cadherin and catenin are vital for cell to cell contact (Abbott et al. 2006, 
Liu et al. 2012). 
In addition, there are a number of cytoplasmic proteins that associate with tight junction 
proteins to stabilise them in the membrane via anchoring proteins to the actin cytoskeleton 
(Bauer et al. 2014). Therefore cytoplasmic proteins are important for tight junction integrity. 
These cytoplasmic proteins include the zonula-occludens (ZO) (1, 2, and 3). ZO1 forms 
heterodimers with ZO2 and ZO3 and interacts with occludin, claudin, and the JAMs via a 
PDZ motif (Bauer et al. 2014). ZO family members are therefore essential to the assembly 
of these proteins at tight junctions. It is important to consider the numerous components of 
the BBB that contribute to barrier function when interrogating BBB-disruption. 
1.2.2 DISRUPTION OF THE BLOOD-BRAIN BARRIER 
The BBB is a dynamic barrier that can respond to a variety of signals from the blood and the 
brain in normal and pathological conditions. The neurovascular unit and microvascular 
architecture have been shown to be highly affected by a variety of CNS diseases such as 
traumatic brain injury (TBI), stroke, multiple sclerosis, and dementia (Chodobski et al. 2011, 
Lakhan et al. 2013, Rosenberg 2014).  
BBB-disruption can result in severe exacerbation of pathology and results in increased brain 
injury. Characteristics of BBB breakdown include increased permeability, loss and 
redistribution of tight junction proteins, impaired transport across the BBB, and pathogenic 
changes to the cells of the neurovascular unit including pericytes, astrocytes, and microglia 
(Obermeier et al. 2013). These characteristics result in the pathogenic extravasation of 
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neurotoxic blood products and peripheral cells, greater neuroinflammation via enhanced 
cytokine transport across the BBB and peripheral immune cell invasion, oedema formation, 
impaired energy delivery through dysfunction of glucose transport, and pH alterations 
(Obermeier et al. 2013). All of these processes have been shown to exacerbate pathological 
processes in disease states and contribute to neuronal degeneration (Zhao et al. 2015). 
Disruption to the BBB is characterised by loss of the specialised properties of neurovascular 
endothelial cells. Damage to the endothelial cell and tight junctions leads to fenestrations 
developing and a marked loss of matrix proteins and receptors as well as a thinning of the 
basement membrane (Baeten and Akassoglou 2011). Such changes to endothelial cells and 
tight junctions are presumed to result in permeability alterations of the BBB due to the role 
they play in limitation of transport across the BBB. 
Loss or redistribution of tight junctions is one of the best characterised markers of BBB-
disruption following CNS disease or damage (Luissint et al. 2012). There is substantial 
evidence that HI events and reoxygenation can cause changes to tight junction protein 
expression – particularly occludin and claudin 5 (Mark and Davis 2002, Witt et al. 2003, 
Yamagata et al. 2004, Lochhead et al. 2010). Function can also be altered by re-distribution 
or phosphorylation due to HI, excessive glutamate, or inflammation in vitro (Staddon et al. 
1995, Andras et al. 2007, Lochhead et al. 2010, Shen et al. 2011). For example, hypoxia 
can redistribute ZO1 and occludin causing permeability alterations without altering total 
protein level or mRNA expression (Fischer et al. 2004). Ischaemia can also cause 
phosphorylation changes to occludin which resulted in an increase of BBB permeability 
(Kago et al. 2006, Muthusamy et al. 2014). Similarly, Lochhead et al, (2010) found that 
oxidative stress caused alterations in occludin structure and localisation away from the tight 
junction. 
1.3 Is the BBB disrupted following neonatal HIE? 
1.3.1 AGE-RELATED EFFECTS ON THE BBB  
HI has similar effects on the brain in both adults and neonates, however there are key 
differences (Blomgren et al. 2003). For example, age appears to have a distinct effect on 
the ratio of apoptosis and necrosis in brain tissue following HI. Apoptosis is more 
pronounced in immature (P5 – human preterm equivalent) rats than older rats (P9, P21, or 
P60 –human term to adult equivalent), whereas necrosis was similar across all age groups. 
Also, brain injury due to ischaemia or excitotoxicity is more pronounced in immature rats 
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(P2-6) and progressively decreases with age (Ikonomidou et al. 1989). It has also been 
suggested that the immature brain has a better capacity to respond to brain injury than adult 
brains because they are more ’plastic’. However, abnormal development resulting in 
aberrant neuronal connectivity has been proposed to result in poorer long term outcomes 
(Giza and Prins 2006).  
Inflammation is another area with developmental differences. For example, neutrophils do 
not invade the brain tissue in neonates with HI to the same extent as adults with HI-type 
injuries (Hudome et al. 1997, Bona et al. 1999). Whereas inflammation via 
lipopolysaccharide infection exacerbates HI brain injury in neonatal mice, but not adults 
(Wang et al. 2007).  
Similarly, there are important differences between adults and neonates that may affect the 
vulnerability of the BBB in the perinatal period. It was once thought that the BBB was not yet 
fully functional and “leaky” in newborns. However, we now understand that most of the 
functional components of the BBB are present at birth. This includes tight junctions which 
are primarily responsible for the restrictive barrier properties of the BBB (Ek et al. 2006, 
Saunders et al. 2012). However, it is important to note that the neonatal brain and the 
neonatal BBB respond differently to pathological stimuli than the adult and studies have 
demonstrated differences in BBB-disruption depending on the developmental age of the 
animal (Muramatsu et al. 1997, Stonestreet et al. 2006, Fernandez-Lopez et al. 2012). 
Newly formed blood vessels are at a greater risk of rupture and have significantly less 
protective astrocytic end-feet coverage (Trommer et al. 1987, El-Khoury et al. 2006). In 
premature neonates there is increased risk of cerebral microvasculature rupture and 
haemorrhage (Bolisetty et al. 2014), however, increased risk of rupture is not the only 
developmental difference for the cerebral vasculature. 
There is evidence that some aspects of the BBB are more resistant to acute injury in 
neonates than in adults. For example, Fernandez-Lopez and colleagues (2012) found in a 
rat stroke model that adult rats were more vulnerable to BBB-disruption than neonatal rats 
(P7 – human newborn equivalent). Adult rats in this model had greater gene expression 
changes that were associated with BBB breakdown, greater loss of tight junction and 
basement membrane proteins, as well as greater BBB permeability alterations (Fernandez-
Lopez et al. 2012). However, Stonestreet and colleagues (2006) found that the BBB 
becomes more resistant to hyperosmolality with age in preterm, newborn, and older lambs 
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and the heterogeneity of BBB permeability was greatest in immature animals; indicating that 
the response of the BBB to stress improves with age. The authors point out that increased 
permeability of the BBB in younger animals is not due to a generalised immaturity of the 
BBB, rather a specific vulnerability to osmotic stress in younger animals. This is consistent 
with other research which demonstrates periods of vulnerability of the BBB across 
development to various stressors. 
Stolp et al (2005) described this phenomenon well in a study that investigated white matter 
damage and BBB-disruption due to inflammation in rats and opossums at various ages. Rats 
at P0, P8, and P20 (human brain equivalent of premature, newborn, and juvenile), and 
opossums at P15, P20, P50, and P60 (similar developmental range) and adults of both 
species were injected with lipopolysaccharide (LPS) and BBB permeability to serum protein 
and white matter damage was assessed. In rats, the BBB was more permeable to serum 
proteins in P0 and P8 rats up to 24h post-LPS injection, but adult brains showed no evidence 
of protein leakage into the parenchyma. Whereas in the opossum at corresponding brain 
development ages to the rat (P20, P60 and adult) the P20 brain and the adult was not 
permeable to protein, whereas the P60 brain demonstrated increased BBB permeability at 
24h post-LPS injection, particularly in the white matter. These results indicate that there is 
a developmental period from that corresponds to the human timeframe of late premature to 
neonatal that is vulnerable to BBB-disruption due to inflammation. 
This finding was similar to one by Brochu and colleagues (2011) who found that LPS 
injections induced BBB permeability increases in white matter in P1 day old rats, but in the 
grey matter primarily in P12 rats, indicating an age effect in tissue type vulnerability as well. 
Whereas Anthony et al. (1997) showed that intracerebral injections of interleukin 1 beta into 
newborn rats resulted in a marked increase of BBB permeability to horseradish peroxidase 
(HRP) in P21 day rats (juvenile rats), but not in P0 (human premature), or adult rats. Finally, 
a HI rat model and found increased BBB permeability in P7 rats (human term equivalent) 
compared with P21 rats (Muramatsu et al. 1997). 
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1.3.2 BLOOD-BRAIN BARRIER DISRUPTION FOLLOWING PERINATAL BRAIN INJURIES 
There is very little evidence of BBB disruption in human neonatal HI studies. Neurovascular 
unit disruption has been demonstrated in neonates with HIE and animal models of HI. Direct 
injury to neurovascular endothelial cells that can last between days to weeks has been 
demonstrated in human neonates with HIE (Pourcyrous et al. 2015). Pourcyrous and 
colleagues demonstrated that newborns with HIE had significantly greater brain-derived 
endothelial cells in circulating blood which implies damage to the cerebral vasculature. 
Endothelial cell and tight junction deformities have also been described in a neonatal HI 
rodent model (Zhang et al. 2016). These changes to endothelial cells and tight junction 
proteins of ZO1, occludin, and claudin 5 were associated with increased permeability of the 
BBB (Zhang et al. 2016). Similarly, occludin and ZO1 protein levels were reduced whereas 
claudin 5 protein was redistributed in a neonatal ischaemic mouse model with increased 
BBB permeability (Ek et al. 2015). 
Although it is recognised as a pathological process following neonatal HIE, there is very little 
characterisation of BBB-disruption in humans with HIE. Kumar and colleagues (2008) 
demonstrated that neonates with HIE have increased cerebrospinal fluid (CSF) /plasma 
ratios of albumin (a relatively common biomarker for increased BBB permeability). The 
albumin CSF/plasma ratio was also related to HIE severity (Kumar et al. 2008). Whereas 
Schiering and colleagues (2014) investigated histopathological changes in deceased infants 
with HIE and found immunoreactivity for albumin in the hippocampus, indicating increased 
permeability of the BBB to the serum protein. This finding was particularly evident in 
neonates with seizure. 
A number of animal studies have shown that the BBB is affected by HI in neonatal models. 
The majority of investigations have been performed in rodent models of HI, which as noted 
previously, usually involve carotid artery ligation and subsequently result in a specific infarct 
area, therefore BBB-disruption found in these models may be different from the global injury 
found in humans. In terms of relation to human brain development, the P7-P10 rat is 
approximately term-equivalent. Tu and colleagues (2011) demonstrated that HI in P7 rats 
resulted in increased permeability to serum IgG and impaired endothelial cell integrity. 
Similarly, Ma et al (2017) described increased oedema and IgG immunoreactivity in brain 
tissue that was related to regulation of tight junctions. Ferrari et al (2010) showed also in P7 
17 
 
rats that HI resulted in persistent BBB alterations (oedema formation, and permeability to a 
low molecular weight tracer) up to 7 days after the HI insult. 
However, given the evolving nature of HIE, specific temporal alterations to the BBB have 
been insufficiently described in the current literature. There have only been a handful of 
studies describing how BBB-disruption evolves over time in neonatal models of HI injury, 
the majority of which have been performed in rodents. Peak BBB permeability to IgG was 
found at 24h post-HI in P7 rats compared with P14 and P21 (Muramatsu et al. 1997). Rats 
at P14 are approximately developmentally equivalent to a 1-2 year old infant, whereas P21 
rats are considered juvenile (Semple et al. 2013, Agoston 2017). Vulnerability in P7 rats was 
confirmed by Qiao and colleagues (2001) who found peak permeability to IgG and hyper-
intensity on MRI at 24h post-HI. Additionally, Ek and colleagues (2015) showed increased 
sucrose permeability at 6h post-HI and increased permeability to albumin at 24h post-HI, 
along with tight junction changes. 
There have been limited studies investigating BBB-disruption in large animal models with 
more clinically applicable injury types. Mirro and colleagues (1991) demonstrated increased 
BBB permeability of urea, sodium, and sucrose at 0.5h and 2h post-insult in a newborn (<P5 
day old) piglet model of ischaemia. However, in a hypoxia/hypercapnia piglet (<P4 day old) 
model there was no difference in BBB permeability to sodium or mannitol at 24h post-insult 
(Stonestreet et al. 1992). Chen and colleagues (2012) investigated BBB permeability of a 
radio-labelled tracer and alterations to tight junction proteins in a fetal sheep HI model at 4, 
24, and 48h post-HI and found peak permeability at 4h post-insult. These results are 
summarised in Table 1.1.
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Table 1.1. Summary of temporal evaluations of BBB-disruption in models of neonatal hypoxia ischaemia. Peak BBB permeability is shown in 
bold. In general, periods of peak BBB-disruption range between 4-6h post-injury and 24h post-injury. 
Abbreviations: IgG: immunoglobulin G, IHC: immunohistochemistry, O2: oxygen, qPCR:  quantitative polymerase chain reaction, WB: western 
blot, P: postnatal day
Author,   
Year 
Animal Age Model of HI Measurement(s) Period of increased BBB permeability Sampling 
time points 
Mirro et al,  
1991 
Piglets <P5 Reduction of cerebral 
perfusion pressure to 
0mmHg for 20mins 
Blood to brain transfer of 
urea, sodium, and 
sucrose 
Urea and sodium transfer elevated at 
30mins and 2h post-insult, sucrose 
elevated only at 2h post-insult 
30mins, 2h 
post-insult 
Stonestreet 
et al, 1992 
Piglets <P4 Hypoxia (10-12% O2), 
hypercapnia (15% 
CO2), 60mins 
Blood to brain transfer of 
sodium and mannitol 
None Cessation of 
insult, 24h 
post-insult 
Chen et al, 
2012 
Sheep 120-122 
days of 
gestation 
30mins of carotid 
artery occlusion in 
utero followed by 4h, 
24h, or 48h of 
reperfusion 
Blood to brain transfer of 
a radio-labelled tracer, 
tight junction changes 
(WB) 
Tracer brain transfer was increased at 
4h, 24h, and 48h post-ischaemia. 
Variable tight junction changes. 
Decreases in tight junction proteins were 
associated with increased BBB 
permeability 
4h, 24h, 48h 
post-
ischaemia 
Muramatsu 
et al, 1997 
Rats P7, P14, 
P21 
Carotid artery ligation, 
and 1.5h of 8% O2 
IgG immunoreactivity Greater and earlier (6h) IgG 
immunoreactivity in P7 rats compared 
with P14. No IgG in P21. Peak IgG 24h 
post-HI 
3, 6, 9, 12, 18, 
24h post-HI 
Qiao et al,  
2001 
Rats P7 Carotid artery ligation 
and 2h of 8% O2 
T2 weighted MRI, IgG 
immunoreactivity 
MRI hyper-intensity during and at 24h 
post-HI but not at 1h. 
IgG immunoreactivity during, 1h post-HI, 
and 24h post-HI 
During HI, 1h 
and 24h post-
HI 
Ek et al,  
2015 
Mice P9 Carotid artery ligation 
and 50mins of 10% O2 
Sucrose permeability, 
albumin immunoreactivity, 
tight junction changes 
(IHC, WB, qPCR) 
2, 6, 24h post-HI (sucrose) 
2, 6, 24h post-HI (albumin) 
2h, 6h, 24h, 
3d, 7d 
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1.3.3 FUNCTIONAL CONSEQUENCES: BRAIN INJURY 
BBB-disruption is a key component of many major CNS diseases. While it is likely that 
neurodegenerative processes impact the BBB, BBB-disruption is also thought to contribute 
to neurodegeneration via multiple pathogenic pathways including neuroinflammation, 
oedema formation, excitotoxicity, and worsened oxidative stress. There is strengthening 
evidence that BBB-disruption contributes to the injury processes following CNS pathology 
which may then contribute to long term outcome. BBB-disruption is associated with 
increased epilepsy risk and long term neurological alterations (Tomkins et al. 2001, Korn et 
al. 2005, Tomkins et al. 2008), can contribute to Alzheimer’s pathogenesis (Yamazaki and 
Kanekiyo 2017, Nation et al. 2019), and is associated with cognitive dysfunction (Wang et 
al. 2017, Geng et al. 2018). BBB-disruption induces in vivo degeneration of dopaminergic 
neurons which indicates a possible mechanism for Parkinson’s disease onset in later life 
(Rite et al. 2007). Another study in a rat model of diabetes found BBB-disruption was linked 
to cognitive decline and an upregulation of pro-inflammatory cytokines (Geng et al. 2018). 
Although several studies have demonstrated that the BBB is affected by HI in the neonate, 
there is exceedingly little evidence regarding the relationship between BBB-disruption and 
outcome. Ek and colleagues (2015) demonstrated a relationship between areas of BBB-
disruption and areas of brain infarction. Whereas another rat model of HI found a biphasic 
oedema formation due to BBB-disruption which correlated with neuronal and glial changes 
(Nedelcu et al. 1999). A study that utilised a matrix metalloproteinase 9 knock out in mice 
showed decreased BBB permeability and inflammation, which was associated with 
neuroprotection following HI – indicating that preventing BBB-disruption and subsequent 
inflammation results in less brain injury . BBB-disruption has also been shown to have a 
direct influence on vasogenic oedema formation. A significant proportion of infants with 
severe HIE have MRI changes consistent with vasogenic oedema formation which is 
strongly predictive of outcome (Boichot et al. 2006, Chang et al. 2007).  
There is also evidence in other diseases and disorders that BBB-disruption is associated 
with pathogenic brain alterations. Directly disturbing the BBB through focused ultrasound for 
therapeutic purposes has been shown to increase glial activation, pro-inflammatory cytokine 
levels, increase albumin extravasation and cause neuronal cell death for up to 24h (Kovacs 
et al. 2017). Whereas osmotically opening the BBB can result in seizure activity (Marchi et 
al. 2007) which can independently be associated with brain injury in neonates with asphyxia 
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(Miller et al. 2002). Stolp et al (2005) demonstrated that there are long-term changes in BBB 
permeability following inflammation which can result in white matter volume changes. 
Whereas a study that infused plasma into frontal white matter of adult pigs found a resulting 
increase in vasogenic oedema, oxidative stress, increased cytokine gene expression, and 
DNA fragmentation between 1 and 24h post-infusion – indicating that increased BBB 
permeability to plasma proteins can rapidly damage white matter and have pathogenic 
effects on oedema formation and inflammation status (Wagner et al. 2005). 
1.3.4 FUNCTIONAL CONSEQUENCES: ALTERATIONS TO NEURONAL EXCITABILITY  
The neurovascular unit is critical in maintaining effective neuronal function. Consequently, 
disruption of the BBB can alter neuronal excitability which may lead to brain injury, seizure 
generation, and epilepsy. In the adult brain, increased BBB permeability results in 
extravasation of peripheral immune cells, serum proteins, and ions. This extravasation can 
disrupt the delicate homeostasis of the brain and result in modification of the neuronal 
environment (Labus et al. 2014). BBB-disruption results in a net flow of ions, 
neurotransmitters, and proteins flow down a concentration gradient from high blood 
concentrations into the interstitial space of the brain (Smith 2000, David et al. 2009, Iffland 
et al. 2014) (Figure 1.4). This leads to excitatory synapse formation, decreased seizure 
threshold, and impaired ion buffering; all of which prime the brain towards excitability and 
increase the likelihood of seizing (Ivens et al. 2007, Weissberg et al. 2015). Studies in adults 
have shown that BBB-disruption is associated with long term neurological changes such as 
epilepsy and brain wave alterations (Tomkins et al. 2001, Korn et al. 2005, Oby and Janigro 
2006, Tomkins et al. 2008). 
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Figure 1.4: Schematic representing relative concentrations in the blood and the brain with larger 
font text indicating higher concentration than smaller font text. The third column represents the 
relative change in concentration of each substance in the brain following BBB-disruption and the 
subsequent effect on neuronal excitability. Abbreviations: Calcium (Ca++), potassium (K+), 
immunoglobulin G (IgG), blood brain barrier disruption (BBB-D). Adapted from Iffland et al, 2014. 
Blood brain barrier disruption and neonatal seizures 
Increased BBB permeability has been shown to be associated with seizure via a number of 
mechanisms. Serum albumin is one protein that has been linked to ictogenesis following 
BBB-disruption in a number of pathologies, including epilepsy, TBI, and stroke. There is a 
significant correlation between the extent of serum albumin leakage through a disrupted 
BBB and the subsequent number of seizures (van Vilet et al. 2007). Albumin leakage has 
also been utilised as a measure of BBB-disruption in deceased human neonates who 
suffered from seizure (Schiering et al. 2014). Albumin uptake into astrocytes can alter 
neuronal excitability by its regulatory effects on ion channels. Albumin can alter extracellular 
ion concentrations (increased K+ and decreased Ca2+ and Mg2+) leading to increased 
neuronal excitability (Weissberg et al. 2015). Furthermore, albumin can activate 
transforming growth factor β, leading to short term changes in extracellular K+ and glutamate 
buffering and longer term excitatory synapse formation (Ivens et al. 2007, Weissberg et al. 
2015). 
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Another serum protein – immunoglobulin G (IgG) brain extravasation has been associated 
with BBB-disruption and seizures in both adults and neonates (Tu et al. 2011, Michalak et 
al. 2012). IgG can be taken up by neurons and this occurs concomitantly with seizures in 
adult patients and rodent animal models (Michalak et al. 2012). IgG uptake in humans and 
rodents with seizure results in neuronal eosinophilia, shrinkage, and structural alterations 
(Michalak et al. 2012). It is unclear if IgG extravasation into brain tissue and uptake into 
neurons is pathogenic and what impact it has on seizure in either adults or neonates. In a 
neonatal model of HI, BBB disruption was demonstrated via measurement of IgG 
extravasation (Zhang et al. 2016) however, seizure was not investigated. A full 
characterisation of IgG entrance into brain tissue, uptake into neurons, and investigation into 
neuronal morphology changes has not been performed in a model of neonatal seizures. 
Extravasation of serum proteins is one example of how BBB-disruption and increased 
permeability can alter neuronal excitability and prime the brain toward seizure.  
The development of seizures during secondary energy failure is one of the major 
consequences of neonatal HIE. Rather than just a benign consequence of injury, neonatal 
seizures have a serious impact on long term neurodevelopmental outcome following HIE. 
Neonatal seizures may exacerbate CNS injury following HI and are associated with 
increased likelihood of neonatal death (Mellits et al. 1982, McBride et al. 2000, Wirrell et al. 
2001, Miller et al. 2002, Yager et al. 2002, Tekgul et al. 2006, Bjorkman et al. 2010, Anand 
and Nair 2014). In addition, neonatal seizures are associated with risk of developing seizure 
disorders in later life (Rodriguez-Alvarez et al. 2015, Fox et al. 2016), and long term 
neurodevelopmental disorders (Huang et al. 1999, Lee et al. 2001, Sayin et al. 2004, Tekgul 
et al. 2006, Glass et al. 2009). The risk of developing long term neurodevelopmental 
disorders is independent of initial insult severity in pathological states like HI, suggesting 
that seizures themselves exacerbate injury (Glass et al. 2009, Payne et al. 2014). While it 
is now generally accepted that seizures exacerbate CNS injury in an injured neonatal brain, 
the exact mechanism of this action remains unclear (Thibeault-Eybalin et al. 2009, 
Ramantani 2013, Kang and Kadam 2015). 
Effective treatment and control of neonatal seizures is a significant clinical challenge as 
inadequately controlled seizures are associated with an increased risk of poor outcome such 
as death or cerebral palsy (van der Heide et al. 2012). Currently used anti-epileptic drugs 
(AEDs) are extremely ineffective in controlling neonatal seizures (Painter et al. 1999, 
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Lundgrist et al. 2013) and there is insufficient evidence to suggest treatment with any of the 
commonly utilised AEDs reduce the long term risk of neurodevelopmental disorders (Evans 
et al. 2007, van der Heide et al. 2012). In fact, neonates treated with more AEDs show a 
trend toward poorer outcomes and there is evidence that AEDs in the neonatal period could 
inhibit normal brain development or worsen neurological injury in pathological states 
(Ikonomidou et al. 2001, Bittigau et al. 2002, Bittigau et al. 2003, Forcelli et al. 2012a, Forcelli 
et al. 2012b). 
Given the impact of neonatal seizures on short and long term neurodevelopmental injury 
and the inadequacy of currently utilised seizure treatments, there is an urgent need for novel 
ways to protect the vulnerable neonatal brain from seizure. However, very little is known 
regarding the role BBB-disruption plays in the evolution of neonatal seizure. To the best of 
my knowledge, the only pieces of evidence that BBB-disruption following HIE are associated 
with seizures are from Pourcyrous et al, 2015 and Schiering et al, 2005. Pourcyrous and 
colleagues (2015) found that neonates with seizures following HIE have been found to have 
increased levels of circulating brain-derived endothelial cells than control babies and HIE 
babies without seizure, which suggests that seizures are associated with damage to the 
NVU which is essential for BBB integrity. In this study the level of brain derived endothelial 
cells in peripheral blood was reduced with seizure control, suggesting appropriate seizure 
treatment could reduce NVU damage (Pourcryrous et al. 2015). Whereas Schiering and 
colleagues (2014) demonstrated in deceased neonates that BBB-disruption was most 
evident in those newborns with seizure. BBB-disruption is now considered to be a causal 
factor in ictogenesis and epileptogenesis in many neurological diseases (Marchi et al. 2007, 
Tomkins et al. 2007, Tomkins et al. 2008, Michalak et al. 2012, Li et al. 2013, Lippmann et 
al. 2016). It has been proposed that protecting the BBB may reduce seizure burden after 
TBI or stroke. Therefore, BBB-disruption may be a major untapped avenue of potential 
treatments for neonatal HI-induced seizure. 
1.3.5 ROLE REVERSAL – THE IMPACT OF SEIZURES ON THE BBB  
Increased BBB permeability may play an important role in increasing neuronal excitability 
and seizure; however, seizure activity can also result in BBB-disruption. The effect of seizure 
on the BBB has been documented in epilepsy conditions in adults, children, and in animal 
models (Oby and Janigro 2006, van Vilet et al. 2007). BBB-disruption has been 
demonstrated in adults and children with temporal lobe epilepsy in the absence of 
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measurable neuronal damage – suggesting that the seizures themselves caused the 
observed BBB-disruption rather than both as a consequence of CNS damage (Rigau et al. 
2007). This hypothesis is further supported by Librizzi et al (2012) who demonstrated a 
single seizure was sufficient to cause BBB permeability changes. 
The impact of seizures on BBB-disruption is thought to be attributable to two major 
mechanisms. Firstly, due to an increase in metabolic demand, seizures cause significant 
haemodynamic alterations which can induce BBB-disruption. This has been demonstrated 
in a neonatal HI model where alterations in cerebral blood flow were associated with BBB 
disruption and increased neuronal damage (Ek et al. 2015). The second mechanism of 
seizure-induced BBB disruption involves inflammation which will be discussed further later 
in the chapter.  
Seizures can have significant impacts on cells of the neurovascular unit that may result in 
alterations of BBB permeability (Seiffert et al. 2004, Marchi et al. 2007, van Vilet et al. 2007, 
Tomkins et al. 2008, Friedman 2011, Vezzani and Friedman 2011, Librizzi et al. 2012, 
Weissberg et al. 2015). Endothelial cell damage and sloughing off of vascular walls has 
been demonstrated within hours of seizure activity in a chemically-induced neonatal model 
of seizures (Parfenova et al. 2010). This type of endothelial cell damage has also been 
described in human neonates and positively correlated with increased seizure severity 
(Pourcyrous et al. 2015).  
These data suggest that the BBB and seizures may have a reciprocally damaging 
association. However, neonatal seizures are often symptomatic of underlying CNS 
pathology which may impact the BBB-disruption. Therefore, it is very difficult to determine if 
the association between BBB-disruption and seizure is a result of seizure exacerbation of 
BBB-disruption, or simply a consequence of higher levels of initial injury. A temporal 
characterisation of BBB-disruption and seizures following a neonatal injury may help to 
address these questions, however this work has not yet been performed. 
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1.4 Mechanisms of BBB disruption following hypoxia ischaemia 
A number of injurious cascades have been identified as disruptive to the BBB in TBI, and 
stroke. Identified pathways to BBB-disruption include oxidative stress, excitotoxicity, and 
inflammation which are also common to neonatal HIE. These pathological processes are 
therefore proposed to be the mechanism behind disruption to the BBB in this disease.   
1.4.1 INFLAMMATION 
Inflammation in neonatal HI 
Inflammation is a key pathological cascade following a HI insult and is a major mediator of 
neuronal death (Hagberg et al. 2015). HI induces microglia to become active and exhibit 
macrophage-like abilities which include phagocytosis, release of cytokines (both pro- and 
anti-inflammatory) and release of matrix metalloproteinases (MMPs) (Ziemka-Nalecz et al. 
2017). In general, microglial activation following neonatal HI is considered pathological, 
however, phagocytic debris clearing abilities and growth factor released by these cells 
provides some level of protection. In addition to microglia, there are a number of other cell 
types that can release cytokines which can further exacerbate inflammation and 
neuropathology which include endothelial cells (Michiels et al. 2000) and astrocytes which 
can activate and release of pro-inflammatory cytokines (Orzylowska et al. 1999, Sizonenko 
et al. 2008, Xiong et al. 2009). 
A number of pro-inflammatory cytokines and chemokines have been shown to increase 
following neonatal HIE such as tumour necrosis factor alpha (TNFand the interleukins 
(IL). TNF has been demonstrated to increase following neonatal HIE in serum and CSF 
and level of TNF has been shown to be related to both HIE severity and neurological 
outcome (Silveira and Procianoy 2003, Aly et al. 2006, Bajnok et al. 2017, Sumanovic-
Glamzina et al. 2017). Interleukins IL-6, IL-8, and particularly IL-1 have also been found to 
be elevated in response to HI injury, and related to poor neurodevelopmental outcomes 
(Savman et al. 1998, Silveira and Procianoy 2003, Aly et al. 2006, Orrock et al. 2016, Bajnok 
et al. 2017, Sumanovic-Glamzina et al. 2017).  
In addition to TNF and the interleukins, a number of other cytokines and chemokines have 
been demonstrated to play a role in the inflammatory cascade following HI. However, 
detailed information regarding their release following neonatal HIE is limited. Transforming 
growth factor beta (TGF), for example, has been found to be upregulated at 24h to 1 month 
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post-birth in serum from neonates with moderate HIE (Bajnok et al. 2017).  Cyclooxygenase 
2 (COX2) is another pro-inflammatory cytokine believed to be involved in inflammation and 
neurodegeneration in HIE. A study in deceased neonates following HIE found strong 
expression of COX2 (Toti et al. 2001). In terms of animal models, a piglet model of neonatal 
HIE did show that COX2 was increased following HI (Varga et al. 2018). Rodent models 
have also shown that COX2 is upregulated following HI and COX2 inhibition is associated 
with improved neurobehavioural and histopathological outcomes (Fathali et al. 2010, Wixey 
et al. 2012, Wang et al. 2014). 
Inflammation and BBB-disruption 
In addition to its role in brain injury, there is strong evidence that inflammation can have a 
profound effect on the BBB in a variety of CNS diseases and disorders (Stolp and 
Dziegielewska 2009, Coisne and Engelhardt 2011, Erickson et al. 2012, Banks et al. 2015, 
Brown et al. 2016).  
Previous reports have shown that high-dose lipopolysaccharide (LPS) treatment can 
increase the permeability of the BBB (Stolp et al. 2005, Banks et al. 2015). This includes 
evidence from neonatal piglets and fetal sheep (Temesvári et al. 1993, Yan et al. 2004). 
LPS-activated microglia have been shown to decrease tight junction protein expression in 
in vitro BBB models (Sumi et al. 2010). In addition, LPS can exacerbate brain injury in rodent 
models of preterm HI injury by increasing inflammation and BBB-disruption (Wang et al. 
2010). As stated earlier in the chapter, inflammation-induced BBB-disruption may be 
influenced by the developmental age of the animal. Stolp and colleagues (2005) 
demonstrated that BBB permeability to plasma proteins was only increased following LPS 
injection during a narrow window of susceptibility (P0-8 in rat and P35-60 in opossum). 
Similarly, increased inflammation and BBB-disruption have been shown in LPS enhanced 
HI injury in P12 rats compared with P1 rats (Brochu et al. 2011). 
Further evidence that inflammation impacts on the BBB includes evidence that upregulation 
of various cytokines can increase BBB permeability. Cytokines can have direct effects on 
endothelial cells such as apoptosis and promotion of vasculogenesis (Sprague and Khalil 
2009). Some of the cytokines that have found to have an effect on the BBB include TNF 
the interleukin family, TGF, COX2, and interferon gamma protein 10 (CXCL10). 
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For example, treatment of endothelial cells in vitro with TNF causes a decrease in trans-
endothelial electrical resistance (TEER) and enhanced leukocyte migration (de Vries et al. 
1996, Anda et al. 1997, Wong et al. 2007). A study adult rats did demonstrate that TNF 
causes delayed BBB permeability increases (Rosenberg et al. 1995). Additionally, Yang and 
colleagues (1999) found that TNF upregulation in an adult mouse stroke model was related 
to BBB-disruption and that treatment with a TNF antibody could attenuate this disruption.  
Similarly to TNF, IL1 has also been found to decrease TEER in vitro (de Vries et al. 1996) 
and IL1 was found to increase BBB permeability to serum and increase neutrophil 
migration in a rodent model (Anthony et al. 1997). IL1 also increases BBB permeability as 
measured by MRI in juvenile rats by Blamire and colleagues (2000). Mechanisms of IL1-
mediated alterations to BBB permeability include transcriptional regulation of claudin 5 
expression (Beard et al. 2014). 
Although having both pro- and anti-inflammatory effects in the CNS following injury (Erta et 
al. 2012), the presence of IL6 does appear to be related to BBB-disruption. IL6 treatment 
has been shown to decrease TEER and cause ZO1 disorganisation (de Vries et al. 1996, 
Desai et al. 2002). Occludin and claudin 5 expression on isolated microvessels from juvenile 
and adult sheep are modulated by IL6 treatment (Cohen et al. 2013). In addition, treatment 
with anti-IL6 in a fetal sheep HI model prevents damage to the BBB (Zhang et al. 2015).  
While TGFhas anti-inflammatory effects, it has been shown to exacerbate BBB 
permeability in a number of models (Ma et al. 2008, Kim et al. 2017). TGF treatment can 
increase MMP expression, decrease claudin 5 expression, and increase BBB permeability 
– effects that can be inhibited with a TGF antagonist (McMillin et al. 2015). Additionally, a 
study in humans with TBI found that TGF elevations in CSF were associated with BBB 
function (Morganti-Kossmann et al. 1999). However, it should be noted that TGF has also 
been associated with BBB maintenance; exogenous TGF treatment of mice can result in 
decreased BBB permeability in a chronic pain model and increased expression of tight 
junctions (Ronaldson et al. 2009). 
COX signalling is not only important in the inflammation cascade, but has also been 
associated with BBB-disruption. A study showed that COX2-null mice have enhanced BBB-
disruption following LPS injection (Aid et al. 2010). Additionally, COX2 inhibition has been 
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found to be protective, COX inhibition in a rat injected with TNF was found to reduce BBB-
disruption and attenuate MMP upregulation (Candelario-Jalil et al. 2007, Tsao et al. 1999). 
. CXCL10 is an important chemoattractant for neutrophil infiltration, which may be more 
intense in younger animals compared with adults (Anthony et al. 1998).  
Seizures, inflammation, and the BBB 
While HI initiates a strong, pathogenic inflammatory response, seizure activity alone can 
induce inflammation and have severe consequences for the BBB. Seizures also activate 
microglia, astrocytes, and endothelial cells of the neurovascular unit and prompt further 
secretion of pro-inflammatory cytokines (Crespel et al. 2002, Ravizza et al. 2008). Ravizza 
et al, (2008) demonstrated that status epilepticus results in release of pro-inflammatory 
cytokines from microglia and astrocytes within hours. Librizzi et al, (2012) demonstrated that 
a single chemically-induced seizure can induce release of pro-inflammatory cytokine 
interleukin-perivascular astrocytes and microglia which results in disruption of the BBB and 
increased permeability to albumin. The BBB-disruption mediated by seizures is thought be 
an important contributor to astrocytic dysfunctions that further promote seizure and 
eliptogenesis (Librizzi et al. 2012). 
Inflammation is so closely associated with seizures and BBB-disruption that it has been 
suggested that BBB-disruption can be used as a surrogate marker for inflammation in order 
to predict seizure. In addition to being used to predict seizure, inflammation is an emerging 
therapeutic target to reduce BBB-disruption in neonatal excitotoxicity models (Moretti et al. 
2015), neonatal HI models (Tu et al. 2011), and in paediatric patients with status epilepticus 
(Marchi et al. 2011). 
1.4.2 VASCULAR ENDOTHELIAL GROWTH FACTOR 
In response to hypoxia, hypoxia-inducible factor (HIF1) is generated and released to 
regulate oxygen homeostasis. HIF1 can then induce upregulation of vascular endothelial 
growth factor (VEGF). There are 6 members of the VEGF family, but the most prominent in 
brain tissue is VEGFA. VEGFA plays a key role in vasculogenesis, angiogenesis, and 
endothelial permeability (Shibuya, 2010) and can play both a protective and detrimental role 
in the compromised brain (Fischer et al. 2002, Feng et al. 2008, Vasiljevic et al. 2011).  
Hypoxia-induced VEGF release and angiogenesis is believed to occur as a compensatory 
mechanism for failing energy supply in order to increase blood and oxygen delivery. Intra-
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cerebroventricular injections of VEGF in a neonatal HI rat model have been shown to 
decrease infarct area, and histopathological damage (Feng et al. 2008). VEGF has also 
been shown to have a protective role in hypoxic conditions via ameliorating apoptotic 
cascades, and stimulating neurogenesis (Jin et al. 2001, Jin et al. 2002, Sun et al. 2003). 
However, in humans with HIE, increased presence of VEGF in CSF is correlated with 
increasing severity of the disorder (Vasiljevic et al. 2011). Increased BBB permeability has 
also been associated with VEGF. Treatment with VEGF in newborn mice caused a 
reversible increase in BBB permeability to Evans blue from 2-24h post-injection (Young et 
al. 2004). VEGF also has a direct effect on endothelial cells and pericytes contributing to the 
generation and maturation of new blood vessels (Hippenstiel et al. 1998, Yamagishi et al. 
1999, Thanabalasundaram et al. 2010). However, these newly formed blood vessels can be 
weak and prone to rupture (Volpe, 1989). VEGF promotes endothelial sprouting and pericyte 
migration, however the net effect is to increase the permeability of existing vessels (Bates 
2010). VEGF has also been shown to increase BBB permeability by inducing changes to 
tight junctions (Fischer et al. 2002, Hudson et al. 2014). 
1.4.3 MATRIX METALLOPROTEINASES 
MMPs are proteolytic enzymes that are involved in breakdown of neurovascular basement 
membrane and tight junction proteins (Cardoso et al. 2012, Hou et al. 2014, Qin et al. 2015). 
Currently, 24 homologues of MMP have been described – many of which have been 
implicated in disease processes (Rempe et al. 2016). The two best investigated MMPs in 
terms of BBB-disruption are the gelatinases – MMP2 and 9.   
MMPs can be strongly activated by a variety of inflammatory cytokines (McColl et al. 2008). 
MMPs can cause further exacerbation of the inflammatory response via increasing 
peripheral immune cell invasion through a compromised BBB and enhanced chemokine 
expression, and via activation of cytokines such as IL1 and TGF (Schonbeck et al. 1998, 
Yu and Stamenkovic 2000). MMP9 can also release and activate VEGF stored in 
extracellular matrix which may cause further BBB-alterations (Bergers et al. 2000, Bauer et 
al. 2009). 
MMPs have also been found to be strongly upregulated following HI events such as stroke, 
and following neonatal HIE (Rosenberg et al. 1995, Horstmann et al. 2003, Rosell et al. 
2006, Lee et al. 2007, Leonardo and Pennypacker 2009, Lv et al. 2015, Chen et al. 2018). 
MMP upregulation by TNF treatment has been shown to increase BBB permeability in adult 
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rats (Rosenberg et al. 1995). MMP expression in CSF has been found to be related to BBB 
permeability as measured by CSF albumin ratio in patients with ischaemic vascular disease 
(Candelario-Jalil et al. 2011). Whereas, MMP inhibition has been associated with improved 
BBB function and neuroprotection (Leonardo et al. 2008). 
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1.6 Aims and Hypotheses  
1.7.1 HYPOTHESIS 
I hypothesise that disruption of the BBB is dynamic, and permeability fluctuates with the 
evolution of neonatal HI brain injury. Seizures and inflammation are important regulators of 
this permeability. Therapeutic hypothermia will provide neuroprotection through amelioration 
of BBB-disruption. 
 
1.7.2 AIMS  
Aim 1: Examine the temporal evolution of BBB-disruption after a HI insult in a clinically 
relevant, large animal model of neonatal HIE 
Aim 2: Determine the impact of seizures following neonatal HI on BBB permeability  
Aim 3: Evaluate the efficacy of therapeutic hypothermia on reducing BBB-disruption and 
improving neurodevelopmental outcomes 
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CHAPTER 2 - GENERAL METHODOLOGY 
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2.1 Animals 
Approval for this study was obtained from the University of Queensland Animal 
Experimentation Ethics Committee and carried out in accordance with National Health and 
Medical Research Council guidelines (Australia) (UQCCR/565/09/NHMRC, 
UQCCR/566/09/NHMRC, UQCCR/576/12/NHMRC, UQCCR/426/14/NHMRC 
UQCCR/224/16/NHMRC) (Appendices 2-6). 92 animals (41 female) with an average 
weight of 1.64kg (±0.21) and age of 13.85h (±4.94) were utilised for this thesis. Animals 
were transported from University of Queensland Gatton Piggery to University of Queensland 
Herston Medical Research Centre on the day of birth in pairs. 
2.1.1 ANAESTHESIA PROTOCOL 
Piglets were sedated with 2-4% Isoflurane (Bayer, Pymble, NSW, AUS) via a facemask and 
a Goldman Vaporiser. Piglets were then anaesthetised with a 5mg/kg propofol (Diprivan 1%, 
AstraZeneca Pty Ltd., NSW, AUS) injection through a cannulated (24 gauge) ear vein. 
Intravenous anaesthesia was maintained with propofol (9mg/mL) / alfentanil (50g/mL) 
(Rapifen, ICI Pharmaceuticals, VIC, AUS) throughout the experiment. Anaesthesia was 
delivered at a rate of 10mg/kg/h until intubation with a size 3.0 cuffed endotracheal tube. 
Anaesthesia was then increased to 20mg/kg/h for 15 minutes, reduced to 15mg/kg/h for 15 
minutes, and reduced again to 10mg/kg/h for the duration of the hypoxic-ischaemic (HI) 
insult. Following the HI insult, anaesthesia was adjusted between 4 and 12mg/kg/h in order 
to maintain sedation until euthanasia (Chapter 3) or until the animals were weaned off 
anaesthesia and recovered (Chapters 4 and 5). Where possible, anaesthesia was kept at 
the lowest possible dose to maintain light sedation. Anaesthesia was maintained for the 
duration of the experiments in chapter 3 (4-26h) (as per ethical requirements) as all animals 
were subjected to sodium fluorescein injections at the end of the experiment. In chapters 5 
and 6 anaesthesia was maintained until ~40h to allow maximal benefit of hypothermia and 
an appropriate comparison group (normothermic animals) (Thoresen et al. 2001, Tooley et 
al. 2003). 
2.1.2 VENTILATION AND PHYSIOLOGICAL MONITORING 
Piglets were ventilated using a SLE Newborn 250 ventilator (Surrey, United Kingdom). 
Ventilator settings were initially 30 breaths per minute, inspired oxygen (iO2) of 21%, peak 
inspiratory pressure of 12cm H2O, positive end expiratory pressure of 5cm H2O, and 
inspiratory time ratio of 0.74. Ventilator settings were adjusted as necessary to maintain 
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oxygen saturation (sO2) of >95%, and arterial pCO2 between 35 and 45 mmHg. 
Physiological monitoring of sO2, expired CO2, rectal temperature, heart rate, and blood 
pressure was performed continuously using a Marquette Tramscope 12C (Medical Systems, 
WI, USA). Arterial blood gas parameters of pH, arterial base excess (ABE), lactate, pCO2, 
pO2, bicarbonate, and glucose were measured prior to, during, and after the HI insult 
(ABL800, Radiometer, VIC, AUS). 
 
 
Figure 2.1: Piglet set up detailing monitoring measures available including catheterisation for blood 
pressure monitoring and delivery of fluids, temperature, heart rate, oxygen saturation, and EEG 
monitoring. 
 
2.1.3 SURGICAL PREPARATION 
Blood pressure monitoring and arterial blood sampling was achieved via catheterisation of 
the umbilical artery. A 3.5FG dual lumen argyle umbilical artery catheter (Cardinal Health, 
Ohio, USA) was inserted approximately 12cm into an umbilical artery, and sutured and taped 
in place. In addition, the mammary vein was cannulated for infusion of 10% glucose 
(~3mL/kg/hr) for the duration the animals were under anaesthesia. All piglets received 
prophylactic intravenous dose of 2mg/kg cephalothin (100mg/mL, DBL, VIC, AUS) and 
2.5mg/kg gentamicin (10mg/mL, DBL, VIC, AUS). 
Umbilical artery catheter  
And blood pressure 
 transducer 
Temperature 
EEG 
Anaesthesia 
Ventilation 
Venous line 
Heart rate 
Oxygen saturation 
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2.1.4 aEEG MONITORING 
Two-channel amplitude-integrated EEG (aEEG) was recorded for the duration animals were 
under anaesthesia and for a 1h period at approximately 48 and 72h post-HI in animals 
survived to 72h (BrainZ Instruments, Auckland, NZ, USA, or Unique CFM 6.0, Inspiration 
Healthcare, United Kingdom) (Bjorkman et al, 2010). Needle placement was determined by 
the neonatal modification of the International 10-20 system (Fisch 1999). Five subcutaneous 
needle electrodes were positioned at C3–P3, C4–P4 with a reference electrode placed in 
the fat pad on the back of the neck. aEEG recordings at 48 and 72h were performed without 
anaesthesia on sleeping animals after feeding, swaddled in a towel. Needle electrodes were 
inserted after brief (30s) anaesthesia with isofluorane delivered via facemask. 
2.1.5 HYPOXIC ISCHAEMIC INSULT PROTOCOL 
Piglets were stabilised before the HI insult for a period of 90-120min following the 
anaesthesia induction. Following stabilisation, iO2 was reduced from 21% (air) to 4%. The 
HI insult was titrated to each piglet based on individual physiological responses by 
manipulating the inspired oxygen between 2-8% (Figure 2.2). Titration of the insult is based 
on low-amplitude EEG (<5V for at least 25min), pH (<7.1), mean arterial blood pressure 
(MABP) (at least 10min of systemic hypotension), and arterial base excess (< -12). At least 
10min of ischaemia was achieved by hypoxemic cardiovascular de-compensation and 
decrease in MABP to the point of a loss in cerebral autoregulation (limit of 30-40mmHg in 
the piglet). This HI protocol is well established by our laboratory (Bjorkman et al, 2006) and 
results in a consistent, clinically relevant insult. The HI insult was terminated by resuscitation 
with 21% iO2. Arterial blood gas values were recorded at 15, 30, 45 and 60min post-HI and 
4 hourly from 60min onwards.  
2.1.6 SODIUM FLUORESCEIN INJECTION 
Animals in chapter 3 were injected with an exogenous tracer molecule (sodium fluorescein 
– 376Da) in order to evaluate BBB permeability to the molecule.  Sodium fluorescein (4% in 
0.9% sodium chloride, 2mL/kg) was injected intravenously one hour prior to euthanasia and 
allowed to circulate. 
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Figure 2.2: Hypoxic insult flowchart. Adapted from Bjorkman et al. (2006). 
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Figure 2.3: Examples of electroencephalography (EEG) background patterns. Examples of amplitude-integrated EEG (top - blue) and raw trace (bottom 
- black) for five background patterns. Continuous normal voltage is shown in A, discontinuous normal voltage in B, burst suppression in C, continuous 
low voltage in D, and flat or isoelectric trace in F. E and G are zoomed in examples of the raw trace from D and F respectively – note the changed scale. 
The spikes in G are heart rate artefact. Adapted from Bjorkman (2016). 
38 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Example of the beginning of a seizure. Repetitive, rhythmic “sawtooth” waveform beginning at the top arrow in raw EEG trace is accompanied 
by a sharp increase in the amplitude integrated electroencephalogram (aEEG) trace (bottom arrow).
aEEG 
Raw EEG 
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Table 2.1: Neurobehavioural scoring sheet 
Respiration 
Normal respiration = 2 
Oxygen required/laboured breathing = 1 
Intubated = 0 
Consciousness 
Fully conscious = 2 
Under effects of anaesthetic/drowsy  = 1 
Orientation 
Alert, looking at and investigating surroundings = 2 
Aware of surroundings but not investigating = 1 
Unaware of surroundings = 0 
Walking ability 
Walk in forward direction without falling = 2 
Walks in circles, backward or falls = 1 
Unable to walk = 0 
Forelimb control 
Raises quickly from a lying position and keeps together in upright position = 2 
Delayed use of one or both limbs = 1 
Unable to raise from lying position = 0 
Hind limb control 
Raises quickly from lying position and keeps together in upright position = 2 
Delayed use of one or both limbs = 1 
Unable to use hind limbs to raise from lying position = 0 
Limb Tone 
Equal and steady tone in all limbs when standing = 2 
Unsteady when standing = 1 
Unable to maintain standing position = 0 
Overall activity 
Normal activity when awake = 2 
Some activity when awake = 1 
No activity = 0 
Vocalisation 
Normal = 2 
Abnormal = 1 
Absent = 0 
Sucking reflex 
Present = 2 
Absent = 1 
Pathological movements 
Absence of pathologic movements = 2 
Occasional cycling or myoclonic jerks = 1 
Sustained clonic movements or tonic postures = 0 
TOTAL 
(max=22) 
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2.1.7 RECOVERY FROM ANAESTHESIA AND MONITORING 
Animals in chapters 4, and 5 were recovered from anaesthesia at 36h post-HI until 
euthanasia at 72h post-HI. At 36h post-HI anaesthesia was ceased and animals were 
recovered until such time they could be extubated. Animals were monitored until euthanasia 
at 72h post-HI (76-96h of life). During this time, animals were housed in pairs and fed 40–
50 mL of artificial pig milk every 3–4 h via orogastric tube (ProfeLAC ® milk replacer, 
ProviCo, AUS) Body temperature was monitored at each feed and maintained at normal 
body temperature of 38.5 ± 1.0°C. 
2.1.8 NEUROBEHAVIOURAL SCORING 
Animals were assessed every 4h from 48h until the end of the experiment (72h) with a 
neurobehavioural scoring system, adapted from: (Thoresen et al. 1996, Bjorkman et al. 
2010). The neurobehavioural scoring includes assessment for respiration, consciousness, 
walking and limb control, overall activity, and presence of seizures (Table 2.1). Any 
individual score less than 2 is considered abnormal, whereas any individual score less than 
1 is considered severely abnormal. 
2.1.9 SEIZURE MONITORING AND TREATMENT 
Animals were monitored for signs of clinical seizures while they were not under anaesthesia. 
Clinical seizures were defined as myoclonic jerks, rhythmic pathological movements (E.g. 
cycling), or tonic postures (Volpe 2008). Animals with clinical seizures were treated with 
anticonvulsants as per ethical guidelines. Piglets with clinical seizures were first dosed with 
20mg/kg of phenobarbitone, followed by subsequent midazolam doses (0.2mg/kg). Animals 
that had three severe clinical seizures as per our seizure scoring guidelines were 
euthanised. 
2.1.10 EUTHANASIA 
At the designated euthanasia time point, animals were sedated with 1-2% inhalational 
isofluorane (Bayer, NSW, AUS) and administered an overdose of lethabarb (I.P. 120 mg/kg, 
sodium pentobarbitone 325 mg/ml). Brains were flushed with ~250mL saline via an 
intracardiac injection and dissected from the skull. Brains were coronally sliced (3 mm) using 
an in-house brain mould and a skin graft knife and hemisected. Brains from animals injected 
with sodium fluorescein were kept protected from the light. The coronally-sliced right 
hemisphere (including the hippocampus/thalamus section) was immersion fixed in 4% 
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paraformaldehyde, 0.1 M phosphate buffered saline (PBS, pH 7.4) overnight (18-20h) at 
room temperature with agitation. Sections were then stored in 0.1% paraformaldehyde-
0.1 M PBS, until tissue processing through graded alcohols and xylenes for 20h and 
subsequent paraffin-embedding. The left hemisphere was dissected into regions of interest, 
snap frozen in liquid nitrogen and stored at −80°C. 
2.1.11 BACKGROUND PATTERN SCORING AND SEIZURE BURDEN ANALYSIS. 
30min (15min either side of the hour point) of EEG recording at 1, 2, 4, 8, 12, 24, 36, 48 and 
72h was analysed and the background pattern (from continuous normal voltage to flat trace) 
was determined as previously described (Hellstrom-Westas and Rosen 2006, Hellström-
Westas et al. 2006, Bjorkman 2016, Miller et al. 2016). aEEG with amplitudes of between 
10 and 25V was classified as continuous normal voltage (CNV). Discontinous normal 
voltage (DNV) was aEEG background patterns with variable amplitude, but a minimum 
voltage or <5V and a maximum >10V. Burst suppression was defined as background 
patterns with a minimum amplitude <5V with ‘bursts’ of activity >25V. Continuous low 
voltage is defined as background patterns with the maximum amplitude <5V, and flat trace 
was defined as completely inactive background <5V (Hellstrom-Westas and Rosen 2006). 
In term infants the predominant pattern of EEG activity is CNV, with brief periods of DNV, 
which may be more common following depressive medications such as anaesthetics or anti-
epileptic drugs (Hellstrom-Westas and Rosen 2006). Prolonged DNV or patterns that are 
predominantly BS or CLV are considered abnormal. Examples of the above EEG 
background patterns can be found in Figure 2.3. 
EEG data from 0h post-HI to approximately 36h post-HI, and data from 1h recordings at 48h 
and 72h post-HI were analysed by a single observer (KG) for presence of seizure. 
Electrographic seizures were defined as “repetitive, rhythmic waveforms with a distinct 
beginning and end with a duration >10 s” (Clancy and Legido 1987).  All electrographic 
seizures were manually annotated from the start of the seizure on either channel to the end 
of the seizure on either channel (Lynch et al. 2012). An example of the start of a typical 
seizure is shown in Figure 2.4. The total number of seizures, time to first seizure, average 
seizure duration, and total seizure burden (time spent in seizure), and maximal seizure 
burden (greatest seizure burden in a single hour epoch) were recorded (Lynch et al. 2012). 
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2.2 Laboratory Techniques 
2.2.1 HISTOPATHOLOGY 
Blocks of tissue were cut in 6mm sequential sections using a microtome on Menzel 
Superfrost plus slides. Tissue sections including parietal cortex and hippocampus were then 
dewaxed in xylene and rehydrated through graded alcohols. Sections were stained with 
haematoxylin and eosin with an automated system (Leica ST5010 Autostainer XL, Leica 
Biosystems North Ryde, NSW, AUS). Histological injury from two slides 48m apart for each 
brain region were scored by a blinded observer using validated scoring criteria (Bjorkman et 
al. 2006). Parietal cortex and hippocampus areas were assessed and scored, 0 = no injury, 
9 = maximum severe injury. Damage to individual neurons was scored 1-3, damage within 
a defined area or cortical later was graded 4-6 and damage to all cells within an area was 
scored 7-9 (Table 2.2). 
Table 2.2: Histopathological scoring system 
 
 
 
2.2.2 SODIUM FLUORESCEIN ASSAY 
Snap frozen parietal cortex and hippocampus brain samples were separately homogenised 
in a five x volume of sterile water. An equal volume of 60% trichloroacetic acid was added 
to the homogenate and gently mixed. The homogenate/acid mixture was incubated at 4°C 
for 30min and then centrifuged at 4°C for 10min at 14000 x g. The supernatant was diluted 
1:0.8 with 5M sodium hydroxide. Samples were added to a 96 well black walled, clear bottom 
assay plate (#3603, Corning Costar, distributed by Sigma Aldrich, NSW, AUS) along with a 
sodium fluorescein (NaFlsc) standard ranging from 10ng/mL to 1000ng/mL. The plate was 
Morphological changes % area affected Neuropathological score 
No injury 0 0 
Neuronal necrosis <20 1 
20-50 2 
>50 3 
Laminar necrosis <20 4 
20-50 5 
>50 6 
Confluent infarct <20 7 
20-50 8 
>50 9 
43 
 
read with an excitation of 495nm and emission of 525nm. Data is presented as ng of NaFlsc 
per mg tissue. 
2.2.3 TOTAL RNA EXTRACTIONS 
Snap frozen brain tissue (parietal cortex and hippocampus) (~30mg) was disrupted via 
mortar and pestle in the presence of liquid nitrogen and total RNA was extracted using a 
Macherey-Nagel nucleospin kit (Scientifix, VIC, AUS), according to the manufacturer’s 
instructions.  
2.2.4 cDNA SYNTHESIS 
2g of total RNA was treated with RQ1 Rnase-free DNase (cat#M6101, Promega, NSW, 
AUS) as per the manufacturer;s instructions. cDNA was synthesised from DNase-digested 
RNA with SuperScript III (Life Technologies, VIC, AUS), using random hexamers (New 
England Biolabs, distributed through Genesearch, QLD, AUS). 
2.2.5 ANNEALING TEMPERATURE OPTIMISATION 
Polymerase chain reaction (PCR) was performed prior to quantitative PCR (qPCR) to 
optimise the annealing temperature for each primer pair and confirm the presence of a single 
product. PCR was performed using BIOtaq DNA polymerase (Cat # BIO-21040, Bioline, 
Paris, France). 50L reactions consisting of biotaq polymerase buffer (final concentration 
1x), 1.5mM MgCl2, 0.2mM dNTPs, 0.5U of biotaq, 1m primer pair, and 2g cDNA. Thermal 
cycling conditions consisted of initial denaturation at 95°C for 5min, then 35 cycles of 95°C 
– 30s, 55-70°C gradient for 30s, and 72°C for 30s, followed by a final elongation at 72° C 
for 5min. Six temperatures were tested across a gradient (55, 56.2, 59.7, 63.4, 67.3, 69.6°C). 
PCR product was separated in a 2% agarose gel, post-stained with ethidium bromide and 
visualised on a Biorad XR+ Gel Documentation system (NSW, AUS). The annealing 
temperature of the brightest band for each primer pair was chosen for qPCR conditions. 
2.2.6 QUANTITATIVE POLYMERASE CHAIN REACTION 
Quantitative polymerase chain reaction (qPCR) was performed using a Rotor-Gene 6000 
(Qiagen, VIC, AUS). The total reaction volume was 20µL, containing 100ng cDNA, 10µL 
SYBR green PCR master mix (Invitrogen, QLD, AUS), and 2μM each of forward and reverse 
gene-specific primers (Sigma Aldrich, NSW, AUS: CLDN5, occludin (OCLN), ZO1, vascular 
endothelial growth factor 1 (VEGF), matrix metalloproteinase 2 (MMP2), transforming 
growth factor beta (TGF), cyclooxygenase 2 (COX2), tumour necrosis factor alpha (TNF), 
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C-C chemokine receptor type 5 (CCR5), C-X-C motif chemokine 10 (CXCL10), interleukin 
1 beta (IL1), interleukin 6 (IL6), interleukin 8 (IL8)). Reactions were incubated for 10min at 
95°C, followed by 40 amplification cycles (20s - 95°C, 30s - 55-65°C (annealing - primer 
specific), and 40s - 72°C). No template controls, and no SYBR controls were included in 
every run. Results were normalised to glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). Data were analysed using the DDCT method and presented as log fold changes 
(log(2)2^(DDCT)) plus SEM (Livak and Schmittgen 2001). Gene specific primers are 
detailed in Table 2.3.  
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Table 2.3: Quantitative polymerase chain reaction primers utilised in this study 
Gene 
Name 
Primer sequence (F,R) Relevance Efficiency Product 
Length 
(base 
pairs) 
Annealing 
Temp (°C) 
Accession 
number 
AQP4 CCACGGTTCATGGAAATCTT Water transport 86% 109 56 NM_00111042
3.1 
 
TCAGTCCGTTTGGAATCACA 
CCR5 TGGTCAGAGGAGCTGAGACA Chemokine 106% 86 60 NM_00100161
8.1 
 
AGAAGGGACTCGTCGTTTGA 
CLDN5 CTCTGCTGGTTCGCCAACA Tight junction 108% 75 60 NM_00116163
6.1 
 
CAGCTCGTACTTCTGCGACATG 
COX2  CCCAATTTGTTGAATCATTT Enzyme – 
inflammation 
related 
86% 119 56 NM_214321.1 
 
TCTCATCTCTCTGCTCTGGT 
CXCL10 CCCACATGTTGAGATCATTGC Chemokine 89% 168 55 NM_00100869
1.1 
CATCCTTATCAGTAGTGCCG 
GAPDH CTTCACGACCATGGAGAAGG Reference gene 90% 170 60 XM_00336156
8.3 
 
CCAAGCAGTTGGTGGTGCAG 
GLUT1 GCGGTTTTCTATTACTCCACAAGC Glucose transport 86% 122 55 XM_02109690
8.1 
 
TCCACCACGAACAGCGACAC 
IL1 GGCCGCCAAGATATAACTGA Cytokine 91% 70 58 NM_214055.1 
 
GGACCTCTGGGTATGGCTTTC 
IL6 ATCAGGAGACCTGCTTGATG Cytokine 109% 177 60 NM_00125242
9.1 
 
TGGTGGCTTTGTCTGGATTC 
Il8  GAAGAGAACTGAGAAGCAACAACA Cytokine 91% 99 60 NM_213867.1 
 
 
TTGTGTTGGCATCTTTACTGAGA 
MMP2 CTGTGCAATACCTGAACACC Enzyme – 
extracellular matrix 
breakdown 
112% 85 55 NM_214192.1 
 
TGCATCTTCTTTAGTGTGTCC 
OCLN ATCAACAAAGGCAACTCT Tight junction 112% 157 55 NM_00116364
7.2 
 
GCAGCAGCCATGTACTCT 
TGF CGAGCCCTGGATACCAACT Cytokine 97% 135 60 NM_214015.2 
 
GCAGAAATTGGCATGGTAG 
TNF CCAATGGCAGAGTGGGTATG Cytokine 87% 116 55 NM_214022.1 
 
TGAAGAGGACCTGGGAGTAG 
VEGFA CAACGACGAAGGTCTGGAGTG Angiogenesis 95% 155 55 NM_214084.1 
 
GCCTCGCTCTATCTTTCTTTGG 
ZO1 GAGGGCATTTCCCACGTTTC Tight junction 85% 256 55 XM_02109882
7.1 
 
GCTTTAGAGCCGAGTCCTTG 
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2.2.7 WESTERN BLOTTING 
Approximately 150mg of tissue of snap frozen parietal cortex and hippocampus was 
homogenised in a 10x volume of 1M Tris-hydrochloride with 0.5M 
ethylenediaminetetraacetic acid (EDTA) and centrifuged at 12,000 x g for 10min at 4°C. A 
bicinchoninic acid (BCA) assay was performed to estimate total protein concentrations 
(Cat#23225, Life Technologies, Thermo Fisher Scientific, AUS). Protein lysates were 
resolved on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels 
and transferred to polyvinylidene difluoride (PVDF) membranes (Table 2.4 for antibody 
specific methods).  
Table 2.4: Antibody specific methods for western blot detection. 
 IgG CLDN5 OCLN ZO1 
Catalogue Number 014-005-004 ab131259 ab222691 ab965587 
Supplier Jackson 
Immuno-
research 
Abcam Abcam Abcam 
Location PA, USA Vic, AUS Vic, AUS Vic, AUS 
Host species Goat Rabbit Rabbit Rabbit 
SDS-PAGE Gel % 10% 15% 10% 7.5% 
g of total protein 
loaded 
5g 5g 15g 15g 
Run voltage / time 150V / 60min 150V / 50min 150V / 60min 150V – 
90min 
Transfer Voltage / time 100V – 60min 100V – 60min 100V – 60min 100V – 
90min 
Primary Antibody 
concentration/time of 
incubation/temperature 
1:50000 / 2h / 
RT 
1:50000 / ON 
/ 4°C 
1:2500 / ON / 
4°C 
1:3000 / ON / 
4°C 
Secondary antibody 
concentration/time of 
incubation/temperature 
1:50000 / 1h / 
RT 
1:50000 / 1h / 
RT 
1:30000 / 1h / 
RT 
1:30000 / 1h 
/ RT 
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Abbreviations: immunoglobulin G (IgG), Claudin-5 (CLDN5), Occludin (OCLN), zoluna occludens 1 
(ZO1), Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-Page), overnight (ON), 
room temperature (RT). 
Following transfer, membranes were incubated with 5% skim milk powder in tris-buffered 
saline with 1% tween-20 (TBST) for 1h at RT to block non-specific binding sites. Membranes 
were then incubated with primary antibody as per Table 2.4. Following primary antibody 
incubation membranes were washed 3 x 10min in TBST and incubated with either anti-goat 
or anti-rabbit horseradish peroxidase (HRP) (#A0545 or #A5420, Sigma Aldrich, USA) 
(Table 2.4). Secondary antibody was washed with 2 x 10min TBST washes, and 1 x 10min 
TBS wash. Signal was developed with ECL luminata forte (WBLU0500, Merck, Victoria, 
AUS) and proteins of interest were visualised on Fuji Super-RX Film (Konica SRX-101A, 
distributed by Shimadzu, Queensland, AUS). A 4-point standard curve generated from each 
gel using a pooled standard was used for quantification (Goasdoue et al. 2016). 
Densitometry analysis was performed using Image J software (National Institutes of Health, 
MD, USA). 
2.2.8 IMMUNOHISTOCHEMISTRY 
 Immunofluorescence 
Paraffin-embedded 6m coronal sections were dewaxed and rehydrated (Leica Autostainer 
XL). Antigen retrieval was performed using Diva decloaker (pH 6.0, Biocare Medical, 
Queensland, AUS) or citrate buffer (pH 6) in a decloaking changer (80°C – 20min) (Biocare 
Medical). Sections were then blocked with phosphate buffered saline (PBS) containing 5% 
normal donkey serum (NDS), 2.5% bovine serum albumin (BSA), 0.5% triton-x-100 (TX-
100), and 0.1% tween-20 for 30min at RT. Sections were incubated with primary antibodies 
diluted in PBS containing 1% NDS, 0.5% TX-100, and 0.1% tween-20 (specific antibody 
details and incubation conditions in Table 2.5). Tissue sections were washed with TBST 
prior to incubation with appropriate species-specific secondary antibodies (AlexaFluor 488, 
594, 680; Invitrogen, Life Technologies, AUS, 1:1000) for 1h at RT in a dark humidifying 
chamber. Sections were counterstained with 4’,6-diaidino-2-phenylindole (DAPI, Invitrogen, 
Life Technologies, AUS), washed with TBST and mounted with Prolong Gold Antifade 
(#P10144, Invitrogen, Life Technologies, AUS).  Negative control sections omitting primary 
antibodies were processed in parallel. 
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Table 2.5: Antibody specific methods for immunohistochemistry protocols. 
Abbreviations: immunoglobulin G (IgG), Claudin-5 (CLDN5), zonula occludens 1 (ZO1), neuronal nuclei (NeuN), laminin (LAMA), overnight (ON), room 
temperature (RT).
 IgG CLDN5 ZO1 NeuN LAMA CD31 
Target Blood product Tight junction Tight junction Neurons Basement 
membrane of 
blood vessels 
Endothelial cells 
Catalogue 
Number 
014-005-004 ab131259 ab965587 ab177487 L8271 ab28364 
Supplier Jackson 
Immunoresearch 
Abcam Abcam Abcam Sigma Aldrich Abcam 
Location Pennsylvania, 
USA 
Victoria, AUS Victoria, AUS Victoria, AUS Missouri, USA Victoria, AUS 
Species Goat Rabbit Rabbit Rabbit Mouse Rabbit 
Antigen 
retrieval 
Diva or citrate Citrate Citrate Diva Diva Citrate 
Primary 
antibody 
dilution 
1:1000 1:1000 1:100 1:500 1:200 1:100 
Primary 
antibody inc: 
temp and time 
1h - RT ON – 4°C 2h – 37°C ON – 4°C ON – 4°C 2h – 37°C 
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 DAB Staining 
Tissue sections were prepared for staining as described above. Sections were incubated with 
goat anti-swine IgG (1:1000, Jackson Immunoresearch, #014-005-003, PA, USA) for 1h at RT 
in blocking solution (PBS with 5% NDS, 2.5% BSA, 0.5% TX-100, 0.1% tween-20). 
Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide for 15min at RT. 
Slides were then washed with TBST 3 x 10min and incubated with 1:500 goat biotin in PBS for 
1h at 37°C. Following biotin incubation, slides were washed with TBST 3 x 10min and incubated 
with 1:500 HRP avidin in PBS for 1h at RT. Slides were then washed with 3 x 10min TBST and 
metal enhanced 3,3’-diaminobenzidine (DAB) substrate (#34065, Merck, Victoria, AUS) was 
applied to slides for 1 min before being washed in water and mounted with DEPEX (Ajax 
FineChem, NSW, AUS). Sections were batch processed within a week of staining/labelling and 
negative control sections without primary antibodies was included in every run. 
 Double-labelling: Fluoro Jade-C and IgG 
Tissue sections were dewaxed and rehydrated as above. Antigen retrieval was performed using 
citrate buffer (pH 6) in a decloaking chamber (80°C - 20min). Sections were blocked with PBS 
containing 5% NDS, 5% BSA, 0.5% TX-100, and 0.1% tween-20 for 1h at RT. Slides were then 
incubated with goat-anti-Swine IgG (1:1000, Jackson Immunoresearch,  # 114-585-003, 594 
conjugated, PA, USA) was incubated in the blocking solution (PBS containing 5%NDS, 0.5% 
TX-100 and 0,1% tween-20) at 37°C for 1h. Cell nuclei were counterstained with DAPI. Slides 
were washed with TBST and incubated with 0.006% potassium permanganate in dH2O for 
2.5min at 50°C. Following washing, slides were stained with 0.0001% Fluoro Jade-C in 0.1% 
acetic acid for 15min. Slides were rinsed with dH2O, cleared with xylene and mounted with 
DEPEX. Imaging was performed within one week of staining. 
2.2.9 IMAGE ACQUISITION AND ANALYSIS 
Image acquisition was conducted using an Olympus FV3000 confocal laser scanning 
microscope equipped with 3 excitation diode laser lines (473, 559, and 635 nm) running 
Fluoview FV31S-SW (Version 2.3) (Olympus, Tokyo, Japan). Images were acquired at a 
resolution of 1024 x 1024 pixels using an Olympus UPlanFL N 40x oil NA = 1.30 objective or 
PlanApo N 60x oil NA = 1.4 objective and a scan speed of 2sec per pixel. ZO1 and CLDN5 
images were acquired with a z-step size of 0.3m. 
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Fluoro Jade-C stained slides were imaged with an Olympus BX41 light microscope with a DP70 
camera. IgG DAB stained slides were scanned with a Pannoramic SCAN II digital slide scanner 
by 3D HISTECH with a 20x Plan-apochromat objective. 
All images were processed with Adobe Photoshop. Fiji ImageJ (Schindelin et al, 2012) with the 
Cell Counter plugin (Image Processing and Analysis in Java; National Institutes of Health, 
Maryland, USA) was used for quantification of positively labelled cells. Cell counts were 
performed in five fields from each animal, in duplicate – areas of cell counting from lobe two of 
the parietal cortex are indicated in Figure 2.5. Lobe two was chosen because it is an area of 
vulnerability of neuronal damage in our model. 
 
Figure 2.5: Image indicating five fields of view in cortex for immunohistochemistry quantification. 
Lobe 2  
Lobe 3  
Lobe 1  
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CHAPTER 3 - THE TEMPORAL EVOLUTION OF BLOOD-
BRAIN BARRIER DISRUPTION IN A PIGLET MODEL OF 
NEONATAL HYPOXIC-ISCHAEMIC ENCEPHALOPATHY 
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3.1 Abstract  
Hypoxic ischaemic encephalopathy (HI) is a serious birth complication arising from insufficient 
oxygen and blood flow that can result in neonatal death or poor long term outcome. A key 
process that is incompletely understood in neonatal HIE is disruption to the blood brain barrier 
(BBB). We utilised a piglet model of neonatal HIE to address the question of whether BBB-
disruption occurs in this disease state and how it evolves over time. Piglets (<24h) were 
anaethetised, catheterised and ventilated, and inspired oxygen was reduced from 21% (air) to 
~4% for 30min. Piglets were recovered from hypoxia by returning inspired O2 to 21% and 
survived to 2, 4, 8, 12, or 24h post-HI. BBB-disruption was estimated by extravasation of an 
exogenous tracer molecule (sodium fluorescein) or endogenous serum protein (IgG). Protein 
level for claudin 5 (CLDN5), occluding (OCLN), and zonula occludens 1 (ZO1) was analysed 
with western blotting, immunofluorescence, and qPCR. qPCR was also used to quantify the 
expression of genes associated with BBB-disruption including vascular endothelial growth 
factor (VEGF), matrix metalloproteinase 2 (MMP2), and several inflammatory cytokines and 
chemokines.  
There was no significant difference in sodium fluorescein amount in parietal cortex or 
hippocampus between control and HI animals at any time-point. Similarly, there was no 
significant difference in IgG level in parietal cortex between control and HI animals at any time 
point. However, there was a significant increase in IgG level in hippocampus at 24h post-HI. 
Qualitatively, there appeared to be evidence of IgG extravasation to varying degrees in animals 
from every time point. Labelling patterns of IgG included leaks surrounding vessels, 
parenchymal labelling, and cell labelling. However, there was no consistent pattern over time. 
Tight junctions mRNA and protein were altered. CLDN5 mRNA was upregulated by HI, whereas 
ZO1 mRNA expression was downregulated. Protein alterations were also evident with OCLN 
protein level increasing in the early hours following HI, and decreasing back to control levels by 
24h. While ZO1 protein was significantly reduced at 8h post-HI. CLDN5 and ZO1 also appeared 
to have altered protein localisation at the vessel when assessed by immunofluorescence – 
particularly at 8h post-HI. VEGF mRNA expression was not altered following HI, but MMP2 was 
increased in the parietal cortex. mRNA expression of pro-inflammatory genes was substantially 
upregulated at early time-points and persisted over the 24h time-course. In particular, tumour 
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necrosis factor alpha and interleukins 1beta, 6, and 8 were significantly upregulated. In 
conclusion, there is evidence that BBB permeability is altered within the first 24h post-HI, tight 
junction expression and localisation are altered, and inflammation is substantially increased. 
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3.2 Introduction 
The BBB is the major interface between the brain and the systemic blood circulation. It is made 
up of endothelial cells forming tight cell-to-cell junctions (tight junctions) which restrict the 
paracellular movement of substances across the barrier and is supported by surrounding 
astrocytes, pericytes, microglia and neurons (Ballabh et al. 2004). The BBB has two primary 
roles – the first is protective by restricting invasion of neurotoxic and pathogenic substances 
into the brain. The second is to regulate the movement of ions, metabolites and nutrients in 
order to maintain the balance of the CNS microenvironment (Daneman and Prat 2015). These 
two actions are essential for the correct metabolic and neuronal function of the brain.  
Hypoxic ischaemic encephalopathy (HIE) is a leading cause of neonatal morbidity and mortality 
(Lawn et al. 2005, Pierrat et al. 2005, de Vries and Jongmans 2010) and affects 1-5 per 1000 
live term births in developed countries (Graham et al. 2008, Kurinczuk et al. 2010, Byford et al. 
2014). Birth asphyxia, which is the leading cause of HIE globally, accounts for approximately 
60% of all neonatal deaths (Shankaran et al. 2005) and surviving neonates with moderate to 
severe HIE have a significant risk of poor long term outcome: including cerebral palsy, epilepsy, 
or cognitive deficits (Shankaran et al. 2005). HIE results in substantial social cost for families, 
and is a financial burden on healthcare systems worldwide (Eunson 2015). One of the defining 
characteristics of HIE is that brain injury evolves over time. Hypoxia-ischaemia (HI) initiates an 
evolving cascade of pathological processes that contribute to cell death and poor outcome. 
There is increasing evidence that blood-brain barrier (BBB) disruption plays a role in HI brain 
injury but is incompletely understood in neonates. 
The BBB is a dynamic barrier than can respond to a variety of signals from the brain and the 
systemic circulation in both physiological and pathological conditions (Daneman 2012). BBB-
disruption is considered a major contributor to brain injury in a variety of central nervous system 
diseases pathologies, but relatively little is known about BBB-disruption in the neonatal HIE 
brain (Daneman 2012). Kumar and colleagues (2008) demonstrated that neonates with HIE 
have increased CSF/plasma ratios of albumin which indicated greater BBB permeability. 
Whereas Schiering and colleagues (2014) investigated histopathological changes in deceased 
infants with HIE and found immunoreactivity for albumin in the hippocampus – indicating 
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increased permeability of the BBB to the serum protein. However, the evolution of BBB-
disruption following neonatal HIE is incompletely understood. Much of what we understand 
regarding damage or alteration to the BBB following HI injury is derived from studies in adult 
models. However, many of the pathological responses to HI are developmentally determined 
and translation of data from adult studies should be applied with caution to neonates. The few 
studies that have investigated BBB-disruption in neonatal HI models have been performed in 
rodents (Chapter 1, Table 1.1). There are limited studies demonstrating BBB-disruption in large 
animal models and to our knowledge this is the first study to fully evaluate the evolution of BBB-
disruption in a large clinically relevant neonatal animal model. 
Better understanding the pathological processes that occur following neonatal HI is essential in 
developing new, effective therapies to protect the brains of newborns. Therefore, the aim of the 
current study was to characterise the evolution of BBB-disruption via analysis of BBB 
permeability, expression of the tight junctions, and mRNA changes of genes associated with 
BBB-disruption. 
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3.3 Methods 
3.3.1 ANIMALS 
Approval for this study was obtained from the University of Queensland Animal Experimentation 
Ethics Committee and carried out in accordance with National Health and Medical Research 
Council guidelines (Australia) (UQCCR/224/16/NHMRC) (Appendix 5). Care was taken to 
minimise the number of animals used and ensure no undue pain or distress. 31 newborn large-
white piglets (<24h old) with an average age of 12.4h (±6.22h) and average weight of 1.7kg 
(±0.24kg) were obtained from University of Queensland Gatton piggery. Animals were allocated 
to either postnatal day 0 (P0) control group (n=4), or HI group (n=27). 
3.3.2 HYPOXIC ISCHAEMIC INSULT PROTOCOL 
Animals were anaesthetized with a propofol/alfentanil mixture (propofol: Diprivan 1% 
AstraZeneca Pty Ltd., NSW, alfentanil (Rapifen): Pharmaceutical, VIC, AUS), intubated, 
ventilated, and catheterised with intravenous (I.V) and intra-arterial lines to enable fluid delivery 
and monitor arterial blood gases (ABGs). Hypoxia was induced (n=27) by reducing the fraction 
of inspired oxygen (FiO2) to 4% and adjusting as necessary (2-6%) to achieve and maintain 
low amplitude electroencephalography (LaEEG <5V) for a period of 30min. The insult was 
titrated to achieve blood gas parameters (arterial pH<7.0 or arterial base excess (ABE) <-12) 
and hypotension (mean arterial blood pressure (MABP) <30mmHg) was maintained for a period 
>10min. The HI insult was titrated to individual animal physiological responses to achieve 
moderate-severe survivable brain injury. 
At the conclusion of HI, animals were resuscitated in air (21% O2). Anaesthesia was reduced 
and maintained (4-12% propofol/alfentanil mix) until euthanasia at the designated time point. 
One hour prior to euthanasia, animals were administered 2mL/kg of a 4% solution of sodium 
fluorescein (NaFlsc) IV. Animals were euthanised at 2, 4, 8, 12, and 24h post-HI in this study. 
At the designated euthanasia point lethabarb (intraperitoneal IP 120mg/kg, sodium 
pentobarbitone 325mg/mL) was administered. Controls were collected on day of birth and 
euthanised by sedation with isoflourane and an overdose of lethabarb. Brains were flushed with 
~250mL saline via intracardiac perfusion, dissected from the skull, coronally sliced (3 mm) and 
hemisected. The right hemisphere was immersion fixed in 4% paraformaldehyde, 0.1 M 
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phosphate buffered saline (PBS, pH 7.4) overnight (18-20h) at room temperature with agitation, 
then stored in 0.1% paraformaldehyde-0.1 M PBS, until tissue processing (standard 20h tissue 
processing through graded alcohols and xylenes) and paraffin-embedding. For molecular 
studies, regions of interest (parietal cortex and hippocampus) were dissected from the left 
hemisphere, snap frozen in liquid nitrogen and stored at −80°C until analysis. 
3.3.3 EEG MONITORING AND BACKGROUND PATTERN SCORING 
Two-channel amplitude-integrated EEG (aEEG) was recorded for the entire duration animals 
were under anaesthesia (Unique CFM 6.0, Inspiration Healthcare, United Kingdom) (Bjorkman 
et al. 2010). Electrographic seizures were defined as “repetitive, rhythmic waveforms with a 
distinct beginning and end with a duration >10s” (Clancy and Legido 1987). aEEG Background 
pattern was scored in 15min epochs until 1.5h post-HI, and 30 min epochs (15min either side 
of the h) at 2, 4, 8, 12, and 24 post-HI or until scheduled euthanasia time-point. aEEG 
background pattern was determined as previously described (Bjorkman et al. 2006, Hellström-
Westas et al. 2006, Bjorkman 2016, Miller et al. 2016). Background patterns were classified 
from the aEEG trace as follows; continuous normal voltage, discontinuous normal voltage, burst 
suppression, continuous low voltage, flat trace (Hellström-Westas et al. 2006). 
3.3.4 SODIUM FLUORESCEIN ASSAY 
The NaFlsc assay was adapted from (Lenzser et al. 2005). Snap frozen brain samples from 
parietal cortex and hippocampus were homogenised in a 5x volume of water and an equal 
volume of 60% trichloroacetic acid was then added to the homogenate, and incubated at 4°C 
for 30min. Homogenate was then centrifuged for 15min at 10000 x g at 4°C. The supernatant 
was diluted 1:0.8 with 5M NaOH. Samples were analysed using a Tecan Spark 
spectophotometer at excitation of 495nm and emission of 525nm. Sodium fluorescein content 
was estimated by comparison with a standard curve (10ng/ml to 1000ng/ml sodium 
fluorescein). 
3.3.5 IMMUNOHISTOCHEMISTRY 
Coronal sections containing parietal cortex and hippocampus were dewaxed and rehydrated 
through graded alcohols. For immunofluorescence, antigen retrieval was performed using Diva 
decloaker (pH 6.0 Biocare Medical, QLD, AUS) (NeuN sections), or sodium citrate buffer (pH 
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6.0) (ZO1, CLDN5 sections) in a decloaking chamber (80°C - 20min) (Biocare Medical) (Table 
2.5, chapter 2). Sections were blocked with PBS containing 5% normal donkey serum (NDS), 
2.5% bovine serum albumin (BSA), 0.5% triton x-100 (TX-100), and 0.1% tween-20 for 1h. 
Incubations with primary antibodies diluted in PBS containing 1% NDS, 0.5% TX-100, and 0.1% 
tween-20 were carried out overnight at room temperature (RT) for mouse anti-NeuN (1:500 
Abcam #ab177487), goat anti-swine IgG (1:1000 Jackson Immunoresearch, #014-005-003) 
and rabbit anti-CD31 (1:100, Abcam, #ab28364) or at 37°C for 2h for rabbit anti-zonula 
occludens 1 (ZO1, 1:200 Abcam, #ab965587) and rabbit anti-claudin 5 (CLDN5, 1:1000 Abcam, 
#ab131259). Tissue sections were washed with TBS-tween-20 (TBST) prior to incubation with 
appropriate species-specific secondary antibodies (1:1000 AlexaFluor AF488, 568, 594, 680, 
Invitrogen, Life Technologies, AUS, 1:1000) for 1h in a dark humidifying chamber. Sections 
were counterstained with 4′,6-diamidino-2-phenylindole (DAPI; Invitrogen), washed with TBST 
and mounted with Prolong Gold Antifade (Invitrogen Life Technologies, AUS, #P10144). 
Negative control sections were processed in parallel. 
DAB staining was performed for whole section visualisation of IgG extravasation. Sections were 
incubated with goat anti-swine IgG (1:1000 Jackson Immunoresearch, Pennsylvania, USA, 
#014005003) for 1hr at RT in 5% NDS, 2.5% BSA, 0.5% TX-100, and 0.1% tween-20 in PBS. 
Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide for 15min at RT. 
Slides were washed in TBST and incubated with goat biotin (1:500 GE Healthcare, QLD, AUS) 
in PBS for 1h at 37°C. Slides were washed in TBST and incubated with HRP avidin (1:500 
Sigma Aldrich, NSW, AUS, #A3151) in PBS for 1h at RT.  Slides were then washed again in 
TBST and metal enhanced DAB substrate (Merck, VIC, AUS, #34065) was applied to slides for 
1min. Slides were rinsed in H2O, cleared with xylene and mounted with DEPEX (Ajax 
FineChem, NSW, AUS). Sections were processed in batches containing negative control 
sections. 
For assessment of neuronal degeneration slides were IgG labelled and stained with fluoro jade-
C (FJC) as follows. Sections were antigen retrieved using sodium citrate buffer (pH 6) in a 
decloaking chamber (80°C – 20min). Sections were blocked with 5% NDS, 2.5% BSA, 0.5% 
TX-100, and 0.1% tween-20 in PBS for 1h at RT. Primary antibody goat-anti-swine IgG (1:1000 
Jackson Immunoresearch, Pennsylvania, USA, #014585003) was incubated in the blocking 
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solution at 37°C for 1h. Cell nuclei were counterstained with DAPI. Slides were washed and 
incubated with 0.006% potassium permanganate in dH2O for 2.5min at 50°C. Following 
washing, slides were stained with 0.0001% FJC in 0.1% acetic acid for 15min. Slides were 
rinsed with dH2O, cleared with xylene and mounted with DEPEX. 
3.3.6 IMAGE ACQUISITION AND ANALYSIS 
Immunofluorescence image acquisition was conducted using an Olympus FV3000 confocal 
laser scanning microscope equipped with 3 excitation diode laser lines (473, 559, and 635nm) 
running Fluoview FV31S-SW (Version 2.3) (Olympus, Tokyo, Japan). Images were acquired at 
a resolution of 1024 by 1024 pixels using an Olympus UPlanFL N 40x oil NA = 1.30 or PlanApo 
N 60x oil NA = 1.4 objective and a scan speed of 2sec per pixel. For ZO1 and CLDN5 images 
were acquired with a z-step size of 0.3m. IgG DAB slides were scanned with a Pannoramic 
SCAN II digital slide scanner by 3D HISTECH with a 20x Plan-apochromat objective. FJC 
stained slides were imaged with an Olympus BX41 light microscope with a DP70 camera and 
a 40x objective. Fiji ImageJ (Schindelin et al. 2012) with the Cell Counter plugin (Image 
Processing and Analysis in Java; National Institutes of Health, Bethesda, MD, USA) was used 
for quantification of positively labelled cells. All imaging and image analysis was completed 
under blinded conditions. 
3.3.7 QUANTITATIVE POLYMERASE CHAIN REACTION 
Parietal cortex and hippocampal tissue (~30mg) were disrupted by mortar and pestle in the 
presence of liquid nitrogen and total RNA was extracted using a Macherey-Nagel nucleospin 
kit (Scientifix, VIC, AUS). 2μg of total RNA was treated with RQ1 Rnase-free DNase (Promega, 
NSW, AUS, #M6101) and cDNA was synthesised from DNase-digested total RNA with 
SuperScript III (Life Technologies, VIC), using random hexamers (New England Biolabs, 
distributed through Genesearch, QLD, AUS). Quantitative polymerase chain reaction (qPCR) 
was performed using a Rotor-Gene 6000 (Qiagen, VIC, AUS). The total reaction volume was 
20µL, containing 100ng cDNA, 10µL SYBR green PCR master mix (Invitrogen, QLD, AUS), 
and 2μM each of forward and reverse gene-specific primers (Sigma Aldrich, NSW, AUS: 
CLDN5, occludin (OCLN), ZO1, vascular endothelial growth factor 1 (VEGF), matrix 
metalloproteinase 2 (MMP2), transforming growth factor beta (TGF), cyclooxygenase 2 
(COX2), tumour necrosis factor alpha (TNF), C-C chemokine receptor type 5 (CCR5), C-X-C 
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motif chemokine 10 (CXCL10), interleukin 1 beta (IL1), interleukin 6 (IL6), interleukin 8 (IL8)). 
Reactions were incubated for 10min at 95°C, followed by 40 amplification cycles (20s - 95°C, 
30s - 55-65°C (annealing - primer specific), and 40s - 72°C). No template controls, and no 
SYBR controls were included in every run. Results were normalised to glyceraldehyde 3-
phosphate dehydrogenase (GAPDH). Data were analysed using the DDCT method and 
presented as log fold changes (log(2)2^(DDCT)) plus SEM (Livak and Schmittgen 2001). Gene-
specific qPCR primers are detailed in Chapter 2 – table 2.3. 
3.3.8 WESTERN BLOTTING 
Snap frozen tissue from parietal cortex or hippocampus was homogenised in a 5x volume of 
1M Tris-HCl with 0.5M EDTA and centrifuged at 12,000 x g for 10min (4°C). A BCA assay was 
performed on the supernatant to estimate total protein lysate concentrations (Life Technologies, 
Thermo Fisher Scientific, AUS, #23225). Protein lysates (5-15ug) were resolved on 7.5, 10, or 
15% SDS-PAGE gels (antigen specific) at 150V for 90min. Proteins were transferred to PVDF 
membrane (100V – 60min) and the membrane was then blocked for 1h at RT with 5% skim 
milk powder in TBST. Membranes were incubated with Goat anti-swine IgG (1:50,000 Jackson 
Immunologicals, PA, USA, #114-005-003) for 2h at RT or with CLDN5 (1:50,000 Abcam, 
ab131259), ZO1 (1:2500 Abcam, ab96587) or OCLN (1:3000 Abcam, ab222691) overnight at 
4°C. Following primary antibody incubation, membranes were washed in TBST. Membranes 
were incubated with anti-goat HRP (1:30,000 Sigma-Aldrich, #A0545) for 30min at RT (IgG) or 
with anti-rabbit HRP (1:30,000 #A5420, Sigma-Aldrich, USA) for 1h at RT (CLDN5, ZO1, and 
OCLN). Signal was developed with the use of enhanced chemiluminescence (ECL) Luminata 
forte (Merck, VIC, AUS, #WBLUF0500) and proteins of interest were visualised on Fuji Super-
RX Film (Konica SRX-101A, distributed by Shimadzu, QLD, AUS). A four point standard curve 
generated from each run using a pooled standard was used for quantification (Goasdoue et al. 
2016). Densitometry analysis was performed using ImageJ software (NIH, Maryland, USA). 
3.3.9 STATISTICAL ANALYSES 
Data were analysed with SPSS software (IBM Corp. SPSS Statistics 22.0, NY, USA). 
Physiological parameters were analysed with a one-way MANOVA. qPCR data (log(2) 2^(-
DDCT)) were analysed by a one-way ANOVA with a Tukey-Kramer post-hoc test. Western blot 
data were analysed by a one-way ANOVA with Tukey HSD post-hoc test. Significance was set 
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at p<0.05. Data are presented as means ± standard error of the mean (SEM) unless otherwise 
stated. 
3.4 Results 
3.4.1 ANIMALS WERE SUBJECTED TO A SIMILAR INITIAL HI INSULT 
Physiological data 
Thirty-one animals, including four controls and 27 HI animals were run as part of this study. 
One animal died prior to the scheduled euthanasia point due to complications from HI, seven 
others were excluded as they did not reach cut off physiological values to be deemed moderate 
to severely HI-injured. Physiological data for end insult parameters for the remaining animals 
(n=19) are shown in Table 3.1. Normal physiological values of control piglets are as follows: 
MABP of between 35-50mmHg, pH between 7.38 and 7.45, ABE between 1 and 5 mmol/L, 
PaCO2 between 35-45mmHg. There was no difference between any of the HI groups in terms 
of pre or end insult physiological parameters, indicating they received a similar initial HI insult.
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Table 3.1: Animal characteristics 
 
2h n=3 4h n=4 8h n=4 12h n=4 24h n=4 
MABP before insult (mmHg) 
 
39.67 (3.21) 39.5 (6.95) 39.5 (5.32) 40.5 (11.03) 40.5 (3.51) 
MABP end insult (mmHg) 
 
19 (8.72) 18 (7.87) 22.25 (9.54) 20.5 (7.23) 14.5 (2.65) 
Time hypotensive during insult 11.17 (7.97) 16.90 (7.31) 13.67 (8.42) 14.63 (12.58) 15.94 (5.41) 
pH before insult 
 
7.42 (0.04) 7.43 (0.11) 7.46 (0.03) 7.44 (0.05) 7.42 (0.02) 
pH end insult 
 
7.01 (0.08) 7.09 (0.03) 7.04 (0.06) 7.04 (0.03) 7.06 (0.05) 
ABE before insult 
 
2.77 (3.35) 2.13 (6.60) 4.2 (0.25) 1.1 (2.64) 1.6 (0.59) 
ABE end insult (mmol/L) 
 
-18.17 (5.49) -15.58 (2.52) -15.63 (3.35) -17.3 (4.25) -17.35 (1.69) 
pCO2 before insult (mmHg) 
 
38.33 (4.83) 39.85 (2.60) 39.85 (4.09) 37.2 (2.18) 41.14 (3.72) 
pCO2 end insult (mmHg) 
 
48.23 (11.58) 46.3 (11.2) 54.98 (6.29) 47.78 (13.70) 42.98 (1.92) 
pO2 before insult 104.8 (22.1) 109.9 (26.8) 131.8 (2.3) 100.7 (13.0) 96.1 (1.78) 
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MABP: mean arterial blood pressure, mmHg: millimetres mercury, ABE: arterial base excess, mmol/L: millimoles per litre, PaCO2: partial 
pressure carbon dioxide
pO2 after insult 15.7 (2) 22.2 (8.4) 36.8 (13) 19.4 (8.1) 20.6 (4.8) 
Total insult duration 29.01 (2.83) 32.30 (6.18) 29.83 (4.55) 30.93 (3.14) 31.48 (2.87) 
Total time under anaesthesia 
(h) 
4.22 (0.21) 6.25 (0.19) 10.15 (0.13) 14.23 (0.13) 26.12 (0.07) 
Number of seizures 0 0 0 1 0 
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Recovery from HI 
In order to assess if animals responded to HI insult and recovered in the same way, 
physiological parameters of pH and ABE were assessed throughout the HI insult and during 
recovery. The evolution of pH and ABE values during HI and into recovery for the five HI 
groups are shown in Figure 3.1. Insult and recovery pH and ABE values up to 12h post-
insult did not differ between any of the HI groups. 
 
Figure 3.1: Physiological parameters during hypoxia ischaemia (HI) and recovery: pH (A), arterial 
base excess (B) for each of the HI groups (2, 4, 8, 12, and 24h post-HI). Data are presented as 
group means±SEM. 
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aEEG background pattern scoring 
Background aEEG pattern was examined and scored to assess brain activity following HI. 
Background pattern aEEG scores are a robust indicator of short and longer term brain 
outcome in neonates with HIE (Nash et al. 2011, Weeke et al. 2016). Background pattern 
aEEG scores for HI animals are presented in Figure 3.2. As expected, background pattern 
scores between HI groups were not significantly different at any time point, indicating 
animals responded to HI and recovery in a similar manner. In general, scores for animals in 
all groups decreased as expected from a score of 4 (continuous normal voltage) prior to HI 
to a score between 0 and 1 (flat trace and continuous low voltage) for the first hour post-HI. 
Scores generally improved over the course of the next 6-8h before the onset of secondary 
energy failure (Chapter 1.1.2) and a decline in brain activity as demonstrated by animals in 
the 24h group. However, the 8h group did not improve as expected from approximately 1.5h 
post-HI to the scheduled euthanasia point at 8h post-HI, instead animals remained at a score 
of 1 (indicating continuous low voltage). 
 
Figure 3.2: Amplitude integrated electroencephalogram background pattern scores across time for 
hypoxic ischaemic animals. 
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3.4.2 ANIMALS WITH HI HAVE INCREASED BBB PERMEABILITY FOLLOWING HI 
Sodium Fluorescein Assay 
Sodium fluorescein (NaFlsc) is an exogenous, small molecular weight tracer molecule that 
can be injected into the systemic circulation and under normal physiological conditions is 
excluded from the brain (Kozler and Pokorny 2003). We investigated the presence of NaFlsc 
in parietal cortex and hippocampus tissue samples as a measure of BBB permeability. We 
found NaFlsc was present in HI animals at every time-point (Figure 3.3), with a peak 
infiltration at 8h in both brain regions. However, low levels of NaFlsc was also detected in 
control animals and there was no significant difference between control levels and NaFlsc 
in HI animals at any time-point.  
Figure 3.3: Sodium fluorescein (NaFlsc) amount (ng/mg brain tissue) in parietal cortex (A) and 
hippocampus (B) in animals following hypoxia ischaemia (HI) (2-24h) and in controls with NaFlsc 
injected (+ cont) and without NaFlsc injected (- cont). Negative control n=2, control n=3, 2h post-HI 
n=3, all other HI groups n=4. Data are presented as mean±SEM. 
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IgG extravasation into brain tissue 
We investigated the presence of serum-IgG as a marker of BBB-disruption using 
immunohistochemistry to grossly evaluate if the BBB was more permeable to IgG at any 
time-point. We found IgG staining in some animals appeared substantially greater than 
controls (Figure 3.4). IgG staining was quite variable within groups and in the early hours 
post-HI (2-8h). Within the 2h post-HI group, patterns of staining were inconsistent with 
significant extravasation in cortical regions and parts of the hippocampus in one animal, 
focal areas of intense staining in another, and lack of IgG staining similar to control brains 
in the third. While there was still some variability, between 8 and 24h post-HI there was 
progressively greater IgG extravasation into brain tissue. Common areas of vulnerability 
include intragyral white matter, subcortical white matter, periventricular white matter, and 
the area between lobes 2 and 3. 
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Figure 3.4: BBB permeability to Immunoglobulin G is altered by neonatal hypoxia ischaemia (HI). 
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Parietal cortex and hippocampus in control brain have very little evidence of IgG staining. However, 
HI show areas of IgG extravasation which is variable between 2-4h post-HI, but progressively more 
severe between 8 and 24h post-HI. Intragyral, subcortical and periventricular white matter IgG 
vulnerability is indicated by an arrow, whereas extravasation between lobes 2 and 3 is indicated by 
*. Tissue processing artefacts are denoted with +. Control n=3, 2h post-HI n=3, all other HI groups 
n=4. 
 
Western blot estimation of IgG in brain tissue 
Western blotting was performed in order to quantify the level of IgG extravasation into 
parietal cortex and hippocampus. Figure 3.5 shows changes to IgG level across time 
following the HI insult in parietal cortex (Figure 3.5A) and hippocampus (Figure 3.5B). 
Greater levels of IgG were observed in HI animals in both brain regions compared with 
controls, however, the temporal pattern of IgG protein differed between groups. Although 
not significant, in parietal cortex there is an initial peak at 2h post-HI, followed by a decrease 
at 4h post-HI and progressive increase from 8 to 24h post-HI. Whereas in the hippocampus, 
IgG protein level progressively increased from 2 to 24h post-HI, with 24h post-HI significantly 
different from P0 control levels. 
Figure 3.5: Immunoglobulin G (IgG) protein level in parietal cortex (A) and hippocampus (B) for P0 
control, and animals 2-24h post-hypoxia ischaemia. Data are presented as mean±SEM. Control n=4, 
2h post-HI n=3, all other HI groups n=4. Significantly different from sham is indicated by * (p<0.05). 
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IgG labels in distinct ways in hypoxic ischaemic animals 
Due to the variability of IgG staining and apparent areas of vulnerability, we further 
interrogated IgG extravasation patterns using immunofluorescence. We noted several 
different types of IgG labelling in our HI groups and examples of different labelling patterns 
are shown in Figure 3.6. The predominant pattern, occurring in every HI animal, was 
perivascular labelling (Figure 3.6 A-D), where IgG labelled vessel walls as determined by 
morphology, and proximity to endothelial cell labelling with CD31. 17 of the 19 HI animals 
also had evidence of ‘halo leaks’ – in which intense staining surrounded vessels – and 
parenchymal staining in which IgG labelled the parenchyma without any obvious point of 
origin (Figure E-H). There was no consistent change in frequency or number of halo leaks 
across time. Whereas 12 of the 19 HI animals had neuronal cell labelling as evidenced by 
co-localisation with NeuN (a neuronal marker) (Figure 3.6 I-L). IgG labelling of neurons 
occurred more commonly in animals from 12 and 24h post-HI groups, as was more severe 
in these animals. IgG labelling was rare in control animals and predominantly constrained 
to within blood vessels (Figure 3.6 M-P). 
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Figure 3.6: Immunoglobulin G (IgG) labelling patterns in parietal cortex in animals following hypoxia 
ischaemia (A-L) and control animals (M-P). IgG (A, E, I, M) labels in distinct patterns; These include 
perivascular labelling (A-D) as demonstrated by labelling near blood vessels (arrow) (indicated by 
CD31 – B, N) which was found to be evident in every HI animal from every time-point. ‘Halo’ leaks 
surrounding blood vessels (*) and parenchymal IgG labelling was also frequently evident in HI 
animals (E-H), patches in earlier time-points (2-8h) rarely had evidence of cell staining (indicated by 
lack of colocalisation with NeuN, F). Neuronal IgG labelling (arrowhead) was evident strongly at 12 
and 24h post-HI (I-L) as evidenced by co-labelling with NeuN (J). Control animals rarely labelled with 
IgG (M-P) and the small evidence of IgG labelling was constrained to within vessels. Scale bars 
100m, except cropped sections (D, H, and L) where scale bars = 50m.  
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IgG is associated with degenerating neurons 
Given some cells appeared to label with IgG, and that IgG uptake is associated with cellular 
damage, we co-labelled parietal cortex tissue sections with FJC – a marker of degenerating 
neurons. Example images from 2, 12, and 24h groups for FJC staining and IgG labelling are 
shown in Figure 3.7. We found that in general the numbers FJC+ cells increased over time 
from 25.1 cells/mm2 on average in control animals, to 440.6 cells/mm2 on average in 24h 
post-HI animals (Figure 3.7J). Numbers of IgG+ cells were also substantially greater at 12 
and 24h post-HI groups than earlier time points at 128.6 (12h) and 112.8 (24h) cells/mm2 
versus between 1.4 (4h) and 21.4 (2h) cells/mm2 (Figure 3.7K). IgG+ cells from all time-
points reliably co-localised with FJC. The percentage of IgG+ cells that co-localised with 
FJC was between 60% (4h) and 93% (2h). 
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Figure 3.7: Fluoro jade-C (FJC) and IgG co-localisation and quantification in animals at 2, 12, and 
24h post hypoxia ischaemic (HI) insult. Parietal cortex from animals 2h (A-C), 12h (D-F), and 24h 
(G-I) shows that FJC in general stains more neurons over time (A, D, G). IgG+ neurons, however, 
are rare at 2-8h post-HI and substantially elevated at 12 and 24h post-HI. Quantification of co-
localised neurons in control (n=4), 2h (n=3), 4h (n=4), 8h (n=4), 12h (n=4), and 24h (n=4) are shown 
in J. Data are presented as mean±SEM. 
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3.4.3 ALTERATIONS TO TIGHT JUNCTIONS 
Hypoxia ischaemia changes the mRNA expression of tight junctions 
Tight junction mRNA and protein expression of CLDN5, OCLN, and ZO1 was investigated 
to explore possible mechanisms of increased BBB permeability. mRNA expression 
alterations for the tight junctions are shown in Figure 3.8. In the parietal cortex, CLDN5 
expression upregulated over time to be significantly increased at 24h post-HI compared with 
control animals and the 2h post-HI group (p<0.01 cf. control, p<0.05 cf. 2h HI group) (Figure 
3.8A). In the hippocampus, CLDN5 mRNA expression was upregulated between 4 and 24h 
post-HI when compared with control mRNA levels (p<0.05), with the most substantial 
change occurs at the 8h time-point (p<0.001) (Figure 3.8B). There is no significant 
difference in the mRNA expression of OCLN compared with control animals at any time-
point, in either brain region (Figure 3.8C-D). Whereas ZO1 in the parietal cortex was 
significantly downregulated at the 8h time-point when compared with controls, and the other 
HI groups (8h HI group cf. controls and 24h HI group p<0.001, 8h group cf. 2, 4, and 12h HI 
groups p<0.05) (Figure 3.8E). In the hippocampus, ZO1 mRNA expression was significantly 
downregulated at 4 and 8h post-HI compared with the control group and the 24h post-HI 
group (4h group cf. control and 24h group p<0.01, 8h group cf. control and 24h group 
p<0.05) (Figure 3.8F). 
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Figure 3.8: Expression changes for tight junction genes claudin 5 (CLDN5) (A&B), occludin (OCLN) 
(C, D), and zonula occludens 1 (ZO1) (E, F) between animals 2-24h post-HI compared with P0 
controls in parietal cortex (A, C, E), and hippocampus (B, D, F). Significantly different from P0 control 
is indicated by *, different from 2h post-HI is indicated by #, different from 4h post-HI with +, different 
from 8h group is denoted by +, different from 12h group is denoted by Ø, different from 24h group 
by ¥. Significance level is indicated by the number of times the symbol appears (* p<0.05, ** p<0.01, 
*** p<0.001). 
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Hypoxia ischaemia changes the protein level of tight junctions 
Analysis of protein changes of CLDN5, OCLN, and ZO1 was performed by western blot and 
protein changes are shown in Figure 3.9. There was no significant alteration to CLDN5 
protein level in either parietal cortex or hippocampus at any time-point (Figure 3.9A-B). 
There was a significant increase in OCLN protein level in parietal cortex in the first 4h after 
HI. This was significant at 4h post-HI compared with both control and the 24h group 
(p<0.05), whereupon protein levels returned to control levels (Figure 3.9C). There was no 
significant change in OCLN protein in the hippocampus (Figure 3.9D). ZO1 protein in the 
parietal cortex was significantly reduced at 8h post-HI compared with control animals 
(p<0.05), returning to near control levels at 12h post-HI, but decreasing again at 24h – 
although this was not significant (Figure 3.9E). Whereas, ZO1 protein level in the 
hippocampus appeared to increase over time, however this was not significant (Figure 
3.9F). 
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Figure 3.9: Protein changes over time following hypoxia ischaemia (HI) for claudin 5 (CLDN5) (A, 
B), occludin (OCLN) (C, D), and zonula occludens 1 (ZO1) (E, F). Protein changes for parietal cortex 
are shown in A, C, and E, protein changes for hippocampus are shown in B, D, and F. Significantly 
different from control is denoted by *, significantly different from 24h post-HI is denoted by ¥ (p<0.05). 
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Hypoxia ischaemia alters tight junction localisation 
We further investigated two of the tight junction proteins (CLDN5 and ZO1) using 
immunofluorescence to assess if HI affected localisation of the proteins. Parietal cortex from 
controls, 8h, and 12h post-HI groups for CLDN5 was assessed, and control, 8h, and 24h 
post-HI animals were investigated for ZO1. The antibody for OCLN could not be optimised 
for immunofluorescence. CLDN5 in control animals labelled vessels in control brain in 
distinct, thin strands. The majority of CLDN5 labelling in the HI animals appeared unchanged 
from controls, even in groups that had lower total CLDN5 levels indicated by the western 
blots (Figure 3.10 A, C). However, we did identify patches in animals from the 8h post-HI 
group where CLDN5 labelling appeared weak and diffuse, without clear strands of protein 
(Figure 3.10B). ZO1 labelling in controls was also evident in distinct, linear patterns (Figure 
3.10D), whereas loss of ZO1 was evident in patches. This was particularly evident again in 
the 8h group, confirming western blot protein analysis (Figure 3.10E). ZO1 labelling at 24h 
most resembles control patterns, however, gaps in the labelling along vessels was evident 
(Figure 3.10F).
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Figure 3.10: Hypoxia ischaemia alters tight junction localisation. Claudin 5 (CLDN5) (A-C) and Zonula-occludens 1 (ZO1) (D-F) immunofluorescence 
in control (A, D), 8h post-hypoxia ischaemia (HI) (B, E), and 12 or 24h post-HI (C or F). 2D projections of z-stacks obtained by confocal microscopy. 
Areas of diffuse CLDN5 labelling are indicated by an open arrow. Areas of gaps in ZO1 labelling are indicated by closed arrows.
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3.4.4 MEDIATORS OF BLOOD-BRAIN BARRIER DISRUPTION  
VEGF is a growth factor that is involved in vasculogenesis, and angiogenesis. Its presence 
has been implicated in pathologies with BBB-disruption and associated with increased 
permeability of the BBB. In our study, mRNA expression of VEGF was not altered compared 
with control in either the parietal cortex (Figure 3.11A), or hippocampus (Figure 3.11B).  
MMP2 is a proteolytic enzyme that is associated with degeneration of the basement 
membrane of the neurovascular unit, and BBB-disruption. MMP2 mRNA expression in the 
parietal cortex appears to upregulate over time; MMP2 mRNA is significantly upregulated at 
both 12h (p<0.05) and 24h post-HI (p<0.01) compared with control animals. MMP2 
expression at 12 and 24h was also upregulated compared with 2 and 8h groups (12h cf. 2h 
and 8h groups p<0.05) (24h group cf. 2h and 12h groups p<0.01) (Figure 3.11C). However, 
MMP2 mRNA expression in the hippocampus does not follow the same pattern of 
upregulation (Figure 3.11D). MMP2 mRNA expression at 4h post-HI decreases in 
expression compared with the control, and 12 and 24h groups (p<0.05). 
Aquaporin 4 (AQP4) and glucose transporter 1 (GLUT1) are important transporters at the 
BBB. AQP4 perturbations are implicated in oedema formation following pathology, and 
GLUT1 alterations reduce the availability of glucose to the brain. We identified minimal 
changes to GLUT1 expression in parietal cortex (Figure 3.11E) and hippocampus (Figure 
3.11 F). The only significant alteration was a slight upregulation at 24h in the parietal cortex 
compared to mRNA expression at 2 and 8h (p<0.05), however there was no significant 
difference between any HI time-point and the control group. Similarly, AQP4 was not 
significantly altered compared with the control group at any time-point, however, in the 
parietal cortex APQ4 expression was lower at 8h post-HI compared with 4 and 24h (8h group 
cf. 4h group p<0.05, 8h group cf. 24h group p<0.01) (Figure 3.11 G). Whereas in the 
hippocampus AQP4 expression was increased at 24h compared with 4 and 8h animals 
(p<0.05) (Figure 3.11H). 
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Figure 3.11: Gene expression changes of genes associated with blood-brain barrier dysfunction 
across time following hypoxia ischaemia (HI). mRNA alterations in control and HI animals (2-24h 
post-HI) for vascular endothelial growth factor (VEGF) (A, B), matrix metalloproteinase 2 (MMP2) 
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(C, D), glucose transporter 1 (GLUT1) (E, F), and aquaporin 4 (AQP4) (G, H) in parietal cortex (A, 
C, E, , G) and hippocampus (B, D, F, H). Significantly different from sham is denoted by *, 
significantly different from 2h group is denoted by #, significantly different from 4h group is denoted 
by ^, significantly different from 8h group is denoted by +, significantly different from 12h group is 
denoted by Ø, significantly different from 24h group is denoted by ¥. Significance level is indicated 
by the number of times the symbol appears (* p<0.05, ** p<0.01, *** p<0.001). 
 
3.4.5 HYPOXIA ISCHAEMIA RESULTS IN SUBSTANTIAL ALTERATIONS TO PRO-
INFLAMMATORY GENE EXPRESSION 
Inflammation has been shown to be strongly related to BBB-disruption in a number of CNS 
pathologies. There is strong evidence that BBB-disruption can exacerbate inflammation, and 
evidence that inflammation can worsen BBB-disruption (Chapter 1). We therefore 
investigated the expression of inflammatory chemokines and cytokines that have previously 
been associated with BBB-disruption and increased BBB permeability. Alterations to the 
mRNA expression of inflammatory cytokines and chemokines in animals between 2 and 24h 
post-HI and control animals for parietal cortex are demonstrated in Figure 3.12, and for 
hippocampus in Figure 3.13. 
TGF is an anti-inflammatory cytokine, its release is proposed to stimulate long-term repair 
(Zhang et al. 2012). Despite this, TGF has been shown to exacerbate BBB permeability 
through regulation of MMP, and direct effects on CLDN5 expression (McMillin et al. 2015). 
TGF in the parietal cortex was significantly upregulated compared with control at every HI 
time-point (p<0.05-0.001) (Figure 3.12A). TGF appears to become more upregulated over 
time; TGF mRNA is significantly greater at 12h compared with 2h (p<0.01), and 8h post-HI 
(p<0.05), and mRNA expression is further increased at 24h post-HI compared with 2h 
(p<0.01), 4h (p<0.05), and 8h post-HI (p<0.01). TGF mRNA expression in the hippocampus 
follows a similar pattern to the parietal cortex – becoming upregulated over time. TGF 
mRNA expression in the hippocampus is significantly increased at 12h and 24h post-HI 
compared with control (p<0.05), and significantly increased at 24h post-HI compared with 4 
and 8h HI groups (p<0.05) (Figure 3.13A). 
COX2 is thought to play a role in BBB-disruption through its regulatory effects on other 
cytokines such as TNF, and regulation of MMPs (Candelario-Jalil et al. 2007). We 
observed substantial upregulations of COX2 mRNA in the parietal cortex at 12 and 24h post-
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HI, however, this was not significant (Figure 3.12B). In the hippocampus, however, COX2 
mRNA expression was found to be significantly upregulated at 2 and 4h post-HI compared 
with control animals (p<0.05) and returns to control levels by 8h post-HI (2h cf 8h group 
p<0.05, 4h cf 8h group p<0.05) (Figure 3.13B). 
TNF is a cytokine believed to play a vital role in both the inflammatory cascade following 
neonatal HI, and BBB-disruption. Treatment with TNFa decreases endothelial cell electrical 
resistance, enhances leukocyte migration, and alters BBB permeability to serum proteins 
(Anda et al. 1997, De Vries et al. 1996, Wong et al. 2007, Rosenberg et al. 1995). Parietal 
cortex TNF mRNA expression was found to be significantly upregulated at every time-point 
compared with control animals (p<0.05-0.001). In addition, 24h animals have a greater 
upregulation than 4h post-HI (p<0.05) (Figure 3.12C). In the hippocampus, TNF mRNA 
expression was found to be significantly upregulated in 12h and 24h animals compared with 
the control group (12h group cf. control group p<0.01, 24h group cf. control group p<0.001). 
The 24h group was also significantly upregulated compared with the 4 and 8h HI groups 
(p<0.05) (Figure 3.13C). 
CCR5 is a chemokine that has been implicated in enhancement of immune cell migration 
across the BBB (Glass et al. 2005). CCR5 mRNA expression was not found to be statistically 
different at any time in either parietal cortex (Figure 3.12D), or hippocampus (Figure 3.13D). 
CXCL10 is also a chemokine, important for trafficking of immune cell infiltration across the 
BBB (Anthony et al. 1998). CXCL10 has also been shown to cause tight junction protein 
alterations (Wang et al. 2018). CXCL10 mRNA expression was significantly upregulated 
compared with control at every time point (p<0.001 except 12h where p<0.01) in both 
parietal cortex (Figure 3.12E) and hippocampus (Figure 3.13E). In the parietal cortex, the 
most substantial change was found at 2 and 4h post-HI; CXCL10 was significantly more 
upregulated at 2h than at 8 or 24h post-HI (2h group cf 8h group p<0.05, 2h group cf. 24h 
group p<0.01) and significantly higher at 4h than 8, 12, or 24h post-HI (p<0.05). 
IL1 plays a major role in inflammation-induced BBB-disruption. IL1causes enhanced 
immune cell migration across the BBB, decreased endothelial cell electrical resistance, and 
BBB permeability changes to serum proteins (Anthony et al. 1998, de Vries et al. 1996). 
IL1 in the parietal cortex was found to be significantly upregulated compared with control 
animals at 2, 8, 12, and 24h post-HI (p<0.001 except 8h where p<0.01) (Figure 3.12F). 12 
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and 24h groups also had significantly greater upregulation of IL1 at 12 and 24h post-HI 
compared with 4 and 8h post-HI indicating there is a biphasic pattern of IL1 mRNA 
expression. Whereas in the hippocampus, IL1 mRNA was upregulated compared with 
control at 4, 12, and 24h post-HI (p<0.05) (Figure 3.13F). 
IL6 has both pro- and anti-inflammatory effects in the CNS, but also plays a role in BBB 
permeability through tight junction disorganisation (Desai et al. 2012, Cohen et al. 2012). 
IL6 was found to be significantly upregulated at 12h post-HI compared with control animals 
(p<0.01) and the 4h group (Figure 3.12G). Although not significant, IL6 was also 
substantially upregulated at 2 and 24h post-HI. There was no significant difference in IL6 
mRNA level found in the hippocampus, although IL6 does appear to increase over time 
(Figure 3.13G).  
IL8 plays an important role in the inflammation cascade following neonatal HI, but less is 
known about its effects on the BBB, however, IL8 has been associated with BBB-disruption 
in patients with TBI (Kossmann et al. 1997, Savman et al. 1998). IL8 mRNA expression in 
the parietal cortex was upregulated compared with control mRNA levels at every time-point 
(p<0.001), and 24h was more upregulated than 4h post-HI (p<0.05) (Figure 3.12H). 
Whereas, IL8 mRNA expression in the hippocampus was upregulated compared with control 
animals at every time-point except 2h post-HI, despite a substantial increase in expression 
at this time-point (p<0.01) (Figure 3.13H). 
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Figure 3.12: Gene expression changes of inflammatory cytokines and chemokines in the parietal 
cortex in the first 24h after hypoxia ischaemia (HI). mRNA expression changes for inflammatory 
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cytokines and chemokines associated with blood-brain barrier disruption in animals 2, 4, 8, 12, and 
24h post-HI. Data are presented as log fold change ± SEM. Significantly different from sham is 
denoted by *, significantly different from 2h group is denoted by #, significantly different from 4h 
group is denoted by ^, significantly different from 8h group is denoted by +, significantly different 
from 12h group is denoted by Ø, significantly different from 24h group is denoted by ¥. Significance 
level is indicated by the number of times the symbol appears (* p<0.05, ** p<0.01, *** p<0.001). 
Transforming growth factor beta (TGF) (A), cyclooxygenase 2 (COX2) (B), tumour necrosis factor 
alpha (TNF) (C), C-C chemokine receptor type 5 (CCR5) (D), C-X-C motif chemokine 10 (CXCL10) 
(E), interleukin 1 beta (IL1) (F), interleukin 6 (IL6) (G), interleukin 8 (IL8) (H). 
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Figure 3.13: Inflammatory gene mRNA changes in the hippocampus in the first 24h after hypoxia 
ischaemia (HI). mRNA expression changes for inflammatory cytokines and chemokines associated 
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with blood-brain barrier disruption in animals 2, 4, 8, 12, and 24h post-HI. Data are presented as log 
fold change ± SEM. Significantly different from sham is denoted by *, significantly different from 2h 
group is denoted by #, significantly different from 4h group is denoted by ^, significantly different 
from 8h group is denoted by +, significantly different from 12h group is denoted by Ø, significantly 
different from 24h group is denoted by ¥. Significance level is indicated by the number of times the 
symbol appears (* p<0.05, ** p<0.01, *** p<0.001). Transforming growth factor beta (TGF) (A), 
cyclooxygenase 2 (COX2) (B), tumour necrosis factor alpha (TNF) (C), C-C chemokine receptor 
type 5 (CCR5) (D), C-X-C motif chemokine 10 (CXCL10) (E), interleukin 1 beta (IL1) (F), interleukin 
6 (IL6) (G), interleukin 8 (IL8) (H). 
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3.5 Discussion 
In this chapter BBB-disruption was assessed in our pre-clinical, large animal model of 
neonatal HIE. To do this I described the extravasation of an exogenous (fluorescein) and an 
endogenous (IgG) substance from the systemic circulation into brain parenchyma. In 
addition, we investigated mRNA and protein expression changes of several tight junctions 
of the microvascular endothelial cells which are essential for normal BBB paracellular 
movement restriction. The evolution of inflammation over time was also assessed via qPCR 
due to its close relationship with BBB-disruption. 
3.5.1 ALTERATIONS TO BBB PERMEABILITY 
We found BBB-disruption in the form of increased permeability and altered tight junctions 
occurs in the piglet model of neonatal HIE. There was no significant difference in NaFlsc 
amount in either brain region, at any time-point. However, clear extravasation of IgG as 
assessed with IHC was evident in animals from every time-point. This indicates that the 
extravasation of substances across the BBB is not solely determined by size as the small 
molecular weight NaFlsc did not appear to infiltrate the brain tissue to the same degree as 
the large molecular weight IgG. This phenomenon has been previously described in a P7 
rat model of neonatal HI in which extravasation of IgG and three different sizes of dextrans 
(an endogenous tracer molecule) was evaluated (Zhang et al. 2016). Zhang and colleagues 
(2016) demonstrated IgG extravasation occurred to a substantial extent, despite the fact 
that a dextran molecule of a smaller molecular weight (IgG is 140kDa compared with a 
70kDa dextran) did not infiltrate into the brain tissue. The authors postulated that IgG is 
better able to cross the BBB due to alterations in transport mechanisms (Zhang et al. 2016).  
This is evidence that BBB permeability is not solely determined by the size of the molecule 
– endogenously occurring and exogenously occurring molecules have different BBB 
permeability’s. In our study the period of maximal entrance into tissue for NaFlsc was 8h 
post-HI, whereas IgG appeared to somewhat accumulate and high levels were found at later 
time-points (12 and 24h). This result was somewhat similar to a study performed by 
Habgood et al (2007) that found smaller exogenous molecule tracers were able to enter 
mouse brains with traumatic brain injury up to 4 days after the injury, whereas the period of 
increased permeability for large serum proteins was up to 15 minutes post-injury and at 24h 
post-injury. In addition to differences in entrance to the brain via a damaged BBB, 
substances of different origin are cleared from the brain by alternate routes (Hladky and 
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Barrand 2018). This may partly account for the result by Habgood and colleagues that large 
serum proteins accumulate in the brain over time and diffuse away from the entry point, 
whereas small, exogenous molecules do not. With this in mind, we propose that NaFlsc 
might better predict the opening and closing of the BBB to a molecule of that size, however 
IgG and other serum proteins may accumulate and diffuse through the brain tissue. This 
means that IgG is less an indication that the BBB is open at the time of analysis, but had 
been open at some point. 
While clear presence of IgG was found in the parietal cortex and hippocampus of animals 
from every time-point, the only significant difference between control levels of the serum 
protein and extravasation in the HI animals was found in the hippocampus at 24h after HI. 
Despite this, we described examples of IgG extravasation in the HI animals including 
parenchymal labelling and areas of intense IgG surrounding blood vessels which we refer 
to as ‘halo leaks’. Other types of IgG extravasation were observed, such as areas of vessel 
labelling. We hypothesised that IgG labelling of blood vessels was due to reduced integrity 
of vessels or the basement membrane causing perivascular labelling of IgG, or vessel 
labelling of IgG due to efflux. IgG efflux is mediated by the neonatal FC receptor which is 
highly expressed along the cerebrovascular endothelium and choroid plexus (Schlachetzki 
et al. 2002). It is believed that the neonatal FC receptor may play an important role in 
extruding IgG from the CNS following pathologies such as HI or other inflammatory events 
that open the BBB (Zhang and Pardridge 2001, Roopenian and Akilesh 2007). This is 
supported by evidence that neonatal FC receptor expression can be upregulated by TNF 
and downregulated by the anti-inflammatory cytokine interferon gamma (Liu et al. 2007, Liu 
et al. 2008). Future studies should investigate whether the neonatal FC receptor is altered 
following HI and if it does bind to IgG in these models. 
Another observation was that IgG leaks often occurred in the sub-ventricular region between 
lobes 2 and 3 of the parietal cortex, and throughout the white matter. Watershed injury, or 
injury to the boundary zones between arterial supplies, is common following neonatal HI 
(Miller et al. 2005). These zones may also have increased BBB-disruption – either through 
direct injury to the endothelial cells and their tight junctions, or loss of support cells of the 
neurovascular unit. To the best of our knowledge, specific areas of BBB-disruption following 
this type of injury has never been fully characterised, however, white matter vulnerability in 
younger animals has been demonstrated previously. Stolp and colleagues (2005) using an 
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inflammation model showed in postnatal day 0 (P0), P8, and P20 rats (fetal, neonatal, and 
juvenile human equivalent), as well as in opossums at a similar age range, that the BBB was 
permeable to serum proteins in the white matter, but not the grey matter. The authors 
suggest that the white matter vulnerability may be due to differences in the density of 
microglia in the affected regions, the subsequent strength of the response to inflammation, 
and further cytokine release (Stolp et al. 2005). Microglia in the white matter of newborn rats 
increases substantially in the first two weeks of life, before reduction to adult levels in the 
third week (Nikodemova et al. 2015). Large increases in pro-inflammatory cytokines were 
evident in our study, however, we did not differentiate between grey and white matter in the 
parietal cortex in this analysis, and we did not assess the number of activated microglia in 
our animals. Future studies could be performed to more clearly establish a link between 
microglial activation, cytokine release, and areas of vulnerability to BBB-disruption. This 
information may be useful for clinicians to understand areas of specific vulnerability, and for 
researchers to trial targeted anti-inflammatory treatments to reduce this pathological 
cascade. 
We originally designed the experiments to investigate the parietal cortex and hippocampus 
as they are areas that are commonly affected by neonatal HI, and by seizures – which we 
will discuss in the next chapter, rather than areas associated with BBB vulnerability (Swarte 
et al. 2009, Alvarez et al. 2014, Torolira et al. 2016). While we only investigated BBB-
disruption in the parietal cortex and hippocampus in this study, we did note an interesting 
result that the thalamus in the majority of animals was also substantially affected. Thalamus 
has previously been shown to be a brain region which is particularly vulnerable to BBB-
disruption (Calingasan et al. 1995). Future studies may also choose to include the thalamus 
as a vulnerable brain region. 
One of the predominant IgG labelling patterns seen in this study was neuronal IgG. Neurons 
that labelled with IgG were identified with more frequency, and to a greater extent in animals 
at the later time-points. Our data show that neuronal uptake of IgG can occur within the first 
24h of HI injury, and these neurons also appear to be degenerating - as demonstrated by 
co-labelling with FJC. The number of FJC+ cells increased over time, with substantially 
greater numbers at the 12 and 24h time-points than at earlier time-points, corresponding 
with the onset of secondary energy failure (6-72h and when substantial cell death occurs). 
We should note that FJC is a validated marker of neuronal degeneration as it has been 
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associated with other markers of neuronal cell death and appears to label a late stage of 
neuronal death, but as of yet the field is unclear about the mechanism it labels these cells 
(Poirier et al. 2000).  
Previous reports have indicated that serum extravasation into brain tissue and in cells is 
associated with damage; an adult rat model of HI demonstrated that uptake of albumin 
(another common serum protein) was associated with indicators of neuronal damage such 
as shrunken neurons and eosinophilic cytoplasm (Loberg et al. 1993). Another study found 
a large percentage of IgG+ cells in hippocampus of epileptic patients appear to have 
shrunken perikarya and corkscrew shaped dendrites – indicating damage (Michalak et al. 
2012). In addition, uptake of albumin appears to contribute to epileptic cell death in vivo  as 
neurons treated with albumin were found to uptake the serum protein prior to and enhancing 
cell death (Liu et al. 2016). Despite this evidence, we cannot be sure that the relationship 
between IgG and degeneration of neurons is causative as damaged cells have been shown 
to uptake large proteins such as IgG. Given our results show that degenerating neurons as 
assessed by FJC occur prior to IgG+ cells (with the exception of one 2h animal), and that 
IgG+ cells at every time-point are almost entirely found to co-localise with FJC, it in entirely 
possible that IgG uptake is not directly causing cell death. 
3.5.2 ALTERATIONS TO THE TIGHT JUNCTIONS 
There are two major routes from blood to brain across the BBB – the para and trans-cellular 
routes. We have chosen to investigate the paracellular route by describing alterations to 
tight junctions as these proteins are primarily responsible for limiting free diffusion. To do 
this, we investigated changes to mRNA expression and protein abundance for tight junctions 
CLDN5, OCLN, and ZO1. 
We found changes to the mRNA expression CLDN5 and ZO1 in both parietal cortex and 
hippocampus, but not OCLN. CLDN5 mRNA expression was found to increase over time – 
with the highest gene expression at 24h post-HI in the parietal cortex, but after 8h in the 
hippocampus. In contrast, despite some variability in the protein level of CLDN5 there was 
no significant difference in either brain region. Initially we hypothesised that CLDN5 mRNA 
upregulation following HI was a compensatory response for reductions in protein. However, 
the protein analysis did not strongly support this hypothesis. In contrast, ZO1 mRNA 
expression decreased, with the greatest reduction observed at 8h post-HI in the parietal 
cortex and in the 4 and 8h post-HI groups in the hippocampus. The protein level of ZO1 was 
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also significantly reduced in the parietal cortex at 8h, with no difference in the hippocampus. 
While we found there was no change in OCLN mRNA expression, OCLN protein level did 
increase in the first 4h post-HI before returning to control levels. 
Alterations of the tight junctions following neonatal HI have been described in animal models 
previously. Ek and colleagues (2015) described in a P9 rat model (roughly human neonate 
equivalent) changes to ZO1, OCLN, and CLDN5 protein and mRNA expression. They did 
not find any substantial change in any of the tight junctions with IHC at 6 or 24h post-HI, 
however alterations were observed with western blot and qPCR analysis, but was only 
performed at one time-point (6h post-HI). Ek et al (2015) found that ZO1 protein was reduced 
in the cortex and OCLN protein was reduced in both the hippocampus and cortex. However, 
total CLDN5 protein was unchanged. Whereas mRNA expression of CLDN5 was 
upregulated in the hippocampus, but not the cortex, and OCLN and ZO1 mRNA was 
upregulated in the cortex but not the hippocampus (Ek et al. 2015). Another study in a P7 
neonatal rodent model of HI found that HI significantly reduced ZO1, OCLN, and CLDN5 
protein level at 48h post-HI (Zhang et al. 2016). Another study in a large animal model of 
ischaemia (fetal sheep at 80% of gestation which is approximately late preterm in the 
human) did not find any significant differences in CLDN5, OCLN, or ZO1 in the ischaemic 
region of the brain when compared with the non-ischaemic region 72h after HI (Malaeb et 
al. 2007). 
It has long been believed that the key to describing increased BBB permeability in CNS 
disease states lied in alterations to the tight junctions – as the tight junctions are known to 
be an important aspect of maintaining the separation between the brain and the blood. 
However, given the conflicting reports in neonatal HI, and indeed in other CNS diseases, it 
seems they are not the only important aspect in regulating movement across the barrier. We 
see clear extravasation of IgG and some evidence of NaFlsc presence in brain tissue in the 
absence of substantial changes to the mRNA or protein level of the three tight junctions 
investigated. The barrier is not only made up of the endothelial cells and their associated 
tight junctions but is supported by other cells in the neurovascular unit such as astrocytes 
and their end-feet which wrap around blood vessels, neurons, and microglia which release 
factors that support the BBB. While there is some evidence to suggest the neurovascular 
unit as a whole is affected by HI, these results suggest that to understand BBB permeability 
better following brain injury, we need to investigate more than just the tight junctions. 
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Despite this, to the best of my knowledge this study is the most in-depth investigation of tight 
junction changes in a neonatal model of HI with alterations to three significant tight junction 
proteins, in two brain regions, across five time-points in the 24h after injury, all in a clinically 
relevant animal model. However, there are several ways this work may be expanded in 
future studies. These include increasing the number of animals in each group, increasing 
the time after injury investigated, and a more in-depth analysis of tight junction spatial 
arrangement. 
It has been suggested that tight junction protein spatial arrangement may be altered by 
disease without an observable loss in protein abundance. HI injuries have been shown to 
both reduce total protein level, as well as cause tight junction disorganisation (Fischer et al. 
2004, Koto et al. 2007, Willis et al. 2010). Ek and colleagues (2015) showed that areas of 
compromised BBB and increased permeability after HI are associated with disorganisation 
of CLDN5 as measured by confocal microscopy on frozen sections (Ek et al. 2015). To 
assess this in our model, we utilized IHC to visualise the arrangement of CLDN5 and ZO1. 
Unfortunately, the OCLN antibody could not be optimised sufficiently for this technique. 
Particularly at 8h, both CLDN5 and ZO1 immunofluorescence labelling appeared 
disorganised compared with control. However, this pattern of labelling was not uniform 
across all animals in the HI groups, nor across the entirety of the parietal cortex. In addition, 
we did not quantify these differences, and we cannot be certain they are not simply related 
to the plane of section. Nevertheless, it does support the hypothesis that tight junctions are 
altered and matches evidence from western blot analysis and the qPCR results presented 
in this chapter that 8h appears to be a time-point of particular vulnerability in our model.  
3.5.3 MECHANISMS OF BLOOD-BRAIN BARRIER DISRUPTION 
Vascular endothelial growth factor and matrix metalloproteinase 2 
VEGF is a growth factor induced by hypoxia-inducible factor that is related to vasculogenesis 
and angiogenesis. However, VEGF expression is also associated with increased endothelial 
permeability and BBB-disruption (Fischer et al. 2002, Hudson et al. 2014). VEGF protein 
has been found to increase in cord blood of neonates with HIE and is associated with 
severity of the syndrome (Aly et al. 2009). However, elevated levels of VEGF protein in CSF 
within the first 24h of life was found in neonates with mild HIE compared with controls, but 
not moderate and severe HIE (Ergenekon et al. 2004). In a neonatal rat model study of HI 
found VEGF protein increased in brain between 15min and 72h after HI with a peak at 45min 
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(Feng et al. 2008). I did not find any significant difference in VEGF mRNA expression in 
either brain region, at any time-point. The differences here may be because we were 
measuring mRNA rather than protein, future investigation of the protein changes in the brain, 
as well as serum and CSF levels of VEGF may be required to fully understand the role VEGF 
may be playing in BBB-disruption or outcome following neonatal HI. 
The MMPs are proteolytic enzymes that are involved in breakdown of neurovascular 
basement membrane and tight junctions. MMP2 and 9 are the major MMPs involved in BBB-
disruption (Yu and Stamenkovic 2000, Hou et al. 2014, Song et al. 2015). MMP2 mRNA 
expression was found to be upregulated at 12 and 24h post-HI compared with controls and 
other time-points. We observed a different effect in the hippocampus, however, with an early 
downregulation of MMP2 at 4h post-HI. Previous reports have suggested that MMP2 
upregulation may play an important role in the initial BBB opening that has been described 
in stroke research (Rosenberg et al. 1998, Yang et al. 2007). BBB-disruption in stroke is 
often characterised as biphasic – an initial opening of the BBB after injury followed by 
resolution and a later opening after the onset of pathological cascades such as inflammation. 
Rosenberg and colleagues (1998) demonstrated in adult rats following middle cerebral 
artery occlusion (MCAO) as a stroke model, that an initial BBB opening was associated with 
the protein level of MMP2, whereas a late opening was related to the protein level of MMP9 
(Rosenberg et al. 1998). Yang and colleagues (2007) also demonstrated in an adult MCAO 
stroke model that BBB opening occurred 3h post-injury and was related to an increase in 
both MMP2 activity as measured by zymography, and MMP2 mRNA expression. MMP2 
expression appeared to be related to concurrent reorganisation, loss of protein, and 
downregulation of mRNA expression of CLDN5 and OCLN (Yang et al. 2007). 
Here we have shown that the strongest changes in MMP2 mRNA in parietal cortex are not 
occurring until 12 to 24h after HI injury, not within the first few hours as in adult stroke 
models. The next step in investigating MMP in neonatal HIE is to describe changes to the 
other MMPs and their tissue inhibitors in our model. In addition, evaluation of protein 
abundance with western blotting or ELISA assay and activity using substrate zymography 
would allow better understanding of how they are altering following neonatal HI. Future 
research might also evaluate the MMPs as a target to BBB-disruption and inflammation in 
CNS disorders. MMP inhibition has been investigated as a neuroprotective strategy in 
ischemic stroke research with promising results (Chaturvedi and Kaczmarek 2014). 
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Unfortunately, we were not able to sufficiently optimise primers to evaluate MMP9 mRNA 
changes in our model. 
GLUT1 is the major transporter of glucose across the BBB. As such, altered GLUT1 
expression may lead to impaired glucose metabolism. In addition, loss of GLUT1 may be 
related to injury and BBB-disruption, for example, GLUT1 deficiency has previously been 
shown to contribute to pathology and BBB breakdown in an Alzheimer’s model (Winkler et 
al. 2015). Previous studies in rodents suggest that GLUT1 mRNA expression is upregulated 
in the early hours following HI and returns to control levels by 72h (Vannucci and Vannucci 
1997). However, in this study we did not demonstrate any difference in GLUT1 mRNA 
expression compared with controls indicating that GLUT1 at least at the mRNA level GLUT1 
is not significantly affected by HI in our model. There was a significant upregulation in the 
24h post-HI group compared with animals in the 2 and 8h post-HI groups in the parietal 
cortex, but no difference compared with controls. There was no significant difference in 
GLUT1 mRNA in the hippocampus between any time-points. 
AQP4 is a bi-directional water channel located predominantly on perivascular astrocyte end 
feet and is essential for maintaining water homeostasis across the BBB. Differential 
expression (both increases and decreases) of AQP4 have been demonstrated to be 
associated with oedema formation, swollen perivascular astrocytes and BBB permeability 
alterations (Friedman et al. 2009, Higashida et al. 2011, Tourdias et al. 2011). Previous 
studies in models of HIE have shown both up and downregulations of APQ4 (Meng et al. 
2004, Badaut et al. 2007, Ferrari et al. 2010). However, in this study APQ4 mRNA 
expression was not substantially altered at any of the time-points, and not significantly 
different from control in either region. This indicates that at least at the mRNA level AQP4 is 
not changing significantly and may not be well associated with increases in BBB 
permeability. This work could be strengthened again by including protein work, and by 
analysing vasogenic (and cytogenic) oedema formation, in which AQP4 might play an 
important role given its status as a water channel along the cerebral vasculature. 
Given the results it appears that the markers we have chosen to investigate possible 
mechanisms of BBB permeability are not strongly related to our methods for quantifying 
BBB disruption. It is worth noting that the most significant results did occur in the later time-
points, which matches with the IgG extravasation data, however it is possible that these 
measures are just not sensitive enough to correlate well with each other, and are possibly 
97 
 
not good targets for reducing BBB-disruption, at least in early stages of HIE disease 
progression. 
Inflammation 
Inflammation has been robustly shown to be related to BBB-disruption through both direct 
and indirect actions at the neurovascular unit which can alter its permeability (Erickson et 
al. 2012, Makirdes et al. 2017) (Chapter 1.4.1). Once compromised, inflammation can be 
exacerbated via increased invasion of peripheral immune cells, peripherally generated pro-
inflammatory cytokines, and enhanced release of pro-inflammatory cytokines from 
microglia. Thus, a negative feedback loop is begun that can result in substantial brain injury 
and further BBB-disruption. Inflammation is therefore a key drug target when we consider 
how to reduce BBB-disruption, and neuropathology following neonatal HI and understanding 
the temporal changes of inflammatory cytokines in this syndrome is the first step towards 
targeted reduction.  
A number of anti-inflammatory therapies have been investigated in terms of their BBB-
protective effects. For example, melatonin is endogenously produced by the pineal body 
and has a variety of physiological functions and strong anti-inflammatory and antioxidant 
effects (Reiter et al. 2000). Melatonin has been shown to reduce the production of pro-
inflammatory cytokines, and VEGF (Reiter et al. 2000, Kaur et al. 2008). Melatonin has also 
been recently shown to have a protective effect on the BBB in neonatal rats (Moretti et al. 
2015). Other therapies with anti-inflammatory effects also have protective effects on the 
BBB. These include curcumin (Jiang et al. 2007, Dende et al. 2017), stem cell therapy (Horie 
et al. 2011, Menge et al. 2012, Chen et al. 2015), and erythropoietin (Martinez-Estrada et 
al. 2003, Villa et al. 2003, Li et al. 2008). There are a number of studies outside the field of 
HIE that have also demonstrated protective effects of the BBB and it is possible they could 
be trialled in neonates in the future. These include steroids which have been shown to 
increase trans-endothelial electrical resistance and tight junction expression (Singer et al. 
1994, Romero et al. 2003) as well as altering the inflammatory response and the infiltration 
of leukocytes across the BBB (Paul and Bolton 1995). Another potential therapeutic is 
omega 3, which has been shown to reduce BBB-disruption in mice (Zhang et al. 2016). 
In general these data are in agreement with the concept of inflammation following neonatal 
HIE in humans with substantial elevations early and worsened inflammation during 
secondary energy failure (6-72h) (Liu and Mccollough 2013). We found that inflammation in 
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the form of upregulated mRNA expression of inflammatory cytokines and chemokines is 
initiated early following HI and generally sustained, or upregulated further until our latest 
investigated time-point of 24h. mRNA expression of TGF, TNF, CXCL10, IL1, IL6, and 
IL8 were all substantially upregulated from our earliest time-point post-HI (2h). In the cases 
of TGF, TNF, IL1, and IL6, mRNA was further upregulated at the 12 or 24h post-HI time-
points.  
TGF is an anti-inflammatory cytokine and its expression following injury is thought to 
contribute to repair processes rather than injury (Bajnok et al. 2017). However, upregulation 
of TGF can also have the effect of increasing BBB permeability and has been implicated 
in seizure generation (Heinemann et al. 2012). Additionally, TGF signalling is related to 
astrogliosis and can result in exacerbated pro-inflammatory release (Bain et al. 2010). TGF 
has previously been shown to be upregulated in neonates with moderate HIE at 24h, one 
week, and one month post-birth (Bajnok et al. 2017). TGF mRNA has also been 
demonstrated to upregulate following HI in a juvenile rodent model (P21) at 72h post-HI, but 
returned to control levels by 120h post-HI (Klempt et al. 1992). A study using a P7 rat 
germinal matrix haemorrhage model found that TGF protein levels were increased 
significantly at 3 and 6h post-HI and decreased to control levels by 72h post-HI (Manaenko 
et al. 2014). Despite the anti-inflammatory status of TGF, inhibition of the TGF receptor 
in the Manaenko et al (2014) study reduced neurodevelopmental deficits, improved cognitive 
function, and reduced pathological astrogliosis. Given the substantial upregulations of TGF 
mRNA expression demonstrated in this study, future research to define what role TGF 
plays in BBB-disruption and HIE injury is required. 
CXCL10 has been shown to be upregulated in adult HI models, however there is very little 
investigation of CXCL10 in neonatal HI insults. We found one study in a P7 rodent HI model 
where CXCL10 was included in an mRNA panel as a supplemental figure. CXCL10 was 
found to be substantially upregulated in HI animals 3, 6, and 24h post-HI compared with the 
control group (Akamatsu et al. 2014). This is in agreement with our data which shows 
CXCL10 expression is significantly, and substantially upregulated at every time-point 
studied. CXCL10 is implicated in the chemo-attraction of immune cells but has also been 
implicated in increasing BBB-disruption through upregulating TNF expression (Wang et al. 
2018).  
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TNF expression has been strongly implicated both in the inflammatory cascade following 
neonatal HI, and in BBB permeability alterations.(Anda et al. 1997, Liu and Mccollough 
2013). There have been several investigations of TNF protein level in serum and CSF in 
neonates with HIE which indicate that TNF is increased from control and related to the 
severity of injury (Silveira and Procianoy 2003, Aly et al. 2006, Shang et al. 2014). However, 
these studies only sampled at one time-point for each patient, and at variable times after 
birth (within the first 24h for Aly et al. 2006, within the first 48h for Silveira and Procianoy, 
and the sampling time-point was not stated by Shang et al. 2014). 
In addition to TNF, the cytokines that have been best investigated as involved in the 
inflammatory response after neonatal HIE are IL6 and IL1Upregulations of both cytokines 
have been found following HIE and related to severity of the disorder and outcome (Silveira 
and Procianoy 2003, Aly et al. 2006, Shang et al. 2014). But again, most of the studies have 
been in humans at one or two time-points, which are generally between 24 and 72h. We 
provide evidence from multiple defined early time-points (2-24) in a clinically relevant model. 
However future work on protein in brain, serum, and CSF will give us a better idea of these 
inflammatory mediators following HIE. 
Other inflammatory genes that have been associated with immune cell infiltration across the 
BBB include IL8 and CCR5 (Pieper et al. 2013). We demonstrated that CCR5 mRNA is not 
altered by HI in our model. IL8, however, was found to be highly upregulated at all time-
points. Our results here indicate that IL8 is rapidly upregulated (within the first two hours) 
and upregulations are sustained for at least 24h post-insult. IL8 has been previously 
implicated in enhancing neutrophil infiltration across the BBB (Pieper et al. 2013). However, 
neutrophil transmigration occurs at lower rates in neonates than adults following HI, 
therefore it is unclear what impact our observed IL8 upregulations have (Hudome et al. 1997, 
Povroznik et al. 2018). 
3.5.4 PERIODS OF VULNERABILITY 
While there was no significant difference, in terms of NaFlsc, ZO1 protein and mRNA, and 
CLDN5 mRNA, there did appear to be a specific difference in animals from the 8h group. 
There was no difference in HI insult severity in terms of end pH, end base excess, or end 
CO2 between the groups. While the 8h group did have the most CO2 build-up at the end of 
hypoxia, it did not have the most severe alterations in ABE or pH – the two criteria we 
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associate most with hypoxia severity, therefore the significant results in the 8h group do not 
appear to be associated solely with HI insult severity, 
Another possible explanation is seizure – however only 1 animal in this chapter had 
seizures, and it was a 12h animal. It is worth noting that this animal did have significant IgG 
extravasation into brain tissue. Another significantly affected animal occurred the 8h group 
and had epileptiform activity which may have progressed into seizure if we had extended 
the experiment. These results could mean two things – that BBB disruption and subsequent 
extravasation ions, pro-epileptic proteins, and inflammatory signalling molecules into the 
vulnerable brain tissue resulted in increased neuronal excitability and predisposed these 
animals to epileptic activity. Or, seizure activity resulted in increased BBB disruption. Both 
are possible, as previous studies have shown that opening the BBB can directly cause 
seizure activity (Marchi et al. 2011), and seizure activity has been shown to be associated 
with greater BBB-disruption (Librizzi et al. 2012). 
It is interesting that both animals with seizure/epileptiform activity had the most prominent 
IgG extravasation, however there was one other animal with similar levels of IgG that didn’t 
have seizure, so it is not a perfect relationship and may simply be due to chance. However, 
as mentioned before we cannot exclude the possibility that the animal with high levels of 
IgG but no seizures may have gone on to develop seizures had we continued the 
experiment. A full investigation with a longer time-frame may be able to better tease out this 
association. 
3.5.5 STRENGTHS AND LIMITATIONS 
A major limitation of the current study was the small numbers of animals in each group which 
makes it difficult to be confident about the statistical significance of the results. We did not 
originally anticipate that the results would be as variable between animals as previous 
studies have shown strong effects with small numbers (Chen et al. 2012, Ek et al. 2015). 
Given qualitative differences in BBB permeability (IgG IHC) were observed, it is possible 
that greater numbers would generate more significant results. A power analysis confirms 
this, with the current means of IgG extravasation from 2-24h, we would require 
approximately 16 animals per group to detect significant differences. Future studies would 
need to keep in mind that large groups might be required. Another limitation was that we 
were not able to quantify the IgG extravasation into the parenchyma. We ruled out assessing 
signal intensity in IHC sections labelled with IgG due to the variability in the technique from 
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fixation and variable slicing. We also attempted to develop a scoring system for IgG labelling 
based on the three predominant patterns we demonstrated in this chapter (neuronal 
labelling, parenchymal labelling, and perivascular labelling). This technique had merit, but 
greater numbers and examples of each labelling pattern would allow greater confidence in 
the scoring system. We chose instead to rely on western blot quantification and 
immunohistochemistry examples images for qualitative analysis. In the future we would 
suggest multiple methods of quantification and utilising multiple makers of BBB disruption 
to ensure reliable results. 
Despite these limitations, we have characterised BBB permeability across five time-points 
from 2 to 24h after HI insult in two brain regions using an exogenous and an endogenous 
tracer molecules. We have also described changes to the tight junctions that are important 
for maintaining paracellular barrier function in terms of mRNA expression, protein, and 
localisation changes. In addition, multiple mechanisms of BBB-disruption including VEGF, 
MMP, and inflammation mRNA expression changes were investigated. All the above allows 
better understanding of BBB-disruption in a clinically relevant, large animal model of 
neonatal HIE.  
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CHAPTER 4 - INVESTIGATING THE RELATIONSHIP 
BETWEEN BBB DISRUPTION AND SEIZURES 
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Chapter Preface 
One process that occurs commonly following neonatal HIE is the occurrence of seizures – 
which are known to be pathological via exacerbation of inflammation and excitotoxicity. 
Another major consequence of seizure activity is BBB disruption. Therefore, I was very 
interested in investigating the association between seizures and BBB-disruption in our 
model. Given our model has the advantage of HI-induced seizures, and our animals can be 
recovered to allow neurobehavioural outcome testing, we had an unique opportunity to study 
how seizures and BBB-disruption may be related, and how these injurious processes can 
contribute to outcome. The previous chapter focused on the first 24h of injury progression 
following a perinatal hypoxic-ischaemic insult as evidence from adult studies suggest a large 
percentage of BBB-disruption occurs in this period(Zhang et al. 2016, Mendes et al. 2019) . 
However, there is long term pathological changes due to BBB-disruption. To allow analysis 
of the impact of seizures, and the ability to analyse neurodevelopmental outcome, animals 
in this chapter and the next were euthanised at 72h post-HI. This chapter has been accepted 
for publication in Developmental Neuroscience. 
Seizures are associated with blood-brain barrier disruption in a piglet model of hypoxic-
ischaemic encephalopathy. Goasdoue K., Chand K.K., Miller S.M., Lee K.M., Colditz P.B., 
Wixey J.A., Bjorkman S.T. Accepted: Developmental Neuroscience. 2019 
Student’s contribution to publication 
Concept and design of the project 
KG conceived the presented idea and planned the lab based experiments to demonstrate 
that seizures and blood-brain barrier disruption were associated. Design of the overall 
project was performed by KG, TB, and JW jointly. Design of the animal experiments was 
performed by TB and SM. 
Analysis and interpretation 
KG performed analyses of the data including physiological data and seizure analysis and 
statistics, western blot and qPCR optimisation and statistical analysis, and overall 
interpretation of the results in the context of the current literature. 
Histology was primarily interpreted by Chris Burke and SM 
SM assisted KG with aEEG and seizure analysis when necessary 
Drafting 
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KG wrote the majority of the paper including the entirety of the introduction and discussion 
and majority of the methods and results. KG incorporated edits from TB, JW, and KC. 
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4.1 Abstract 
Seizures in the neonatal period are most often symptomatic of CNS dysfunction and the 
most common cause is hypoxic ischaemic encephalopathy (HIE). Seizures are associated 
with poor long-term outcomes and increased neuropathology. Blood-brain barrier (BBB) 
disruption and inflammation may contribute to seizures and increased neuropathology but 
are incompletely understood in neonatal HIE. The aims of the current study were to 
investigate the impact of seizures on BBB integrity in a pre-clinical model of neonatal 
hypoxic-ischaemic (HI) injury. Piglets (<24h) were subjected to a 30-minute HI insult 
followed by recovery to 72h post insult. Amplitude-integrated electroencephalography 
(aEEG) was performed and seizure burden and background aEEG pattern analysed. BBB-
disruption was evaluated in the parietal cortex and hippocampus with IHC and western 
blotting. mRNA and protein expression of tight junction proteins (zonula-occludens 1 (ZO1), 
occludin (OCLN), and claudin-5 (CLDN5) was assessed using qPCR and western blotting. 
In addition, mRNA from genes associated with BBB-disruption vascular endothelial growth 
factor (VEGF) and matrix metalloproteinase 2 (MMP2) as well as inflammatory cytokines 
and chemokines were assessed with qPCR. Piglets that developed seizures following HI 
(HISz) had significantly greater injury, as demonstrated by poorer aEEG background pattern 
scores, lower neurobehavioural scores, and greater histopathology. HISz animals had 
severe IgG extravasation into brain tissue and uptake into neurons as well as significantly 
greater levels of IgG in both brain regions as assessed by western blot. IgG protein in both 
brain regions was significantly associated with seizure burden, aEEG pattern scores, and 
neurobehavioural scores. There was no difference in mRNA expression of the tight 
junctions, however a significant loss of ZO1 and OCLN protein was observed in the parietal 
cortex. Inflammatory genes TGF, IL1, IL-8, IL6 and TNFwere significantly upregulated 
in HISz animals. MMP2 was significantly increased in animals with seizure compared with 
animals without seizure. Increasing our understanding of neuropathology associated with 
seizure is vital due to the association between seizure and poor outcomes. Investigating the 
BBB is a major untapped area of research and potential avenue for novel treatments.
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4.2 Introduction 
Seizures occur more in the neonatal period than any other age; occurring in up to 5 per 1000 
live term births (Lanska and Lanska 1996, Cowan 2002), Glass et al. (2009). Seizures are 
a major component of neonatal Hypoxic Ischaemic Encephalopathy (HIE). Seizures arise in 
the secondary energy failure phase of HIE (Chapter 1), and there is strong evidence that 
seizures can exacerbate underlying central nervous system (CNS) disorders. This includes 
evidence from animal models of HIE (Wirrell et al. 2001, Bjorkman et al. 2010), and clinical 
findings from neonates with HIE (Tekgul et al. 2006, Glass et al. 2009, Kharoshankaya et 
al. 2016, Pisani and Spagnoli 2016, De Haan et al. 2018). The exact mechanisms of 
exacerbated brain injury are yet to be fully understood. The damaging effects of seizures in 
neonatal CNS disorders is worsened by the fact that seizures are poorly controlled by 
standard anti-seizure drugs in this population (Painter et al. 1999, Lundgrist et al. 2013) 
(Chapter 1.3.3).  
As the major interface between the peripheral circulation and the brain parenchyma, the 
blood-brain barrier (BBB) plays a vital protective role and is essential for maintaining the 
microenvironment required for correct neuronal function. The previous chapter 
demonstrates that blood-brain barrier (BBB) disruption occurs in our pre-clinical model of 
neonatal hypoxic ischaemic encephalopathy (HIE). However, the consequences of BBB-
disruption on neuronal function have yet to be established in this model. A major 
consequence of BBB-disruption in adult disease states is the occurrence of seizure (Oby 
and Janigro 2006, Marchi et al. 2012, van Vilet et al. 2014). When the BBB is disrupted, the 
net flow of ions, metabolites, and proteins through a more permeable blood/brain interface 
increases neuronal excitability and primes the brain toward seizure.  
A direct, causative link has been demonstrated clinically (Tomkins et al. 2011) and 
experimentally (Marchi et al. 2007, Rigau et al. 2007, van Vilet et al. 2007, Librizzi et al. 
2012) between BBB-disruption and seizures in a variety of disease states and models. Such 
that BBB-disruption can contribute to epileptogenesis, sustainment of seizure, seizure 
recurrence, and the drug refractory properties of some epilepsies. Further to this, there is 
ample evidence that seizures can disrupt the BBB; resulting in an injurious feedback loop. 
This includes evidence following adult hypoxia ischaemia (HI) (Parfenova et al. 2010, Morin-
Brureau et al. 2011, Vezzani et al. 2013). However, there is extremely limited information 
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regarding the association between seizures and BBB-disruption in the neonate (Carratu et 
al. 2003, Pourcyrous et al. 2015) (Chapter 1.3.3). 
Given neonatal seizures can contribute to neuropathology following HI there is an urgent 
need to better describe pathological processes associated with seizure in the neonate with 
HIE. Better understanding of the mechanisms that drive seizure-exacerbated 
neuropathology may allow the development of therapeutics to protect neonates with seizure. 
Therefore the aim of this chapter was to investigate the effect of seizures on BBB 
permeability and integrity in a clinically-relevant model of neonatal HIE. 
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4.3 Methods 
4.3.1 ANIMALS 
Approval for this study was obtained from the University of Queensland Animal 
Experimentation Ethics Committee and carried out in accordance with National Health and 
Medical Research Council guidelines (Australia) (UQCCR/565/09/NHMRC, 
UQCCR/576/12/NHMRC, UQCCR/426/14/NHMRC) (Appendix 1, 3, 4). Care was taken to 
minimise the number of animals used and ensure no undue pain or distress. 38 Large White 
newborn piglets with an average age of 14.8h (±4.8h) and average weight of 1.55kg 
(±0.21kg) were obtained from University of Queensland Gatton Piggery. 
4.3.1 HYPOXIC ISCHAEMIC INSULT PROTOCOL 
Animals were anaesthetized with a propofol/alfentanil mixture (propofol: Diprivan 1% 
AstraZeneca Pty Ltd., NSW, alfentanil (Rapifen): Pharmaceutical, VIC, AUS), intubated, 
ventilated, and catheterised with intravenous and intraarterial lines to enable fluid delivery 
and monitor arterial blood gases (ABGs). Hypoxia was induced (n=33) by reducing the 
fraction of inspired oxygen (FiO2) to 4% and adjusting as necessary (2-6%) to achieve and 
maintain low amplitude electroencephalography (LaEEG <5V) for a period of 30min. The 
insult was run for approximately 30min or until blood gas parameters (arterial pH<7.0 or 
arterial base excess (ABE) <-12) were achieved, and hypotension (mean arterial blood 
pressure (MABP) <30mmHg) was maintained for a period >10min. The HI insult was titrated 
to individual animal physiological responses to achieve moderate-severe survivable brain 
injury. In our model ~75% of HI animals spontaneously develop seizures. 
Anaesthesia was reduced and maintained (4-12% propofol/alfentanil mix) to monitor 
electroencephalography (EEG) for 36h following the HI insult. At 36h post-HI, anaesthesia 
was ceased and animals were recovered until such time they could be extubated. Animals 
were fed (ProfeLAC ® milk replacer, ProviCo, AUS) and monitored for signs of clinical 
seizures (defined as myoclonic jerks, rhythmic pathological movements, or tonic postures 
(Volpe 2008) until euthanasia at 72h post-HI insult. In this study, only animals with clinical 
seizures were treated with anticonvulsants as per ethical guidelines (phenobarbital first line 
(20mg/kg), followed by subsequent midazolam doses (0.2mg/kg)). Sham animals 
underwent the same protocol excluding the HI (n=5). 
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4.3.2 EEG MONITORING AND BACKGROUND PATTERN SCORING 
Two-channel amplitude-integrated EEG (aEEG) was recorded for the duration animals were 
under anaesthesia (~40h) and for a 1h period at 48 and 72h post-HI insult (BrainZ 
Instruments, Auckland, NZ, or Unique CFM 6.0, Inspiration Healthcare, United Kingdom) 
(Bjorkman et al. 2010). aEEG recordings at 48 and 72h were performed without anaesthesia 
on sleeping animals, wrapped in a towel after feeding. Electrographic seizures were defined 
as repetitive, rhythmic waveforms with a distinct beginning and end with a duration >10 s 
(Clancy and Legido 1987).  
For analysis of background aEEG pattern a 30min (15min either side of the hour point) of 
EEG recording at 1, 2, 4, 8, 12, 24, 36, 48 and 72h was analysed and the background pattern 
was determined as previously described (Hellstrom-Westas and Rosen 2006, Bjorkman 
2016). Background patterns were classified from the aEEG trace as follows; continuous 
normal voltage, discontinuous normal voltage, burst suppression, continuous low voltage, 
flat trace (Hellstrom-Westas and Rosen 2006). For the purposes of classification into mild 
or severe HI-injury, a score of <2 would be considered severe, and >3.5 mild. 
4.3.4 SEIZURE BURDEN ANALYSIS 
EEG data was analysed offline for presence of seizure (36h recording, 1h recordings from 
48 and 72h). Electrographic seizures were annotated from the start of the seizure on either 
channel to the end of the seizure on either channel. The total number of seizures, time to 
first seizure, average seizure duration, and total seizure burden (time spent in seizure), and 
maximal seizure burden (greatest seizure burden in a single hour epoch) were recorded 
(Lynch et al. 2012). 
4.3.5 NEUROBEHAVIOURAL SCORING 
Following recovery, animals were assessed on several neurobehavioural criteria every 4h 
from 48h until the end of the experiment (72h). The neurobehavioural score criteria includes 
assessment for respiration, consciousness, walking and limb control, overall activity, and 
presence of clinical seizures (Bjorkman et al. 2010). For the purposes of classification into 
severe of mild HIE-injury a score of <12 would be considered severe and >15 mild. 
4.3.6 TISSUE COLLECTION AND PROCESSING 
At 72h post-HI animals were sedated with 1-2% inhalational isofluorane (Bayer, NSW, AUS) 
and administered an overdose of lethabarb (I.P. 120 mg/kg, sodium pentobarbitone 325 
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mg/ml). Brains were flushed via an intracardiac injection with ~250mL saline, dissected from 
the skull, coronally sliced (3 mm) and hemisected. Standardised tissue fixation was 
performed on the right hemisphere via immersion fixation in 4% paraformaldehyde, 0.1 M 
phosphate buffered saline (PBS, pH 7.4) overnight (18-20h) at room temperature with 
agitation. Tissue was then stored in 0.1% paraformaldehyde-0.1 M PBS, followed by tissue 
processing through graded alcohols and xylene and paraffin-embedding. Regions of interest 
(parietal cortex and hippocampus) were dissected from the left hemisphere, snap frozen in 
liquid nitrogen and stored at −80°C until analysis. 
4.3.7 HISTOPATHOLOGY 
Tissue sections from the right hemisphere including parietal cortex and hippocampus were 
dewaxed in xylene and rehydrated through graded alcohols. Sections were stained with 
haematoxylin and eosin (H&E) in an automated staining system (Leica ST5010 Autostainer 
XL, Leica Biosystems, NSW, AUS). Histological injury was evaluated and scored (two 
slides/brain region) by a blinded observer using a previously published scoring system (0=no 
injury, 9=maximum severe injury) (Bjorkman et al. 2006). For the purposes of classification 
into severe of mild HIE-injury a score of >7 would be considered severe and <4 mild. 
4.3.8 IMMUNOHISTOCHEMISTRY 
Coronal sections containing parietal cortex and hippocampus were dewaxed and rehydrated 
through graded alcohols. For immunofluorescence, antigen retrieval was performed using 
Diva decloaker (pH 6.0 Biocare Medical, QLD, AUS) in a decloaking chamber (80°C - 20min) 
(Biocare Medical). Sections were blocked with PBS containing 5% normal donkey serum 
(NDS), 2.5% bovine serum albumin (BSA), 0.5% triton x-100 (TX-100), and 0.1% tween-20 
for 30min. Incubations with primary antibodies diluted in PBS containing 1% NDS, 0.5% TX-
100, and 0.1% tween-20 were carried out for 1h at room temperature (RT) (rabbit anti- NeuN, 
Abcam, #ab177487 1:1,000; mouse anti-laminin, Sigma Aldrich, #L8271, 1:500; goat anti-
swine IgG, Jackson Immunoresearch, #014-005-003, 1:1000). Tissue sections were 
washed with TBS-tween-20 (TBST) prior to incubation with appropriate species-specific 
secondary antibodies (1:1000, AlexaFluor AF488, 594, 680, Invitrogen, Life Technologies, 
AUS) for 1h in a dark humidifying chamber. Sections were counterstained with 4′,6-
diamidino-2-phenylindole (DAPI; Invitrogen), washed with TBST and mounted with Prolong 
Gold Antifade (Invitrogen Life Technologies, AUS, #P10144). Negative control sections 
were processed in parallel. 
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DAB staining was performed for whole section visualisation of IgG extravasation. Sections 
were incubated with goat anti-swine IgG (1:1000, Jackson Immunoresearch, PA, USA, 
#014005003) for 1hr at RT in the above blocking solution. Endogenous peroxidase activity 
was blocked with 0.3% hydrogen peroxide for 15minsat RT. Slides were washed in TBST 
and incubated with goat biotin (1:500, GE Healthcare, QLD, AUS) in PBS for 1h at 37°C. 
Slides were washed in TBST and incubated with HRP avidin (1:500, Sigma Aldrich, NSW, 
AUS, #A3151) in PBS for 1h at RT.  Slides then washed again in TBST and metal enhanced 
DAB substrate (Merck, VIC, AUS, #34065) was applied to slides for 1min. Slides were rinsed 
in H2O, cleared with xylene and mounted with DEPEX (Ajax FineChem, NSW, AUS).  
For assessment of neuronal degeneration slides were IgG labelled and stained with fluoro 
jade-C as follows. Sections were antigen retrieved using sodium citrate buffer (pH 6) in a 
decloaking chamber (80°C – 20min). Sections were blocked with the above blocking solution 
for 1h at RT. Primary antibody goat-anti-swine IgG (1:1000, Jackson Immunoresearch, PA, 
USA, #014585003) was incubated in the blocking solution at 1:1000 at 37°C for 1h. Cell 
nuclei were counterstained with DAPI. Slides were washed and incubated with 0.006% 
potassium permanganate in dH2O for 2.5min at 50°C. Following washing, slides were 
stained with 0.0001% Fluoro Jade-C (FJC) in 0.1% acetic acid for 15min. Slides were rinsed 
with dH2O, cleared with xylene and mounted with DEPEX. To minimise variability between 
protocols, all IHC staining was processed in batches containing negative control sections. 
4.3.9 IMAGE ACQUISITION AND ANALYSIS 
Image acquisition was conducted using an Olympus FV3000 confocal laser scanning 
microscope equipped with 3 excitation diode laser lines (473, 559, and 635nm) running 
Fluoview FV31S-SW (Version 2.3) (Olympus, Tokyo, Japan). Images were acquired at a 
resolution of 1024 by 1024 pixels using an Olympus UPlanFL N 40x oil NA = 1.30 objective. 
FJC stained slides were imaged with an Olympus BX41 light microscope with a DP70 
camera and a 40x objective. IgG DAB slides were scanned with a Pannoramic SCAN II 
digital slide scanner by 3D HISTECH with a 20x Plan-apochromat objective.  
Fiji ImageJ (Schindelin et al, 2012) with the Cell Counter plugin (Image Processing and 
Analysis in Java; National Institutes of Health, Bethesda, MD, USA) was used for 
quantification of positively labelled cell counts. All imaging and image analysis was 
completed under blinded conditions. 
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4.3.10 QUANTITATIVE POLYMERASE CHAIN REACTION 
Parietal cortex and hippocampal tissue (~30mg) were disrupted by mortar and pestle in the 
presence of liquid nitrogen and total RNA was extracted using a Macherey-Nagel nucleospin 
kit (Scientifix, VIC, AUS). 2μg of total RNA was treated with RQ1 Rnase-free DNase 
(Promega, NSW, AUS, #M6101) and cDNA was synthesised from DNase-digested total 
RNA with SuperScript III (Life Technologies, VIC, AUS), using random hexamers (New 
England Biolabs, distributed through Genesearch, QLD, AUS). Quantitative polymerase 
chain reaction (qPCR) was performed using a Rotor-Gene 6000 (Qiagen, VIC, AUS). The 
total reaction volume was 20µL, containing 100ng cDNA, 10µL SYBR green PCR master 
mix (Invitrogen, QLD, AUS), and 2μM each of forward and reverse gene-specific primers 
(Sigma Aldrich, NSW, AUS: claudin 5 (CLDN5), occludin (OCLN), zonula occludens 1 
(ZO1), vascular endothelial growth factor 1 (VEGF), matrix metalloproteinase 2 (MMP2), 
transforming growth factor beta (TGF), cyclooxygenase 2 (COX2), tumour necrosis factor 
alpha (TNF), C-C chemokine receptor type 5 (CCR5), C-X-C motif chemokine 10 
(CXCL10), interleukin 1 beta (IL1), interleukin 6 (IL6), interleukin 8 (IL8)). Reactions were 
incubated for 10min at 95°C for 5min, followed by 40 amplification cycles (20s - 95°C, 30s - 
55-65°C (annealing - primer specific – table 2.3), and 40s - 72°C. No template controls, and 
no SYBR controls were included in every run. Results were normalised to glyceraldehyde 
3-phosphate dehydrogenase (GAPDH). Data were analysed using the DDCT method and 
presented as log fold changes (log(2)2^(DDCT)) plus SEM (Livak and Schmittgen 2001). 
Gene-specific qPCR primers are detailed in Table 2.3. 
4.3.11 WESTERN BLOTTING 
Snap frozen tissue from parietal cortex or hippocampus were homogenised in a 5x volume 
of 1M Tris-HCl with 0.5M EDTA and centrifuged at 12,000 x g for 10mins at 4°C. A BCA 
assay was performed on the supernatant to estimate total protein lysate concentrations (Life 
Technologies, Thermo Fisher Scientific, AUS, #23225). Protein lysates (5-15ug) were 
resolved on 7.5, 10, or 15% SDS-PAGE gels (antigen specific – Table 2.4) at 150V for 
90min. Proteins were transferred to PVDF membrane (100V – 60 min) and the membrane 
was then blocked for 1h at RT with 5% skim milk powder in TBST. Membranes were 
incubated with goat anti-swine IgG for 2h at RT (1:50000, Jackson Immunoresearch, PA, 
USA, #114-005-003) or overnight at 4°C with CLDN5 (1:50000, abcam, QLD, AUS, 
ab131259), ZO1 (1:2500, Abcam, ab96587), or OCLN (1:3000, Abcam, ab222691). 
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Following primary antibody incubation, membranes were washed. Membranes were 
incubated with anti-goat HRP (1:30,000, Sigma-Aldrich, USA, #A0545) for 30min at RT (IgG) 
or with anti-rabbit HRP (1:30,000, Sigma-Aldrich, USA, #A5420,) for 1h at RT (CLDN5, ZO1, 
and OCLN). Signal was developed with the use of enhanced chemiluminescence (ECL) 
Luminata forte (Merck, VIC, AUS, #WBLUF0500) and proteins of interest were visualised 
on Fuji Super-RX Film (Konica SRX-101A, distributed by Shimadzu, QLD, AUS). A four point 
standard curve generated from each run using a pooled standard was used for 
quantification. (Goasdoue et al, 2016). Densitometry analysis was performed using ImageJ 
software (NIH, MD, USA). 
4.3.12 STATISTICAL ANALYSES 
Data were analysed with SPSS software (IBM Corp. SPSS Statistics 22.0, NY, USA). 
Normality and equality of variances were assessed using a Shapiro-Wilk test and Levene’s 
test respectively. Physiological parameters were analysed with a one-way MANOVA. 
Neurobehavioural and histology scores were analysed with a Kruskal-Wallis H test with 
pairwise comparisons using Dunn’s procedure and a Bonferroni correction. Correlations 
were performed with either Pearson’s or Spearman’s correlations. qPCR data (log(2) 2^(-
DDCT)) were analysed by a one-way ANOVA with a Tukey-Kramer post-hoc test. Western 
blot data were analysed by a one-way ANOVA with Tukey HSD post-hoc test. Significance 
was set at p<0.05. Data are presented as means ± standard error of the mean (SEM) unless 
otherwise stated. 
  
114 
 
4.4 Results 
4.4.1 PHYSIOLOGICAL DATA AND END INSULT PARAMETERS 
Thirty-eight animals were run as part of this study, nine died prior to the 72h time-point due 
to complications from HI. 29 remaining animals were classified into three groups - sham 
controls (sham) (n=5), HI - no seizures (HI-NoSz) (n=10) and HI - seizures (HI-Sz) (n=14). 
Physiological parameters are presented in Table 4.1. There were no significant differences 
in any of the physiological parameters between the two HI groups at baseline or at the end 
of the HI insult. Significant differences in end pH, end arterial base excess, and period of 
hypotension were observed between the sham group and both HI groups.  
Table 4.1: Insult parameters for sham, HI-Sz, and HI-NoSz animals. 
  Sham (n=5) HI-Sz (n=14) HI-NoSz (n=10) 
MABP before insult (mmHg) 46.4 (±4.5) 46.1 (±7.7) 42.9 (±6.8) 
MABP end insult (mmHg) 45.4 (±4.9) 19.4 (±4.5) 19.1 (±10.9) 
Time hypotensive during insult 0 11.92(±6.6)** 14.49 (±9.1)** 
pH before insult 7.42 (±0.04) 7.47 (±0.05) 7.48 (±0.04) 
pH end insult 7.41 (±0.05) 7.02 (±0.08)** 7.08 (±0.07)** 
ABE before insult (mmol/L) 1.32 (±2.0) 5.31 (±1.9)* 6.1 (±2.7)* 
ABE end insult (mmol/L) 2.5 (±2.97) -18.0 (±2.8)** -14.99 (±4.4)** 
pCO2 before insult (mmHg) 39.97 (±3.9) 39.71 (±5.82) 40.33 (±4.2) 
pCO2 end insult (mmHg) 43.6 (±5.7) 49.16 (±9.0) 49.56 (±16.0) 
pO2 before insult 97.23 (±23.5) 96.94 (±14.7) 99.1 (±20.2) 
pO2 end insult 97.72 (±21.6) 23.1 (±10.3) 26.0 (±14.9) 
Total insult duration (min) 30.00 29.53 (±03.04) 32.95 (±03.85) 
Total period LAEEG (min) 0 23.04 (±4.9)** 24.25 (±6.27)** 
Data are presented as mean±SD. Abbreviations: mean arterial blood pressure (MABP), minutes 
(min), millimetres of mercury (mmHg), millimole per litre (mmol/L), arterial base excess (ABE), partial 
pressure carbon dioxide (PaCO2), low amplitude EEG (LAEEG). 
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4.4.2 ANIMALS WITH SEIZURE HAVE POORER OUTCOMES THAN ANIMALS WITHOUT 
SEIZURE 
Background EEG scores 
Background pattern EEG scores are a robust indicator of short- and long-term brain outcome 
in neonates with HIE (Nash et al, 2011, Weeke et al, 2016). 13 of the 14 animals in the HI-
Sz group had full EEG recordings available for analysis. Nine of the 10 animals in the HI-
NoSz group had full EEG recordings available for analysis. Background aEEG patterns 
evaluated and scored for sham, HI-Sz, and HI-NoSz animals are presented in Figure 4.1. 
HI-Sz animals had significantly lower background pattern scores than Sham and HI-NoSz 
animals from 1h post-HI to 36h post-HI. HI-Sz animals also had significantly lower scores 
than HI-NoSz animals at 48h post-HI. The predominant pattern of aEEG background until 
36h post-HI was continuous low voltage in the HI-Sz animals (indicating poorer brain 
function), whereas sham and HI-NoSz animals exhibited continuous normal voltage and 
discontinuous normal voltage patterns primarily. aEEG background pattern scores in sham 
and HI-NoSz animals did decrease at 36h toward continuous low voltage, this time-point is 
at the end of the anaesthesia period and may reflect anaesthesia build-up.  
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Figure 4.1: Amplitude integrated electroencephalography background pattern scores (mean±SEM). 
* indicates significant difference from sham (p<0.05), # indicates significant difference from HI-NoSz 
(p<0.05). n=5 all sham groups, n=13 all HI-Sz groups, n=9 all HI-NoSz groups. 
 
Seizure burden analysis 
For HI-Sz animals (n=13) the total number of seizures, seizure burden, average seizure 
length, time spent seizing, and time of maximal seizure burden was calculated and 
presented in Table 4.2. The average length of EEG recording was 45h 38min and 15s with 
a range of approximately 37-55h. The average time to first seizure was 23h (range: 
2h21min-38h35min). The average seizure duration was 1min 16s (range: 28s to 2min 57s). 
The time of maximal seizure burden was 48.85h post-HI (range: 34-68h). Every HI-Sz 
animal save 1 had clinical signs of seizure. 13 of the 14 animals received anti-epileptic drugs, 
five animals required second-line treatment after clinical seizures did not resolve. 
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Table 4.2: Characteristics of hypoxia-ischemia induced seizures 
Abbreviations: electroencephalography (EEG), hypoxia ischaemia (HI) 
 
Neurobehaviour 
Neurobehavioural scoring in our piglet model has previously been validated to be associated 
with poor outcomes (Miller et al. 2016). Neurobehavioral assessment was performed at 4 
hourly intervals following recovery from anaesthesia. Neurobehavioural scores for sham, HI-
Sz, and HI-NoSz animals are presented in Figure 4.2. Higher neurobehavioural scores 
indicate better neurobehavioural outcome. The HI-Sz animals scored significantly lower 
compared with both sham and HI-NoSz animals at every time-point (p<0.05). There was no 
significant difference between sham animals and HI-NoSz animals at any time-point.  
Seizure parameter Mean Range 
Length of EEG recording 
(h:min:s) 
45:38:15 37:14:01-54:50:36 
Time to first seizure 
(h:min:s) 
23:10:35 02:21:55-38:35:50 
Total number of seizures 39 4-128 
 
Average seizure duration 
(h:min:s) 
00:01:16 00:00:28-00:02:57 
Total seizure burden 
(h:min:s) 
00:47:47 00:03:54-02:39:30 
Maximal seizure burden  
(min/h) 
15min 45s 2min 25s – 46min 56s             
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Figure 4.2: Neurobehavioural scores in sham, HI-Sz, and HI-NoSz animals from 48h to 72h post-HI 
(mean+SEM).  * indicates significantly different from sham (p<0.05), # indicates significantly different 
from HI-NoSz (p<0.05). n=5 all sham groups, n=14 all HI-Sz groups except 56 and 64h where n=12, 
and 60h where n=13. n=8 all HI-NoSz groups except 48h and 72h (n=10). 
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Histopathology 
Histopathology was assessed in the regions of parietal cortex and hippocampus. 
Haemotoxylin and eosin staining revealed evidence of cell injury and cell death in both HI 
groups - signs included chromatin condensation, vacuolation, and pyknotic nuclei. 
Histopathology scores for shams and HI groups are presented in Figure 4.3. HI animals 
appeared to have greater histopathological injury than sham animals (Figure 4.3). HI-Sz 
animals had significantly greater histopathological injury compared with sham animals in the 
parietal cortex and hippocampus (p<0.01). While more pronounced in the HI-Sz animals, 
there was no significant difference in histopathological score between HI-Sz and HI-NoSz 
animals.  
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Figure 4.3: Example histology scores and haematoxylin and eosin stained parietal cortex (A-C) and 
hippocampus (D-F). Representative images from sham (A, D), Hypoxic ischaemic animals with 
seizure (HI-Sz) (B, E), and hypoxic ischaemic animals without seizure (HI-NoSz) (C, F). Closed 
arrows show healthy neurons, open arrows show damaged neurons with condensed nuclei, and * 
indicates vacuolation. Histopathology scores from sham, HI-Sz, and HI-NoSz animals in parietal 
cortex and hippocampus are presented in G (mean+SEM). ** indicates significantly different from 
sham (p<0.01).  
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4.4.3 BLOOD-BRAIN BARRIER DISRUPTION IS EVIDENT IN ANIMALS WITH SEIZURE 
In animals with seizures, IgG-DAB staining of right hemisphere brain sections revealed 
extensive IgG staining of the parietal cortex and hippocampus (Figure 4.4). IgG staining 
was also observed in HI-NoSz animals but to a much lesser degree.  
Figure 4.4: Examples of immunoglobulin G staining in sham, and hypoxic ischaemic (HI) animals 
with and without seizures (HI-Sz, HI-NoSz respectively) (two examples in the same region for each 
group). 
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Quantification of IgG extravasation by western blotting showed significantly greater levels of 
IgG in the parietal cortex of HI-Sz animals compared with both sham and HI-NoSz animals 
(p<0.001) (Figure 4.5A). Similarly, in the hippocampus we found significantly greater levels 
of IgG in HI-Sz animals compared with both sham (p<0.05), and HI-NoSz animals (p<0.01) 
(Figure 4.5B). There was no significant difference between sham and HI-NoSz animals in 
either brain region. 
Figure 4.5: IgG presence as determined by western blot in parietal cortex (A) and hippocampus (B) 
brain sections in sham (n=5), HI-Sz animals (n=14), and HI-NoSz animals (n=10). * indicates HI-Sz 
significantly different from sham, # indicates HI-Sz significantly different from HI-NoSz (*p<0.05, 
**p<0.01, ***p<0.001) + denotes quantified IgG band.  
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Seizure burden is associated with greater BBB-disruption 
Given our results have demonstrated that animals with seizure have greater IgG 
extravasation, correlation analysis was undertaken to ascertain the degree to which seizure 
may influence IgG extravasation into the brain. The temporal evolution and seizure burden 
are plotted in Figure 4.6A. In the parietal cortex total seizure burden correlated significantly 
with IgG level as determined by western blot analysis (r=0.801 p<0.001) (Figure 4.6B). In 
addition, total seizure burden was strongly associated with IgG level in the hippocampus 
(r=0.717, p<0.01). DAB stained sections demonstrate IgG staining is less intense in animals 
with decreasing seizure burden (Figure 4.6C). 
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Figure 4.6: Seizure burden is associated with degree of IgG extravasation. (A) A temporal raster 
plot of seizure burden (minutes in seizure/minutes of recording) for 13/14 animals with seizure 
ranked from 1=highest seizure burden to 13=lowest seizure burden. Scale is not continuous – 
periods where no animal is in seizure have been excluded. (B) Correlation between IgG presence in 
the parietal cortex as determined by western blot, and seizure burden (C). IgG staining of animals 1, 
3, 5, 9, 11, and 13 (A) demonstrating decreasing intensity of IgG staining with decreasing seizure 
burden, along with representative HI-NoSz and sham animal staining.  
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IgG extravasation following HI and seizures show specific patterns of staining 
IgG extravasation was demonstrated in HI-Sz and HI-NoSz animals, however, both the 
degree of HI injury (based on histology, neurobehaviour, and background aEEG pattern) 
and presence or absence of seizure altered the pattern of IgG-labelling between and within 
the two groups. Representative images of IgG labelling in parietal cortex for sham, mild HI 
animals, and severe HI animals are demonstrated in Figure 4.7. 
In mild HI-NoSz animals, distinct leakage ‘halos’ of IgG surrounding blood vessels was 
observed to varying degrees, however, aside from areas of halo leakage, there was not 
substantial evidence of parenchymal or neuronal IgG labelling (Figure 4.7D-F). In HI-NoSz 
animals with more severe damage, halo leakages of IgG were not obvious, however, there 
was clear labelling of neurons (Figure 4.7G-I). In mild HI-Sz animals, parenchymal labelling 
was not restricted to the tissue immediately surrounding blood vessels but more widespread 
with a large number of neurons demonstrating IgG labelling (Figure 4.7J-L). In severe HI-
Sz animals, parenchymal IgG labelling extensive, indicating large areas of the parietal cortex 
was affected by BBB-disruption (Figure 4.7M-O). Fewer neurons with IgG staining were 
observed, however, this could be due to neuronal loss. Sham animals demonstrated very 
low to absent parenchymal staining, rare IgG positive neurons, and no IgG leakage halos – 
indicating an intact BBB (Figure 4.7A-C). 
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Figure 4.7: Differential labelling patterns of IgG extravasation. Representative immunofluorescence 
of parietal cortex sections labelled with immunoglobulin G (IgG) (green: A, D, G, J, M), neurons 
(NeuN) (purple: B, E, H, K, N), basement membrane of vessels (laminin) (red) and cell nucleai (DAPI) 
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(blue). Merge images are presented in C, F, L, and O. IgG staining is constrained to the blood vessels 
in sham animals (A, B, C). Panels D, E, and F show halo leaks of IgG from compromised blood 
vessels in a mild HI-NoSz animal (indicated by arrow). A mild amount of extravasation of IgG from 
blood vessels and neuronal IgG staining in a severe HI-NoSz animal is evidenced in G, H, and I, and 
a more severe extravasation and neuronal uptake in a mild HI-Sz animal (J, K, L) (indicated by 
arrowhead). Panels M, N, and O demonstrate IgG positive neuron, and high parenchymal IgG 
fluorescence in the severe HI-Sz animal. HI severity is based off neurobehavioural score, histology, 
and background EEG pattern. Scale bars = 50m. 
 
4.4.4 NEURONAL UPTAKE OF IGG IS ASSOCIATED WITH NEURONAL DEGENERATION 
AND POOR OUTCOME 
Given the presence of neuronal IgG in animals with HI and seizure, we assessed if IgG+ 
neurons were associated with neuronal damage. Overall, HI-Sz animals had significantly 
greater numbers of IgG+ cells (599.4 ±196.1 cells/mm2), compared with sham (20.75 ± 14.1 
cells/mm2) and HI-NoSz animals (106.3 ±124.8 cells/mm2) (p<0.001) (Figure 4.8 D, E). FJC 
co-labelling revealed that HI-Sz animals had significantly greater numbers of IgG+/FJC+ co-
labelled neurons compared with sham and HI-NoSz animals (p<0.001) (Figure 4.8J). In the 
HI-Sz group 70.4% of IgG+ cells co-localised with FJC and in the HI-NoSz group 55.9% of 
IgG+ cells co-localised with FJC. There is a significant relationship between total counts of 
IgG+ cells and FJC+ cells (p<0.001, r=0.892).  
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Figure 4.8: IgG-positive cells are associated with neuronal degeneration. Figure A-I shows 
representative images for IgG+ neurons (A, D, G), Fluoro-Jade C (FJC) (B, E, H), and merge (C, F, 
I) demonstrating very few IgG+ cells in sham animals (C-F), a large number of IgG+ and FJC+ cells 
in hypoxic ischaemic (HI) animals with seizures (HI-Sz) (G-K), and fewer IgG+ and FJC+ cells in HI 
animals without seizures (HI-NoSz) (L-O). Graphs J illustrates the cell counts for co-localisation of 
IgG and FJC for sham, HI-Sz, and HI-NoSz animals. Data are presented as mean±SEM. All groups 
n=5. * indicates significantly different from sham, # indicates significantly different from HI-NoSz (*** 
p<0.001).  
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4.4.5 IgG EXTRAVASATION CORRELATES WITH MARKERS OF INJURY 
IgG abundance in the parietal cortex and hippocampus was correlated with aEEG 
background pattern scores, neurobehavioural outcome, and histopathology (Table 4.3). The 
strongest correlation between IgG expression and aEEG background pattern was found at 
48h post HI (p<0.001, rs=-0.812). We found that IgG expression significantly correlated with 
neurobehaviour at all time-points and with histopathology scores in both the parietal cortex 
and hippocampus. IgG did not correlate with end insult parameters in parietal cortex, but a 
moderate correlation was observed between IgG in hippocampus and end HI insult pH 
(p<0.05, r=-0.510). 
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Table 4.3: IgG protein level correlates with outcome indicators 
Abbreviations: arterial base excess (ABE), immunoglobulin G (IgG), post-insult (PI). Significant 
associations are indicated in bold. 
Variable   IgG level Parietal 
Cortex 
IgG level 
Hippocampus 
Background pattern 1h PI 
 rs -0.601 -0.614 
 p 0.004 0.003 
Background pattern 2h PI 
 rs -0.616 -0.629 
 p 0.003 0.002 
Background pattern 4h PI 
 rs -0.778 -0.767 
 p 0.000 0.000 
Background pattern 8h PI 
 rs -0.765 -0.708 
 p 0.000 0.000 
Background pattern 12h PI 
 rs -0.775 -0.713 
 p 0.000 0.000 
Background pattern 24h PI 
 rs -0.686 -0.522 
 p 0.001 0.015 
Background pattern 36h PI 
 rs -0.465 -0.566 
 p 0.034 0.008 
Background pattern 48h PI 
 rs -0.812 -0.784 
 p 0.000 0.000 
Background pattern 72h PI 
 rs -0.770 -0.676 
 p 0.000 0.001 
Histology score- Parietal cortex 
 rs 0.768 
  p 0.000 
Histology score – hippocampus 
 rs 
 
0.558 
 p 0.007 
Neurobehavioural score – 48h 
 rs -0.642 -0.587 
 p 0.001 0.002 
Neurobehavioural score – 52h 
 rs -0.712 -0.638 
 p 0.000 0.001 
Neurobehavioural score – 56h 
 rs -0.743 -0.602 
 p 0.000 0.003 
Neurobehavioural score – 60h 
 rs -0.779 -0.718 
 p 0.000 0.000 
Neurobehavioural score – 64h 
 rs -0.733 -0.713 
 p 0.000 0.000 
Neurobehavioural score – 68h 
 rs -0.700 -0.716 
 p 0.000 0.000 
Neurobehavioural score - 72h 
 rs -0.686 -0.612 
 p 0.000 0.001 
Length of hypoxia 
 r -0.273 -0.216 
 p 0.197 0.31 
Time hypotensive 
 r -0.028 -0.048 
 p 0.898 0.822 
End pH 
 r -0.376 -0.510 
 p 0.070 0.011 
End ABE 
 r -0.277 -0.378 
 p 0.189 0.068 
131 
 
4.4.6 ALTERATIONS TO TIGHT JUNCTIONS 
Seizures do not cause mRNA expression changes to the tight junctions 
Tight junctions are proteins that join cerebrovascular endothelial cells and are responsible 
for the physical barrier properties of the BBB; their presence is indicative of BBB integrity. 
We examined mRNA and protein expression of the tight-junction proteins (CLDN5, ZO1, 
OCLN). mRNA expression of CLDN5, OCLN and ZO1 were not significantly altered in either 
HI group in the parietal cortex or hippocampus compared with sham animals (Figure 4.9 A-
B).  
Figure 4.9: mRNA changes to tight junction genes. mRNA expression of tight junctions in parietal 
cortex (A), and hippocampus (B). Data are presented as mean log fold change ± SEM. Abbreviations: 
Claudin 5 (CLDN5), occludin, (OCLN), zonula occludens 1 (ZO1). 
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Seizure is associated with protein changes to the tight junctions 
However, we did identify reductions to protein expression of several of the tight junction 
proteins (Figure 4.10). A significant reduction in OCLN protein expression was observed in 
the parietal cortex of the HI-Sz group compared with both sham and HI-NoSz groups 
(p<0.05) (Figure 4.10C). Similarly, ZO1 protein was significantly reduced in the parietal 
cortex of HI-Sz animals compared with both sham and HI-NoSz animals (p<0.01) (Figure 
4.10E). There was no difference in OCLN or protein expression in the hippocampus between 
any group (Figure 4.10C). CLDN5 protein expression did not differ between any group in 
either parietal cortex of hippocampus (Figure 4.10A-B). In addition to the expected 
molecular weight OCLN protein (60kDa), we observed a second smaller protein of ~50kDa 
in some samples. This second band appears in 12/14 HI-Sz animals, but only 1/10 HI-NoSz 
animals (Figure 4.10C-D). 
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Figure 4.10: Alterations to protein level of tight junctions in parietal cortex and hippocampus. Claudin 
5 (CLDN5) protein level as determined by western blot in parietal cortex (A), and hippocampus (B). 
Occludin (OCLN) protein level in the parietal cortex (C), and hippocampus (D), and zonula occludens 
134 
 
1 (ZO1) protein level in the parietal cortex (E) and hippocampus (F). Data are presented as 
mean+SEM, (* denotes significantly different from sham, # denotes significantly different from HI-
NoSz: * p<0.05, ** p<0.01, *** p<0.001). 
 
4.4.7 POTENTIAL MECHANISMS OF SEIZURE ASSOCIATION WITH BBB-DISRUPTION 
qPCR analysis of BBB-integrity associated genes 
There are a number of proteins that can breakdown the BBB or have an impact on the 
permeability of the BBB. Vascular endothelial growth factor A (VEGFA) has previously been 
associated with newer, leaky blood vessels, whereas matrix metalloproteinase 2 (MMP2) is 
a mediator of basement membrane breakdown and increases BBB permeability. GLUT1 
and AQP4 are essential transporters at the BBB. AQP4 perturbations are implicated in 
oedema formation following pathology (Badaut et al. 2011). GLUT1 alterations reduce the 
availability of glucose to the brain and have been associated with BBB-disruption (Abdul 
Muneer et al. 2011). 
As a preliminary analysis regarding potential mechanisms of increased BBB dysfunction in 
animals with seizure, we analysed the mRNA alterations to these genes. Alterations to 
VEGFA, MMP2, GLUT1, and AQP4 in parietal cortex and hippocampus are demonstrated 
in Figure 4.11. In the parietal cortex there was a significant downregulation of VEGFA in the 
HI-Sz group compared with both sham, and HI-NoSz animals (p<0.001). MMP2 was 
significantly upregulated in the HI-Sz animals compared with HI-NoSz animals (p<0.001). 
GLUT1 was significantly downregulated compared with sham animals in both HI groups 
(p<0.05) – with no difference between animals with and without seizures. AQP4 was 
significantly reduced in HI-Sz animals compared with both sham (p<0.05) and HI-NoSz 
animals (p<0.01). There was no difference in AQP4 mRNA expression in HI-NoSz animals 
compared with shams (Figure 4.11A). 
In the hippocampus there was a significant downregulation of VEGFA in the HI-Sz group 
compared with the HI-NoSz group (p<0.01) and the sham group (p<0.05). MMP2 was 
upregulated in the HI-Sz group compared with HI-NoSz animals, but not sham (p<0.01). 
GLUT1 was significantly downregulated in the HI-Sz group compared with shams (p<0.05), 
but there was no significant difference compared with HI-NoSz animals. There was no 
change in AQP4 mRNA expression in HI groups compared with shams (Figure 4.11B). 
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Figure 4.11: Differential regulation of genes associated with BBB-disruption in sham (n=5), HI-Sz 
(n=10), and HI-NoSz (n=9) animals. Expression differences between sham, HI-Sz, and HI-NoSz are 
shown for parietal cortex (A, C), and hippocampus (B, D). Significantly different from sham is 
indicated by *, significantly different from HI-NoSz is indicated by # (* p<0.05, ** p<0.01, *** p<0.001). 
Abbreviations: vascular endothelial growth factor A (VEGFA), matrix metalloproteinase 2 (MMP2). 
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qPCR analysis of inflammatory genes that are associated with  BBB-disruption  
To explore potential mechanisms of BBB dysfunction, we analysed inflammatory cytokines 
and chemokines that have been associated with BBB-disruption (Figure 4.12). In the 
parietal cortex, mRNA expression of TGF, TNF, IL6, IL8, and IL1 were significantly 
upregulated in the HI-Sz group compared with sham animals while TNF, CCR5, IL1, IL6, 
and IL8 were significantly upregulated in the HI-Sz group compared with HI-NoSz animals. 
Only TNF and IL6 were significantly upregulated in HI-NoSz animals compared with sham 
(p<0.001) (Figure 4.12A). 
The hippocampus followed a similar pattern with mRNA expression of TGF, COX2, TNF, 
IL1, IL6, and IL8 upregulated in the HI-Sz group compared with sham animals. HI-Sz 
animals also had significantly upregulated COX2, CXCL10, IL1, IL6, and IL8 mRNA 
expression compared with HI-NoSz animals. IL6 was significantly upregulated in the HI-
NoSz group compared with sham group (p<0.001). (Figure 4.12B). 
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Figure 4.12: Differential regulation of genes associated with inflammation in sham (n=5), HI-Sz 
(n=10), and HI-NoSz (n=9) animals. Expression differences between sham, HI-Sz, and HI-NoSz are 
shown for parietal cortex (A), and hippocampus (B). Significantly different from sham is indicated by 
*, significantly different from HI-NoSz is indicated by # (*p<0.05, **p<0.01, ***p<0.001). 
Abbreviations: transforming growth factor beta (TGF), cyclooxygenase 2 (COX2), tumor necrosis 
factor alpha (TNF), C-C chemokine receptor type 5 (CCR5), C-X-C motif chemokine 10 (CXCL10), 
interleukin-1beta (IL1), interleukin 6 (IL6), and interleukin 8 (IL8). 
138 
 
4.5 Discussion 
This chapter explored the association between BBB-disruption and seizure in the neonatal 
HI piglet. We showed that HI animals with seizure have greater BBB-disruption through 
increased permeability to IgG and decreased tight junction protein expression when 
compared with HI animals without seizure. Our study had the advantage of a clinically-
relevant model of neonatal HIE which we could manipulate to achieve a consistent level of 
HI insult, and in which seizures arise spontaneously following HI. We observed that animals 
with seizure displayed substantial changes to BBB permeability compared with animals 
without – despite a similar initial HI-injury.  
4.5.1 SEIZURES AND BLOOD-BRAIN BARRIER DISRUPTION 
Literature, predominantly from traumatic brain injury and adult stroke, tells us that seizure 
and BBB-disruption can substantially influence each other. The reciprocal nature of this 
relationship continues to be a major challenge in this area of research as it is difficult to 
determine the driving factor (Librizzi et al. 2012, Weissberg et al. 2015). Despite this, it is 
likely that seizures and BBB-disruption are processes that worsen each other and may play 
an important role in pathogenesis after neonatal HIE. 
A small number of studies have been performed investigating BBB-disruption in neonates 
with HIE and in animal models of neonatal HI (Mirro et al. 1991, Kumar et al. 2008, Chen et 
al. 2012, Ek et al. 2015, Shi et al. 2016). However, there has been exceedingly little 
investigation on the impact of seizures on BBB-disruption following neonatal HI. Parfenova 
and colleagues (2010) demonstrated that bicuculline-induced seizures in newborn piglets 
cause an increase in brain-derived circulating endothelial cells (BCECs) in blood samples 
collected 2-4h after seizure onset. Endothelial cells make up cerebral microvessels and 
when damaged slough off and can be detected in circulating blood as BCECs (Parfenova et 
al. 2010).  In humans, infants with seizure following asphyxia or intraventricular 
haemorrhage had higher levels of BCECs than infants without seizure and this was 
associated with HIE severity (Pourcryrous et al. 2015). Schiering et al, 2014 showed in post-
mortem tissue from full-term asphyxiated infants that all cases with seizure displayed 
alterations to the BBB. (Schiering et al. 2014). Seizure cases had significantly higher 
permeability to albumin as indicated by immunohistochemistry than asphyxiated infants 
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without seizure, despite the asphyxia insults being severe enough to cause death in all 
cases. 
4.5.2 WHY ARE SEIZURES ASSOCIATED WITH POOR OUTCOME? THE LINK BETWEEN 
BBB-DISRUPTION AND NEUROPATHOLOGY 
Studies have shown that seizures can independently exacerbate HI brain injury (Wirrell et 
al. 2001, Yager et al. 2002). Our evidence suggests that BBB-disruption may also play a 
role in neonates with seizure following HIE in worsening brain injury and outcomes. We have 
demonstrated for the first time that IgG protein level significantly correlates with seizure 
burden in a neonatal HI model. 
We also demonstrated that IgG protein level correlates with aEEG background pattern 
scores, neurobehavioural scores, and histology scores indicating animals with disrupted 
BBB have altered brain activity and poorer outcomes. Importantly, IgG level did not correlate 
strongly with indicators of initial HI severity such as HI length, period of hypotension, end 
pH, or end ABE. This adds weight to the hypothesis that BBB-disruption several days after 
the HI insult is related to the evolution of pathological processes and injury rather than the 
initial HI severity (Yeh et al. 2012). 
Seizures can influence a variety of pathological processes including inflammation and 
excitotoxicity (Yager et al. 2002, Librizzi et al. 2012, Vezzani et al. 2013). BBB-disruption 
has also been shown to result in worsened oedema, inflammation (including invasion of 
peripheral immune cells such as macrophages), and altered brain parenchymal 
microenvironment (changes to ion concentrations, serum protein extravasation, altered 
glutamate concentration, and pH changes) all of which may increase neuropathology (Smith 
2000, David et al. 2009, Iffland et al. 2014).  
Most animals with seizure (13/14) were treated with anti-epileptic drugs and it is not clear 
the effect AED’s may have had on the relationship between seizures and BBB-disruption.  
However, animals were only treated with antiepileptic drugs with clinical seizures – which 
only occurred after recovery from anaesthesia (~40h post-HI). Although the majority of 
animals had electrographic seizures within the anaesthetic period and therefore the majority 
of animals had most of their seizures before treatment with antiepileptic drugs. There is not 
any evidence currently available to suggest that phenobarbital itself may have affected BBB-
disruption, but it is worth noting that BBB changes can alter the effectiveness of 
phenobarbital via buffering of the drug in the brain due to higher concentrations of serum 
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proteins, alterations of the pH gradient at the BBB leading to changes in phenobarbital brain 
uptake, or expression alterations due to HI of the drug transporter responsible for 
phenobarbital influx (Simon et al. 1985, Liu et al. 2007, Marchi et al. 2009) 
4.5.3 THE EFFECT OF IgG EXTRAVASATION 
Our study demonstrated altered BBB permeability to IgG which was present in both brain 
parenchyma and neurons and particularly evident in animals with seizures. Our study also 
demonstrated that IgG+ neurons co-labelled frequently with FJC – indicative of neuronal 
degeneration. IgG in adult epileptic conditions has been found to label a large percentage 
of hippocampal pyramidal neurons as well as smaller numbers of astrocytes. Pyramidal 
neurons labelled with IgG demonstrated shrunken perikarya and corkscrew shaped 
dendrites (Michalak et al. 2012). This result indicates that IgG extravasation – which is more 
severe in our animals with seizure – is related to the degeneration of neurons and is 
potentially contributing to cell death in these animals. However, dying cells are also more 
likely to take up serum proteins and thus we cannot be sure that the association between 
IgG and neuronal degeneration in this case is causative. 
Endogenous blood-product extravasation measurement is a common way of assessing 
BBB-disruption (Chen et al. 2009, Schiering et al. 2014, Zhang et al. 2016). Previous studies 
have suggested that IgG leakage is more prominent than extravasation of similar weight 
dextrans, or Evans blue – two other common ways of assessing BBB-disruption (Zhang et 
al. 2016). Therefore, it is possible IgG build up in the brain parenchyma does not occur solely 
through disruption of vascular endothelial cells and tight junctions per se but through 
transcellular movement, or accumulation in the parenchyma due to impaired or saturated 
efflux mechanisms. Despite this, the result of increased IgG staining in seizure-affected 
animals is significant not only as an indicator of BBB-disruption, but as an indicator of 
pathology. Accumulation of blood products in the brain parenchyma has been shown to 
perturb neuronal function and survival, and contribute to brain injury and pathogenesis 
(Michalak et al. 2012, Liu et al. 2016, Ohmori et al. 2018).  
4.5.4 WHY DO ANIMALS WITH SEIZURE HAVE MORE BBB-DISRUPTION? 
Western blot analysis showed that the tight junction proteins OCLN and ZO1 were 
significantly downregulated in animals with seizure, however CLDN5 did not change in our 
study which is consistent with other investigations (Ek et al. 2015, Barton et al. 2016). In 
addition to these losses, we noticed an increase in an immunoreactive band at a lower 
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molecular weight (approximately 50kDa) in the OCLN western blots. It is unclear why some 
animals had the extra OCLN band on their western blots – it did appear to be associated 
with seizure – it occurred in 9 of the 14 seizure animals, and in only 1 of the no seizure 
animals and was consistently present in the same animals and to the same degree. This 
observation may be due to the fact that OCLN can exist in a number of isoforms and 
structures or may be an inactive OCLN fragment due to proteolytic degradation. A study that 
investigated tyrosine phosphatase activity demonstrated accumulation of a genuine OCLN 
band of a similar size to the one we observed (Wachtel et al. 1999). Inhibition of proteolysis 
of OCLN reduces permeability of human umbilical vein endothelial cell lines in vitro.  
Inflammation might provide a mechanism for the association between seizures, BBB 
disruption, and higher levels of brain injury. There is strong evidence that seizure alone can 
contribute to neuroinflammation (Librizzi et al. 2012), and the current clinical and 
experimental data in children and adult seizure and epilepsy pathologies supports the 
hypothesis that neuroinflammation due to impaired BBB are relevant to the pathophysiology 
of seizures. Exacerbation of neuroinflammation from peripheral immune cells through the 
impaired barrier may contribute to seizure propensity (Kim et al. 2012, Marchi et al. 2014). 
However, in neonates with HI injury peripheral immune cells such as neutrophils or 
lymphocytes have been shown to infiltrate at much lower rates than their adult counterparts 
(Hudome et al. 1997, Benjelloun et al. 1999, Bona et al. 1999). On the other hand, 
inflammation has also been shown to contribute to BBB-disruption (Erickson et al. 2012, 
Varatharaj and Galea 2016).  
We demonstrated using qPCR analysis that a number of genes that have been associated 
with BBB-disruption were differentially expressed in animals with seizure in this study. Pro-
inflammatory markers TGF, IL1, IL6, IL8, and TNF were increased in our HI-Sz group 
compared with sham, and HI-NoSz animals.  
These inflammatory chemokines and cytokines have been associated with BBB-disruption 
in several other studies (Varatharaj and Galea 2016). Intracerebral TNF administration in 
adult rodents results in increased BBB permeability (Rosenberg et al. 1995) whereas 
reducing TNF expression in a rodent stroke model with an anti-TNFantibody can 
attenuate this disruption (Yang et al. 1999). The interleukins IL6, IL8, and IL1 have been 
found to increase BBB permeability (Kossmann et al. 1997, Blamire et al. 2000, Cohen et 
al. 2013, Zhang et al. 2015). IL1 has been shown to increase BBB permeability as 
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measured by MRI in juvenile rats (Blamire et al. 2000). IL6 is associated with OCLN and 
CLDN5 expression on isolated microvessels from juvenile and adult sheep (Cohen et al. 
2013) and treatment with anti-IL6 is protective of the BBB in a fetal sheep HI model (Zhang 
et al. 2015). IL8 has been associated with BBB-disruption in adult patients with TBI 
(Kossmann et al. 1997). Despite the anti-inflammatory effects of TGF, it has been shown 
to exacerbate BBB-disruption via alterations to VEGF and MMPs, and by decreasing CLDN5 
expression (Zhang et al. 2012, McMillin et al. 2015). 
VEGF is a growth factor that plays a key role in inflammation and angiogenesis, VEGF has 
also been shown to play a role in modulating vessel permeability via direct effects on 
endothelial cells and changes to tight junctions (Hippenstiel et al. 1998, Fischer et al. 2002, 
Shibuya 2009). We found a significant downregulation of VEGFA mRNA in our HI-Sz group. 
This finding was unexpected – as the majority of previous work suggests that both seizure 
and hypoxia strongly induce upregulation of VEGF and increased VEGF is associated with 
increased disease severity (Nicoletti et al. 2008, Aly et al. 2009, Vasiljevic et al. 2011, 
Baburamani et al. 2013). It is unclear if the reduction in VEGF we found in our HI-Sz animals 
is contributing to seizure-related pathology – VEGF may contribute to repair processes (Nag 
et al. 1997) therefore a reduction in VEGFA in HI-Sz animals may suggest altered repair 
mechanisms. 
MMP2 has a critical role in inflammation-mediated vascular dysfunction. Inflammatory 
cytokines (such as IL1 and TNF) have been shown to induce MMPs which can result in 
basement membrane breakdown and tight junction protein cleavage (Shigemori et al. 2006). 
We found that MMP2 mRNA expression in the parietal cortex were significantly upregulated 
following HI with seizures. MMP2 has been linked with downregulations of ZO1, OCLN, and 
CLDN5 through proteolytic degradation or rearrangement (Yang et al. 2007, Bauer et al. 
2009, Liu et al. 2012).  MMPs have been shown to cleave OCLN into an 50kDa product, this 
secondary product was particularly evident in our animals with seizures (Wachtel et al. 
1999).  
GLUT1 is the major transporter of glucose across the BBB. As such, altered GLUT1 
expression may lead to impaired glucose metabolism. GLUT1 deficiency has previously 
been shown to contribute to pathology and BBB breakdown in an Alzheimer’s model 
(Winkler et al. 2015). Previous studies in rodents suggest that GLUT1 mRNA expression is 
upregulated in the early hours following HI and returns to control levels by 72h (Vannucci 
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and Vannucci 1997). However, we demonstrate that both HI groups at 72h had decreased 
expression of GLUT1 compared with shams. We note that like VEGF, GLUT1 is regulated 
by HIF1– it is possible that the differential gene regulation we are 
seeing is due to a difference in HIF expression in our model. 
AQP4 is an essential bi-directional water channel, its dysfunction in the forms of both up and 
downregulation has previously been associated with oedema formation (Papadopoulos and 
Verkman 2005, Badaut et al. 2007, Badaut et al. 2011, Tourdias et al. 2011). The loss we 
observed in the animals with seizure could therefore contribute to neuropathology in this 
group via exacerbated oedema formation or impairment of water clearance – especially as 
this time-point 3 days after HI insult is correlated with vasogenic oedema peak. However, 
more work into AQP4’s protein expression, localisation, and timing of alterations needs to 
be performed before we explore APQ4 as a target for therapy due to its complex role in vivo. 
4.5.5 CONCLUSIONS 
It is likely that seizures and BBB-disruption are pathological processes that worsen each 
other. In our study seizures and BBB-disruption are correlated and propose that targeting 
BBB-disruption may be one way to reduce neuropathology in seizing neonates. Future 
studies are required to elucidate the exact nature of the BBB-disruption/seizure relationship 
in the neonate. 
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CHAPTER 5 - THE IMPACT OF THERAPEUTIC 
HYPOTHERMIA ON THE BLOOD-BRAIN BARRIER 
FOLLOWING HYPOXIC ISCHAEMIC 
ENCEPHALOPATHY 
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Chapter preface 
The previous chapters have demonstrated that blood-brain barrier (BBB) disruption occurs 
in our piglet model of neonatal hypoxic ischaemic encephalopathy (HIE), and that BBB-
disruption is most severe in animals with seizure. Figure 5.0 demonstrates the proposed 
model of BBB-disruption in HI animals. BBB-disruption occurs early in animals to varying 
degrees which results in increased serum protein extravasation into brain tissue and 
inflammation, which may predispose animals to seizure or worsen seizure. Seizures then 
exacerbate BBB-disruption and results in a negative, injurious feedback loop. 
Figure 5.0: Diagram describing the hypothesis for the direction of the relationship between BBB-
disruption, seizures, and outcome. Abbreviations: blood brain barrier (BBB), vascular endothelial 
growth factor (VEGF), matrix metalloproteinases (MMPs). 
We next investigated how a commonly used neuroprotective strategy in neonates with HIE 
might affect this process. In order to achieve this aim I utilised the same data set of animals 
from Chapter 4 (referred to here as normothermic (NT) animals and sham animals) and 
compared their outcome, BBB permeability and integrity, and possible mechanisms of BBB-
disruption to animals that were treated with 24h of HT. 
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5.1 Abstract 
Neonatal hypoxic-ischaemic encephalopathy (HIE) can result in death or serious long-term 
sequelae. Therapeutic hypothermia is (HT) is currently the only treatment for neonates 
suffering from HIE. HT improves short and long term outcomes through ameliorating 
pathological processes that occur following a HI event. We sought to understand the effect 
of HT in the context of neonatal HIE on one such process - blood-brain barrier (BBB) 
disruption. Piglets (<24h) were subjected to a 30-minute HI insult followed by recovery to 
72h post insult. At 2h post-HI insult, piglets were either cooled to 33.5°C for a period of 24h, 
or maintained at normal body temperature (normothermia – NT). BBB-disruption was 
evaluated in the parietal cortex and hippocampus with IHC and western blotting. mRNA and 
protein expression of tight junction proteins (zonula-occludens 1 (ZO1), occludin (OCLN), 
and claudin-5 (CLDN5) was assessed using qPCR and western blotting. In addition, mRNA 
from genes associated with BBB-disruption: vascular endothelial growth factor (VEGF) and 
matrix metalloproteinase 2 (MMP2), as well as pro-inflammatory cytokines and chemokines 
were assessed with qPCR. Amplitude-integrated electroencephalography (aEEG) was 
performed and seizure burden and background aEEG pattern analysed. Outcome measures 
of neurobehaviour and histological injury were also assessed. We found no difference 
between HT and NT-treated animals in terms of histopathological or neurobehavioural 
outcome, or aEEG background pattern. Similarly, there was no difference in IgG protein 
level between HT or NT treated animals – although there was a trend towards a reduction 
of IgG in HT-treated animals with seizure. There were alterations to tight junction proteins – 
CLDN5, OCLN, and ZO1. CLDN5 decreased in hippocampus of HT animals, while OCLN, 
and ZO 1 increased in the parietal cortex of HT animals with seizure. There was no 
difference in tight junction mRNA expression between sham and HI animals. HT did appear 
to alter the mRNA expression of several inflammatory markers; HT treatment significantly 
attenuated the HI-induced upregulation of TGF, but upregulated IL1 in the parietal cortex, 
and COX2 in both brain regions. HT has powerful, but incomplete, neuroprotective effects. 
Elucidation of mechanisms of action is required to better develop synergistic strategies to 
treat vulnerable neonates. This study contributes to the literature on the mechanisms of 
action of HT. 
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5.2 Introduction 
Neonates with moderate to severe HIE are routinely treated with therapeutic hypothermia 
(HT) – either selective head or whole body cooling for a period of 72h (Jacobs et al. 2013, 
Shankaran et al. 2014). HT has been shown to reduce brain injury and risk of morbidity and 
mortality (Jacobs et al. 2013) and improves neurocognitive outcomes at 18 months 
(Gluckman et al. 2005, Azzopardi et al. 2009) and in older children (Azzopardi et al. 2014) 
(Chapter 1.6).  
HT is thought to act on a number of pathological pathways that are involved in HI brain 
injury. Hypothermia may reduce excitotoxic cell death via modulation of cerebral 
metabolism, reduce apoptosis and oxidative stress, and modulate inflammatory 
mechanisms (Ma et al. 2012). More recently, it has been suggested in a review of 
hypothermia’s mechanisms of action that it may act to prevent BBB-disruption, however to 
date there is no supporting evidence of therapeutically applied HT’s effect on the BBB in 
perinatal models (Drury et al. 2014). There is exceedingly little published evidence to support 
this claim in neonates with HIE (Laptook 2014). A rat model of paediatric traumatic brain 
injury found that chemically-induced hypothermia significantly reduced BBB permeability to 
Evans Blue and reduced pro-inflammatory cytokine expression (Gu et al. 2015). Due to this 
sparsity of evidence, we must rely on adult models of HI to indicate the effectiveness of HT 
in reducing BBB-disruption. Huang and colleagues (1999) demonstrated in adult rats injured 
with a middle cerebral artery temporary occlusion that BBB-disruption occurs in a biphasic 
pattern and HT reduces late BBB opening (~22h post injury). Similarly, Baumann et al, 
(2009) also showed in rats that 6h of HT can reduce BBB permeability at 24h following global 
cerebral ischaemia.  
Seizures may play an important role in BBB-disruption following neonatal HI. Animal models 
of seizure and HI have shown that HT reduces seizure (Tooley et al. 2003, Bennet et al. 
2007) and seizure burden (Low et al. 2012, Guidotti et al. 2016). HT appears to reduce the 
duration and amplitude of seizures (Tooley et al. 2003). In an observational study, Low and 
colleagues (2012) showed HT was associated with lower overall seizure burden – but only 
in moderately affected HIE babies. However, while seizure burden does appear to be 
reduced by HT, the rates of seizures overall does not appear to be affected by treatment. In 
the Low et al (2012) study incidence of seizure in cooled and uncooled groups were 
unchanged (61% and 54% respectively). This is consistent with other studies which show 
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relatively unchanged rates of seizure in cooled and uncooled babies (Gluckman et al. 2005, 
Simbruner et al. 2010). HT has been shown to alter the function of ion pumps (Thompson 
et al. 1985), downregulate the reverse transport of glutamate (Wang et al. 2013), and slow 
the release of excitatory neurotransmitters (Nakashima and Todd 1996, Aihara et al. 2001). 
These actions overall should have the effect of reducing excitation in the brain and therefore 
reduce seizures.  
Protecting the BBB may have the effect of reducing oedema, the likelihood of haemorrhage, 
serum extravasation, and inflammation (Chapter 1). HT may have effects at the BBB that 
contribute to ameliorating such processes. This study aims to investigate whether HT alters 
the permeability of the BBB, influences tight junctions which contribute to the physical barrier 
properties, or has an impact on various pathological mechanisms that can disrupt the BBB 
following HIE – such as seizures and inflammation. Understanding the mechanisms of action 
of HT neuroprotection will allow further development of therapies that work synergistically 
with HT. 
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5.3 Methods 
5.3.1 ANIMALS 
Approval for this study was obtained from the University of Queensland Animal 
Experimentation Ethics Committee and carried out in accordance with National Health and 
Medical Research Council guidelines (Australia). UQCCR/565/09/NHMRC, 
UQCCR/566/09/NHMRC, UQCCR/576/12/NHMRC, UQCCR/426/14/NHMRC (Appendices 
1-4). Care was taken to minimise the number of animals used and ensure no undue pain or 
distress. 47 animals, (25 female) with an average weight of 1.56kg (±0.22) and age of 15.19h 
(±4.72) were obtained from University of Queensland Gatton Piggery. Animals from the 
previous chapter have been compared in this chapter with a treatment group. 
5.3.2 HYPOXIC ISCHAEMIC INSULT PROTOCOL 
The HI insult protocol is detailed in Chapter 2 (2.1.5). Animals were anaesthetized with a 
propofol/alfentanil mixture (propofol: Diprivan 1% AstraZeneca Pty Ltd., NSW, alfentanil 
(Rapifen): Pharmaceutical, VIC, AUS), intubated, ventilated, and catheterised with 
intravenous and intra-arterial lines to enable fluid delivery and monitor arterial blood gases 
(ABGs). Hypoxia was induced (n=42) by reducing the fraction of inspired oxygen (FiO2) to 
4% and adjusting as necessary (2-6%) to achieve and maintain low amplitude 
electroencephalography (LaEEG <5V) for a period of 30mins. The insult was run for 
approximately 30mins or until blood gas parameters (arterial pH<7.0 or arterial base excess 
(ABE) <-12) were achieved, and hypotension (mean arterial blood pressure (MABP) 
<30mmHg) was maintained for a period >10mins. The HI insult was titrated to individual 
animal physiological responses to achieve moderate-severe survivable brain injury. 
Anaesthesia was reduced and maintained (4-12% Propofol/alfentanil mix) for 36h following 
the HI insult (duration of HT plus rewarm). If animals had a MABP of <30mmHg, combined 
with a heart rate of <120BPM for an extended period (>30mins) the animal was treated with 
an infusion of dopamine at a rate of 5-10g/kg/min. At 36h post-HI, anaesthesia was ceased 
and animals were allowed to recover until such time they could be extubated. Animals were 
monitored until euthanasia at 72h post-HI (76-96h of life). During this time, animals were 
housed in pairs and fed 40–50 mL of artificial pig milk every 3–4 h via orogastric tube 
(ProfeLAC ® milk replacer, ProviCo, AUS). Body temperature was monitored at each feed 
and maintained at normal body temperature of 38.5 ± 1.0°C. Sham animals underwent the 
same protocol excluding the HI-insult (n=5). 
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5.3.3 THERMAL TREATMENT PROTOCOL 
Whole body therapeutic hypothermia was initiated at 2h post-HI, using a servo-controlled 
cooling device (Inspiration Healthcare, distributed by Niche Medical, WA, AUS). Animals in 
the HT group (n=18) were wrapped in pre-cooled mattress and their body temperature was 
reduced from normal pig body temperature (38.5°C - NT) to 33.5°C (HT). HT was maintained 
for 24h (26h post-HI) and then animals were slowly rewarmed by 0.5°C per hour over the 
course of 10h (26-36h post-HI). NT (n=24) and sham (n=5) animals from chapter 4 were 
maintained at normal body temperature (38.5°C±0.5°C) for the duration of the experiment. 
5.3.4 EEG MONITORING AND BACKGROUND PATTERN SCORING 
Two-channel amplitude-integrated electroencephalography (aEEG) was recorded for the 
entire duration animals were under anaesthesia (~40h) and for a 1h period at 48 and 72h 
post-HI insult for offline analysis of seizure and aEEG background pattern (BrainZ 
Instruments, Auckland, NZ, or Unique CFM 6.0, Inspiration Healthcare, United Kingdom) 
(Bjorkman et al. 2010). aEEG recordings at 48 and 72h were performed without anaesthesia 
on sleeping animals after feeding. Animals at 48h and 72h underwent light sedation prior to 
EEG recordings with approximately 30s of inhaled isofluorane to allow scalp needle 
electrode insertion. 
For analysis of background aEEG pattern, a 30min (15min either side of the hour point) of 
EEG recording at 1, 2, 4, 8, 12, 24, 36, 48 and 72h was analysed and the background pattern 
was determined as previously described (Hellstrom-Westas and Rosen 2006, Bjorkman 
2016, Miller et al. 2016). Background patterns were classified from the aEEG trace as 
follows; continuous normal voltage, discontinuous normal voltage, burst suppression, 
continuous low voltage, and flat trace (Hellstrom-Westas and Rosen 2006). 
5.3.5 SEIZURE BURDEN ANALYSIS 
EEG data was analysed offline for presence of seizure (36h recording, 1h recordings from 
48 and 72h). Electrographic seizures were annotated from the start of the seizure on either 
channel to the end of the seizure on either channel. The total number of seizures, time to 
first seizure, average seizure duration, and total seizure burden (time spent in seizure), and 
maximal seizure burden (greatest seizure burden in a single hour epoch) were recorded 
(Lynch et al. 2012). Electrographic seizures were defined as “repetitive, rhythmic waveforms 
with a distinct beginning and end with a duration >10s” (Clancy and Legido 1987). Animals 
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were monitored for clinical signs of seizure. In this study, animals with severe clinical 
seizures were treated with anticonvulsants as per ethical guidelines. (Phenobarbitone first 
line (20mg/kg), followed by subsequent midazolam doses (0.2mg/kg)). 
5.3.6 NEUROBEHAVIOURAL SCORING 
Following recovery, animals were assessed on several neurobehavioural criteria every 4h 
from 48h until the end of the experiment (72h). The neurobehavioural score criteria includes 
assessment for respiration, consciousness, walking and limb control, overall activity, and 
presence of clinical seizures (Bjorkman et al. 2010) (Chapter 2, Table 1). 
5.3.7 TISSUE COLLECTION AND PROCESSING 
At 72h post-HI animals were sedated with 1-2% inhalational Isofluorane (Bayer, NSW, AUS) 
and administered an overdose of lethabarb (I.P. 120 mg/kg, sodium pentobarbitone 325 
mg/ml). Brains were flushed with ~250mL saline via intracardiac injection, dissected from 
the skull, coronally sliced (3 mm) and hemisected. The right hemisphere was immersion 
fixed in 4% paraformaldehyde, 0.1 M phosphate buffered saline (PBS, pH 7.4) overnight 
(18-20h) at room temperature with agitation, then stored in 0.1% paraformaldehyde-0.1 M 
PBS, until tissue processing (20h, graded alcohols and xylenes) and paraffin-embedding. 
Regions of interest (parietal cortex and hippocampus) were dissected from the left 
hemisphere, snap frozen in liquid nitrogen, and stored at -80°C until analysis. 
5.3.8 HISTOPATHOLOGY 
Tissue sections from the right hemisphere including parietal cortex and hippocampus were 
dewaxed in xylene and rehydrated through graded alcohols. Sections were stained with 
haematoxylin and eosin (H&E) in an automated staining system (Leica ST5010 Autostainer 
XL, Leica Biosystems, NSW, AUS). Histological injury was evaluated and scored (two 
slides/brain region) by a blinded observer using a previously published scoring system (0=no 
injury, 9=maximum severe injury) (Bjorkman et al. 2006).  
5.3.9 IMMUNOHISTOCHEMISTRY 
Immunohistochemistry 
Coronal sections containing parietal cortex and hippocampus were dewaxed and rehydrated 
through graded alcohols. For immunofluorescence, antigen retrieval was performed using 
Diva decloaker (pH 6.0 Biocare Medical, QLD, AUS) in a decloaking chamber (80°C - 20min) 
(Biocare Medical). Sections were blocked with PBS containing 5% normal donkey serum 
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(NDS), 2.5% bovine serum albumin (BSA), 0.5% triton x-100 (TX-100), and 0.1% tween-20 
for 30min. Incubations with primary antibodies diluted in PBS containing 1% NDS, 0.5% TX-
100, and 0.1% tween-20 were carried out for 1h at room temperature (RT). Slides were 
incubated with primary antibodies: rabbit anti-NeuN (1:500, Abcam, #ab177487) and goat 
anti-swine IgG (1:1000, Jackson Immunoresearch, #014-005-003). Tissue sections were 
washed with TBS-tween-20 (TBST) prior to incubation with appropriate species-specific 
secondary antibodies (1:1000 AlexaFluor AF488, 594, 680, Invitrogen, Life Technologies, 
AUS) for 1h in a dark humidifying chamber. Sections were counterstained with 4′,6-
diamidino-2-phenylindole (DAPI; Invitrogen), washed with TBST and mounted with Prolong 
Gold Antifade (Invitrogen Life Technologies, AUS, #P10144). Negative control sections 
were processed in parallel. 
DAB staining was performed for whole section visualisation of IgG extravasation. Sections 
were incubated with goat anti-swine IgG (Jackson Immunoresearch, Pennsylvania, USA, 
#014005003, 1:1000) for 1hr at RT in 5% NDS, 2,5% BSA, o.5% TX-100, and 0.1% tween-
20. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide for 15mins 
at RT. Slides were washed in TBST and incubated with goat biotin (1:500, GE Healthcare, 
QLD, AUS) in PBS for 1h at 37°C. Slides were then washed in TBST and incubated with 
HRP avidin (1:500, Sigma Aldrich, NSW, AUS, #A3151) in PBS for 1h at RT.  Slides then 
washed again in TBST and metal enhanced DAB substrate (Merck, VIC, AUS, #34065) was 
applied to slides for 1min. Slides were rinsed in H2O, cleared with xylene and mounted with 
DEPEX (Ajax FineChem, NSW, AUS). Sections were processed in batches containing 
negative control sections. 
5.3.10 IMAGE ACQUISITION AND ANALYSIS 
Image acquisition was conducted using an Olympus FV3000 confocal laser scanning 
microscope equipped with 3 excitation diode laser lines (473, 559, and 635nm) running 
Fluoview FV31S-SW (Version 2.3) (Olympus, Tokyo, Japan). Images were acquired at a 
resolution of 1024 by 1024 pixels using an Olympus UPlanFL N 40x oil NA = 1.30 objective. 
IgG DAB slides were scanned with a Pannoramic SCAN II digital slide scanner by 3D 
HISTECH with a 20x Plan-apochromat objective. All imaging and image analysis was 
completed under blinded conditions. 
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5.3.11 QUANTITATIVE POLYMERASE CHAIN REACTION 
Parietal cortex and hippocampal tissue (~30mg) were disrupted by mortar and pestle in the 
presence of liquid nitrogen and total RNA was extracted using a Macherey-Nagel nucleospin 
kit (Scientifix, VIC, AUS). 2μg of total RNA was treated with RQ1 Rnase-free DNase 
(Promega, NSW, AUS, #M6101) and cDNA was synthesised from DNase-digested total 
RNA with SuperScript III (Life Technologies, VIC), using random hexamers (New England 
Biolabs, distributed through Genesearch, QLD, AUS). Quantitative polymerase chain 
reaction (qPCR) was performed using a Rotor-Gene 6000 (Qiagen, VIC, AUS). The total 
reaction volume was 20µL, containing 100ng cDNA, 10µL SYBR green PCR master mix 
(Invitrogen, QLD, AUS), and 2μM each of forward and reverse gene-specific primers (Sigma 
Aldrich, NSW, AUS: claudin 5 (CLDN5), occludin (OCLN), zonula occludens 1 (ZO1), 
vascular endothelial growth factor 1 (VEGF), matrix metalloproteinase 2 (MMP2), 
transforming growth factor beta (TGF), cyclooxygenase 2 (COX2), tumour necrosis factor 
alpha (TNF), C-C chemokine receptor type 5 (CCR5), C-X-C motif chemokine 10 
(CXCL10), interleukin 1 beta (IL1), interleukin 6 (IL6), interleukin 8 (IL8)). Reactions were 
incubated for 10mins at 95°C for 5mins, followed by 40 amplification cycles (20s - 95°C, 30s 
- 55-65°C (annealing - primer specific), and 40s - 72°C). No template controls, and no SYBR 
controls were included in every run. Results were normalised to glyceraldehyde 3-
phosphate dehydrogenase (GAPDH). Data were analysed using the DDCT method and 
presented as log fold changes (log(2)2^(DDCT)) plus SEM (Livak and Schmittgen 2001). 
Gene-specific qPCR primers are detailed in Chapter 2, table 2.3. 
5.3.12 WESTERN BLOTTING 
Snap frozen tissue from parietal cortex or hippocampus was homogenised in a 5x volume 
of 1M Tris-HCl with 0.5M EDTA and centrifuged at 12,000 x g for 10mins (4°C). A BCA 
assay was performed on the supernatant to estimate total protein lysate concentrations (Life 
Technologies, Thermo Fisher Scientific, AUS, #23225). Protein lysates (5-15ug) were 
resolved on 7.5, 10, or 15% SDS-PAGE gels (antigen specific) at 150V for 90mins. Proteins 
were transferred to PVDF membrane (100V – 60mins) and the membrane was then blocked 
for 1h at RT with 5% skim milk powder in TBST. Membranes were incubated with Goat anti-
swine IgG (1:50,000 Jackson Immunologicals, PA, USA, #114-005-003) for 2h at RT or with 
CLDN5 (1:50,000 Abcam, ab131259), ZO1 (1:2500 Abcam, ab96587) or OCLN (1:3000 
Abcam, ab222691) overnight at 4°C. Following primary antibody incubation, membranes 
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were washed in TBST. Membranes were incubated with anti-goat HRP (1:30,000 Sigma-
Aldrich, #A0545) for 30mins at RT (IgG) or with anti-rabbit HRP (1:30,000 #A5420, Sigma-
Aldrich, USA) for 1h at RT (CLDN5, ZO1, and OCLN). Signal was developed with the use 
of enhanced chemiluminescence (ECL) Luminata forte (Merck, VIC, AUS, #WBLUF0500) 
and proteins of interest were visualised on Fuji Super-RX Film (Konica SRX-101A, 
distributed by Shimadzu, QLD, AUS). A four point standard curve generated from each run 
using a pooled standard was used for quantification (Goasdoue et al. 2016). Densitometry 
analysis was performed using ImageJ software (NIH, MD, USA). 
5.3.13 STATISTICAL ANALYSES 
Data were analysed with SPSS software (IBM Corp. SPSS Statistics 22.0, NY, USA). 
Normality and equality of variances were assessed using a Shapiro-Wilk test and Levene’s 
test respectively. Physiological parameters were analysed with a one-way MANOVA. 
Neurobehavioural and histology scores were analysed with a kruskal-Wallis H test with 
pairwise comparisons using Dunn’s procedure and a Bonferroni correction. Correlations 
were performed with either Pearson’s or Spearman’s correlations. qPCR data (log(2) 2^(-
DDCT)) were analysed by a one-way ANOVA with a Tukey-Kramer post-hoc test. Western 
blot data were analysed by a one-way ANOVA with Tukey HSD post-hoc test. Significance 
was set at p<0.05. Data are presented as means ± standard error of the mean (SEM). 
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5.4 Results 
5.4.1 PHYSIOLOGICAL DATA AND INSULT PARAMETERS 
65 animals were run as part of this study: sham (n=5), NT treated (n=33), HT treated (n=27). 
Nine NT animals died prior to the scheduled euthanasia point. Six HT treated animals died 
prior to the scheduled euthanasia point, and 3 were excluded as they did not meet the HI 
insult criteria for inclusion. Physiological data for start and end insult parameters for the 
remaining animals (sham n=5, NT n=24, and HT n=18) are shown in Table 5.1. There were 
no significant differences in any of the parameters between the two HI groups (HT and NT) 
indicating they had similar HI insults. However, there were significant differences in end 
MABP, start and end pH, start and end arterial base excess, period of hypotension, and total 
length of LAEEG and hypoxia length between the sham group, and the HI groups (** p<0.01, 
*** p<0.001). 13 of the 24 NT (54%) required blood pressure support in the form on 
dopamine infusion, versus 15 of the 18 HT animals (83%). 
Table 5.1: Insult parameters for sham, NT, and HT animals. Significantly different from sham is 
indicated by * (*=p<0.05, **=p<0.01, ***=p<0.001). 
 Sham (n=5) NT (n=24) HT (n=18) 
MABP before insult (mmHg) 47.6 (5.03) 44.8 (7.41) 39.8 (6.48) 
MABP end insult (mmHg) 46.4 (5.86) 19.3 (7.65)*** 17.33 (7.52)*** 
Time hypotensive during insult 0 12.85 (7.82)** 16.13 (7.69)*** 
pH before insult 7.41 (0.04) 7.48 (0.04)** 7.51 (0.05)*** 
pH end insult 7.41 (0.04) 7.04 (0.08)*** 7.05 (0.09)*** 
ABE before insult (mmol/L) 0.8 (2.63) 5.69 (2.35)** 5.69 (2.52)** 
ABE end insult (mmol/L) 2.38 (4.11) -16.79 (3.86)*** -17.20 (3.78)*** 
pCO2 before insult (mmHg) 40.02 (3.98) 39.97 (5.10) 36.34 (6.68) 
pCO2 end insult (mmHg) 42.48 (2.90) 49.33 (12.09) 45.24 (11.12) 
pO2 before insult 97.23 (23.5) 97.8 (17.2) 91.5 (15.2) 
pO2 end insult 97.72 (21.6) 24.4 (11.2)*** 19.7 (6.2)*** 
Total insult duration (min) 0 30.96 (3.74)*** 31.30 (3.21)*** 
Total length LAEEG (min) 0 23.52 (5.39)*** 22.14 (5.35)*** 
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Abbreviations: mean arterial blood pressure (MABP), minutes (min), millimetres of mercury (mmHg), 
arterial base excess (ABE), partial pressure carbon dioxide (PaCO2), low amplitude 
electroencephalography (LAEEG). Data are presented as mean±SD. 
 
5.4.2 TEMPERATURE DATA 
Temperature data from every 4h was recorded for sham, HT, and NT animals. Temperature 
data is presented in Figure 5.1. There was no significant difference in temperature between 
sham and NT animals, but a significant decrease (p<0.001) in temperature in HT animals 
from 4 to 32h post-HI which corresponds to the period of cooling and rewarm. 
Figure 5.1: Temperature recordings from pre-insult to 36h post-HI insult for sham, NT and HT animals. *** 
indicates significant difference (P<0.001) from sham and NT animals. Abbreviations: normothermic (NT), 
hypothermic (HT), post-insult (PI). 
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5.4.3 ANIMALS TREATED WITH HYPOTHERMIA DO NOT HAVE IMPROVED OUTCOMES 
Background EEG scores 
All of the sham (n=5) and HT (n=18) animals had full EEG recordings available for analysis, 
however, three animals in the NT group did not have EEG recordings for available for 
analysis (n=21/24). Background aEEG scores for sham, NT, and HT animals are presented 
in Figure 5.2. aEEG background pattern scores were significantly lower in both HT and NT 
groups compared with the sham group at 1, 2, 4, 8, and 12h post-HI, indicating poorer brain 
function (p<0.001 at 1h, p<0.01 at 2, and 4h, and p<0.05 at 8 and 12h post-HI). However, 
there was no significant difference between HT and NT animals at any time-point. The 
predominant brain pattern in sham animals was continuous normal voltage, except at 
approximately 36h where brain activity drops as a result of anaesthesia build-up and 
recovery from ventilation. Both HT and NT treated animals maintained abnormal continuous 
low voltage to burst suppression patterns until approximately 36h post-HI insult when aEEG 
background pattern tended to increase towards discontinuous normal voltage. 
Figure 5.2: Amplitude integrated electroencephalography background pattern scores for sham, NT, 
and HT animals. Data are presented as mean+SEM. Significant differences from sham are indicated 
by * (* p<0.05, ** p<0.01, *** p<0.001) – colour of significance indicator indicated which group is 
different from sham. n=5 all sham groups, n=21 all NT groups, n=18 all HT groups. 
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Neurobehaviour 
Neurobehavioural scores were performed at 4-hourly intervals following recovery from 
anaesthesia from 48h to 72h post-HI. Higher neurobehavioural scores indicate better 
outcome. Neurobehavioural scores for sham, NT, and HT animals are presented in Figure 
5.3. HT animals had significantly lower scores than sham animals at every time-point 
(p<0.05 for 48-64h, p<0.001 at 64-72h). NT animals also had significantly lower scores 
compared with sham animals at 52, 64, 68 and 72h post-HI (p<0.05 for 52 and 64h, p<0.01 
for 68 and 72h). There was no significant difference between HT and NT treated animals at 
any time point.  
Figure 5.3: Neurobehavioural scores for sham, NT, and HT animals from 48h to 72h post-HI. Data 
are presented as mean+SEM. Significant differences from sham are indicated by * (* p<0.05, ** 
p<0.01, ***p<0.001) – colour of significance indicator shows which group is different from sham. n=5 
all sham groups, n=24(28h, 72h), 23 (52h), 22 (68h), 21 (60, 64) in the NT group, n=18 (48, 72h), 
17 (52, 56, 68h), 16 (60, 64h) in the HT group. 
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Histopathology 
Histopathology was assessed in the regions of parietal cortex and hippocampus for sham 
(n=5), NT (n=21), and HT (n=17) animals. Haematoxylin and eosin staining revealed 
evidence of injury in all HI animals (NT and HT). Cell injury was identified by chromatin 
condensation, vacuolation, and pyknotic nuclei as previously described (Bjorkman et al. 
2010). Histopathology scores for sham, NT, and HT animals in parietal cortex and 
hippocampus are presented in Figure 5.4. There was significantly higher histopathology 
scores in both HT and NT animals compared with sham animals in both brain regions. 
However, there was no significant difference between NT and HT animals in either brain 
region. 
 
Figure 5.4: Histopathology scores from sham, NT, and HT animals in parietal cortex, and 
hippocampus (mean±SEM). Significant differences from sham are indicated by * (*p<0.05, 
***p<0.001). 
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5.4.4 SEIZURE BURDEN ANALYSIS 
Seizure was confirmed with EEG recordings – recordings were performed continuously for 
a period of 40h (i.e. while animals were anaesthetised), and for a 1h period at ~48h and 
~70h post-HI. In one animal, seizures were not noted at all in the continuous recording 
period and were first confirmed by EEG at the 1h recording at 48h. In animals with seizure 
(HT n=12, NT n=13), the total number of seizures, seizure burden, average seizure length, 
time spend in seizure, and time of maximal seizure burden was calculated. Characteristics 
of seizures in HT and NT animals with seizures are presented in Table 5.2. The average 
time to first seizure in NT animals was 23h (2.5h to 38h), whereas in HT animals average 
time to first seizure was approximately 31h post-HI (37mins to 47h). Despite a trend towards 
decreased total number of seizures (38.7 NT cf. 20.6 HT), total time spent in seizure (47min 
NT cf. 31min HT), and seizure burden (0.0171 NT cf. 0.012 HT), these parameters were not 
significantly different between groups. The temporal evolution of seizures in NT treated and 
HT treated animals is shown in Figure 5.5. In general, NT animals had a greater number of 
seizures over a wider range following HI than HT animals. Animals treated with HT generally 
begun having seizures later than NT animals, with only three HT animals (animals #14, 21, 
and 23) beginning to have seizures prior to 24h post-HI, while seven NT animals started 
seizing prior to 24h post-HI, which indicates that HT is preventing, or delaying the beginning 
of seizures. 
Table 5.2: Seizure characteristics in normothermia and hypothermia-treated animals. 
Seizure 
parameter 
Normothermia 
mean 
Range Hypothermia 
mean 
Range 
Length of EEG 
recording 
(h:min:s) 
45:38:15 37:14:01-
54:50:36 
43:11:25 39:24:31-
49:28:39 
Time to first 
seizure 
(h:min:s) 
23:10:35 02:21:55-
38:35:50 
31:12:55 0:37:47-47:37:34 
Total number of 
seizures 
39 4-128 21 2-56 
Average seizure 
duration 
(h:min:s) 
00:01:16 00:00:28-
00:02:57 
0:01:38 0:00:49-0:02:30 
Total seizure 
burden 
(h:min:s) 
00:47:47 00:03:54-
02:39:30 
0:31:03 0:07:45-00:96:45 
Max seizure 
burden (min/h) 
15min 45s 2min 25s - 
46min 56s 
15min 11s 11s – 52min 53s 
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Figure 5.5: Temporal evolution of seizures in animals treated with normothermia or hypothermia. 
Animals 1-13 were maintained at normothermia following hypoxia ischaemia (HI), animals 14-25 
were treated with hypothermia following HI. Animals 1-13 and 14-25 are ranked based on total 
seizure burden from highest to lowest seizure burden (total time spent in seizure / total time of 
recording in minutes). Scale is not continuous – periods where no animal is in seizure have been 
excluded. 
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5.4.5 THE BLOOD-BRAIN BARRIER IS AFFECTED BY HYPOTHERMIA TREATMENT 
Leakage of serum protein 
Figure 5.6 shows representative DAB staining of IgG in parietal cortex and hippocampus in 
HT and NT animals with and without seizures (NT-Sz, HT-Sz (NT or HT treated with 
seizures), NT-NoSz, HT-NoSz (NT or HT treated without seizures). In general, animals with 
seizure appeared to have the greatest level of staining; NT-Sz animals appeared to have 
substantial IgG staining, whereas in HT-Sz animals a slight reduction in IgG staining is 
evident – particularly in the cortex. IgG staining in HT-NoSz animals, however, may be 
slightly greater than NT-NoSz animals. 
IgG protein level in the parietal cortex and hippocampus was assessed by western blotting 
in sham, NT, and HT animals and results are summarised in Figure 5.7. There was 
significantly higher levels of IgG in the parietal cortex of NT animals compared with sham 
(p<0.05). However, there was no difference in IgG protein level between sham and HT 
animals, nor between NT animals compared with HT animals in either brain region. 
IgG protein was also assessed based on presence of absence of seizure. IgG levels in the 
parietal cortex and hippocampus of sham and HT and NT animals split into seizure and no 
seizure groups are shown in Figure 5.8. In the parietal cortex, both NT-Sz and HT-Sz groups 
had significantly higher levels of IgG compared with sham animals (NT p<0.01, HT p<0.05). 
NT-Sz animals also had significantly higher levels of IgG than NT-NoSz animals (p<0.001), 
but there was no effect of seizure in the HT group. There was no effect of HT on IgG level 
in either seizure or no seizure sub-groups, however, the HT-Sz group did tend to have lower 
levels of IgG than the NT-Sz group (p=0.079) (Figure 5.8A). In the hippocampus the NT-Sz 
group had significantly higher levels of IgG compared with sham animals (p<0.05), but HT-
Sz and HT-NoSz animals were not different from sham. NT-Sz animals had significantly 
higher levels of IgG than NT-NoSz animals (p<0.01), but there was no effect of seizure in 
the HT group. There was no effect of HT on IgG level in either seizure or no seizure sub-
groups (Figure 5.8B). Despite this, IgG protein level in the parietal cortex of both HT and 
NT animals was significantly associated with total seizure burden (p<0.01 r2=0.62) (Figure 
5.9).  
Immunofluorescence labelling patterns of IgG in NT and HT animals are shown in Figure 
5.10. Both HT and NT animals had similar patterns of labelling as described in Chapters 3 
and 4 – namely parenchymal, cellular, and halo leaks of IgG. There did not appear to be any 
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substantial differences between the patterns of IgG labelling between HT and NT groups. 
Qualitatively, intense parenchymal staining in appeared with more frequency and to a higher 
degree in NT animals with seizure.  
 
Figure 5.6 Example images of IgG extravasation into brain tissue from the same brain slice from 
four animals from NT and HT animals with and without seizures.  (Abbreviations: normothermia (NT), 
hypothermia (HT), seizure (Sz), no seizure (NoSz). 
 
164 
 
Figure 5.7: IgG presence as determined by western blot in parietal cortex (A) and hippocampus (B) 
brain sections in sham (n=5), normothermia (NT) animals (n=24), and hypothermia (HT) animals 
(n=18). Data are presented as mean+SEM. * indicates significantly different from sham (p<0.05).  
Figure 5.8: IgG presence as determined by western blot in parietal cortex (A) and hippocampus (B) 
brain sections in sham animals (n=5), and normothermia (NT) animals and hypothermia (HT) animals 
sub-grouped into seizure (Sz) and no seizure (NoSz) groups. NT-Sz n=14, NT-NoSz n=10, HT-Sz 
n=12, HT-NoSz n=6. Data are presented as mean+SEM. * indicates HI-Sz significantly different from 
sham, + indicates significantly different from (*=p<0.05, **=p<0.01). 
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Figure 5.9: Correlation between IgG protein level in the parietal cortex and seizure burden (time 
spent in seizure divided by the length of EEG recording) in normothermic (NT) and hypothermic (HT) 
animals 
166 
 
Figure 5.10: Immunoglobulin G labelling patterns in hypoxic ischaemic (HI) animals treated with 
hypothermia or normothermia. HI animals treated with normothermia (A-F) or hypothermia (G-L) had 
evidence of parenchymal (A-C, J-L), and neuronal (NeuN) (indicated by arrowheads) IgG. IgG also 
appeared in both treatment groups as ‘halo’ leaks surrounding compromised blood vessels (D-F and 
J-L) (indicated by arrows). Scale bar= 50m. 
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Expression level of tight junction genes 
mRNA expression of CLDN5, OCLN, and ZO1 were assessed with qPCR in the parietal 
cortex and hippocampus. Log fold changes of mRNA for the tight junctions CLDN5, OCLN, 
and ZO1 in the parietal cortex are presented in Figure 5.11 and in the hippocampus in 
Figure 5.12. There was no difference in mRNA expression identified between sham, NT, 
and HT animals in the parietal cortex or hippocampus (Figure 5.11A, 5.12A). Sub-grouping 
of HI animals based on presence of seizure did not reveal any significant changes between 
any group in either brain region indicating that neither seizure, nor HT treatment is having a 
significant effect on the mRNA expression of the tight junctions (Figure 5.11B-D, 5.12B-D). 
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Figure 5.11: mRNA expression of claudin 5 (CLDN5), occludin (OCLN), and Zonula-occludens 1 
(ZO1) in the parietal cortex after hypoxia ischaemia (HI). Differences between sham, Normothermic 
(NT), and Hypothermic (HT) animals are shown in A. Differences between sham and sub-grouped 
NT and HT animals (seizure –Sz, and no seizure -NoSz) for CLDN5, OCLN, and ZO1 are shown in 
B, C, and D respectively. Sham n=5, NT n=19, HT n=18, NT-Sz n=10, NT-NoSz n=9, HT Sz n=12, 
HT-NoSz n=6. Data are presented as log fold change from sham ±SEM. 
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Figure 5.12: mRNA expression of claudin 5 (CLDN5), occludin (OCLN), and zonula-occludens 1 
(ZO1) in the hippocampus after hypoxia ischaemia (HI). Differences between sham, Normothermic 
(NT), and Hypothermic (HT) animals are shown in A. Differences between sham and sub-grouped 
NT and HT animals (seizure –Sz, and no seizure -NoSz) for CLDN5, OCLN, and ZO1 are shown in 
B, C, and D respectively. Sham n=5, NT n=19, HT n=18, NT-Sz n=10, NT-NoSz n=9, HT Sz n=12, 
HT-NoSz n=6. Data are presented as log fold change from sham ±SEM. 
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Protein changes of the tight junctions 
Alterations to the protein level of the tight junctions was assessed using western blotting. 
Alterations of CLDN5, OCLN, and ZO1 in the parietal cortex are illustrated in Figure 5.13. 
There was no significant difference in protein level of CLDN5 between sham and either HI 
group, or between NT and HT groups (Figure 5.13A). Additionally, there was no difference 
between any of the groups when animals were split into Sz and NoSz sub-groups (Figure 
5.13B).  
There was a significant increase in OCLN protein level in the HT group compared with both 
sham (p<0.05), and NT groups (p<0.001) (Figure 5.13C). HI appears to cause a loss of 
OCLN protein as evidenced by the decrease in protein level in the NT animals, which is 
reversed in the HT groups. This effect was predominantly due to an increase of OCLN 
protein in the HT-Sz group compared with both sham (p<0.05) and NT-Sz groups (p<0.001) 
(Figure 5.13D), however the same trend was evident in the NoSz group, despite not being 
significant. There was no difference in OCLN level identified between the NT-NoSz and HT-
NoSz groups, or between the sham group and either NoSz group (Figure 5.13D). 
While there was no difference in protein level of ZO1 between sham, NT, and HT groups 
(Figure 5.13E), there was a significant effect on ZO1 protein level due to the presence of 
seizure. ZO1 protein was significantly lower in the NT-Sz group compared with the sham 
group (p<0.05). Furthermore, the decrease in ZO1 protein due to seizures appeared to be 
partially restored toward sham levels in the HT-Sz group which was significantly higher than 
the NT-Sz group (p<0.05). Both No-Sz groups were not significantly affected (Figure 5.13F). 
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Figure 5.13: Protein level of claudin 5 (CLDN5) (A,B), occludin (OCLN) (C, D), and Zonula-
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occludens 1 (ZO1) (E, F) in the parietal cortex after hypoxia ischaemia (HI). Differences between 
sham, NT, and HT animals for each of the proteins are shown in A, C, and E. Differences between 
sham and sub-grouped NT and HT animals (seizure –Sz, and no seizure –NoSz) are shown in B, D, 
and F. Sham n=5, NT n=24, HT n=18, NT-Sz n=14, NT-NoSz n=10, HT-Sz n=12, HT-NoSz n=6. 
Data are presented as mean±SEM. * indicates significantly different from sham, # indicates 
significantly different from NT, + indicates different from no seizure sub-group (*p<0.05, **p<0.01, 
***p<0.001). 
Alterations to the tight junction proteins in the hippocampus are illustrated in Figure 5.14. 
There was a significant decrease in CLDN5 protein level in the HT group compared with the 
NT group (p<0.05) (Figure 5.14A). However, there was no difference between sham 
animals and either NT or HT groups. There was no effect of seizure following sub-grouping, 
the decrease in the HT group was evident in both animals with and without seizures (p<0.05) 
(Figure 5.14B). There were no changes of OCLN protein level between sham, NT, or HT 
groups (Figure 5.14C), which persisted when sub-grouping analysis was performed (Figure 
5.14D). Similarly, there was no difference found in ZO1 protein level between sham, NT, or 
HT animals (Figure 5.14E), or between sham, NT, and HT animals sub-grouped by seizure 
(Figure 5.14F). 
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Figure 5.14: Protein level of claudin 5 (CLDN5) (A,B), occludin (OCLN) (C, D), and zonula-occludens 
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1 (ZO1) (E, F) in the hippocampus of hypoxic ischaemic (HI) animals. Differences between sham, 
NT, and HT animals for each of the proteins are shown in A, C, and E. Differences between sham 
and sub-grouped NT and HT animals (seizure –Sz, and no seizure –NoSz) are shown in B, D, and 
F. Sham n=5, NT n=24, HT n=18, NT-Sz n=14, NT-NoSz n=10, HT-Sz n=12, HT-NoSz n=6. Data 
are presented as mean±SEM. # indicates significantly different from NT (# =p<0.05). 
 
5.4.6 HYPOTHERMIA ALTERS GENES THAT IMPACT BBB PERMEABILITY 
Several genes involved in modulation of BBB were examined to assess the effect of HT 
following HI. Vascular endothelial growth factor A (VEGFA) has been shown to be both 
protective and detrimental to BBB permeability (Hudson et al. 2014), whereas matrix 
metalloproteinase 2 (MMP2) is a mediator of basement membrane breakdown and 
increases BBB permeability (Candelario-Jalil et al. 2011). Aquaporin 4 (AQP4) and glucose 
transporter 1 (GLUT1) are important transporters at the BBB. AQP4 perturbations are 
implicated in oedema formation following pathology, and GLUT1 alterations reduces the 
availability of glucose to the brain (Meng et al. 2004, Winkler et al. 2015). 
 Parietal Cortex 
mRNA expression of VEGFA, MMP2, AQP4, and GLUT1 in the parietal cortex are shown in 
Figure 5.15. There was a significant reduction of VEGFA mRNA expression in both NT and 
HT groups compared with the sham group (sham cf. NT p<0.01, sham cf. HT p<0.05). 
However, there was no difference between NT and HT groups (Figure 5.15A). Seizures had 
a significant effect on VEGFA mRNA expression in both the NT and HT group when 
compared to sham (sham cf. NT-Sz group p<0.001, sham cf. HT-Sz group p<0.01). VEGFA 
mRNA expression in NT-Sz animals was significantly downregulated compared with NT-
NoSz animals (p<0.05). However, there was no difference between HT-Sz and HT-NoSz 
groups (Figure 5.15B). There was no effect of HT, HT treated animals were not significantly 
altered in either seizure or no seizure sub-groups (Figure 5.15C). 
There was no significant difference in MMP2 expression between sham and either NT or HT 
groups (Figure 5.15A). However, when animals were sub-grouped, we identified that the 
NT-Sz group had significantly upregulated expression of MMP2 compared with the NT-NoSz 
group (p<0.05). HT treatment in the seizure sub-group attenuates this increase – HT-Sz 
animals were observed to have significantly downregulated MMP2 mRNA expression 
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compared with the NT-Sz group. There was no difference observed between the sham 
group and any HI group, or between the no seizure sub-groups (Figure 5.15C). 
There was a significant reduction in APQ4 mRNA expression in HT animals compared with 
the sham group (p<0.05). However, there was no significant difference between sham and 
NT groups, or between NT and HT groups (Figure 5.15A). Seizures appeared to be the 
driving factor in APQ4 mRNA expression changes. When sub-grouped, the reduction in 
AQP4 in HT group was maintained in animals with seizure when compared with the sham 
group (sham cf. HT-Sz p<0.01). (Figure 5.15D).  
GLUT1 mRNA expression was significantly downregulated by HI as evidenced by a 
downregulation in the NT group compared with the sham group (p<0.01). HT appeared to 
reverse this downregulation to near sham levels and a significant difference between HT 
and NT treated animals was observed (p<0.01) (Figure 5.15A). Seizures did not appear to 
impact expression changes of GLUT1 with relatively equal decreases in both NT-Sz and 
NT-NoSz groups when compared with shams (sham cf. NT-Sz p<0.01, sham cf. NT-NoSz 
p<0.05). There was no significant difference between HT-Sz and NT-Sz groups, or between 
HT-NoSz and NT-NoSz groups, although HT did appear to return GLUT1 mRNA expression 
toward sham levels in both instances (Figure 5.15E). 
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Figure 5.15: mRNA expression of vascular endothelial growth factor A (VEGFA), matrix-
metalloproteinase 2 (MMP2), aquaporin 4 (AQP4), and glucose transporter 1 (GLUT1) in the parietal 
cortex following hypoxia ischaemia (HI). Differences between sham (n=5), normothermic (NT) (n=19) 
and hypothermic (HT) (n=18) animals are shown in A. Sub-group analysis of seizure (Sz) and no 
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seizure (NoSz) animals from the HT and NT groups are shown in B-E. Results are presented as log 
fold change from sham ±SEM. NT-Sz n=10, NT-NoSz n=9, HT Sz n=12, HT-NoSz n=6. Data are 
presented as log fold change from sham ±SEM. Significant differences from sham are indicated by 
* . Significantly different from NoSz sub-group is indicated by + .Significant differences from NT are 
indicated by # . (*p<0.05, **p<0.01, and ***p<0.001).  
Hippocampus 
Alterations in mRNA expression of VEGFA, MMP2, AQP4, and GLUT1 in the hippocampus 
are shown in Figure 5.16. Despite a small drop in VEGFA mRNA expression, there was no 
significant difference between either HI group compared with the sham group (Figure 
5.16A). Following sub-group analysis, there appeared to be a downregulation of VEGF 
mRNA expression in seizure animals in both treatment groups, but this was not significantly 
different from sham. NT-Sz animals had a significant downregulation of VEGFA mRNA 
expression compared with NT-NoSz animals (p<0.05). There was no effect of HT in either 
sub-group (Figure 5.16B).  
MMP2 mRNA expression was similar to the results found in the parietal cortex with MMP2 
expression in NT treated animals slightly upregulated, and MMP2 expression in HT treated 
animals slightly downregulated from the sham group. There was a significant difference 
between the NT and HT groups (p<0.05) (Figure 5.16A). Following sub-group analysis we 
observed a significant effect of HT in the seizure group. Expression of MMP2 in the HT-Sz 
was significantly downregulated towards sham levels compared with the NT-Sz group 
(p<0.001). There was no difference between the sham and any sub-group (Figure 5.16C). 
There was also no difference between NT-NoSz and HT-NoSz groups (Figure 5.16C). 
AQP4 mRNA expression was not altered by HI – there was no difference between sham 
and either HI group or between NT and HT groups (Figure 5.16A). In the sub-group analysis 
there did not appear to be an effect of seizure – seizure and no seizure sub-groups in both 
treatment conditions were not altered from each other (Figure 5.16D). The HT group was 
also not significantly altered from the NT animals in either sub-group (Figure 5.16D). 
GLUT1 mRNA expression was not significantly altered by HI – there was no difference 
between sham and NT, or between sham and HT groups. There was also no difference 
between NT and HT groups (Figure 5.16A). In the sub-group analysis there did not appear 
to be differences between any of the groups (Figure 5.16E).  
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Figure 5.16: Alterations in mRNA expression of vascular endothelial growth factor A (VEGFA), 
matrix-metalloproteinase 2 (MMP2), aquaporin 4 (AQP4), and glucose transporter 1 (GLUT1) in the 
hippocampus. Differences between sham (n=5), normothermic (NT) (n=19) and hypothermic (HT) 
(n=18) animals are shown in A. Sub-group analysis of seizure (Sz) and no seizure (NoSz) animals 
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from the HT and NT groups are shown in B-E. Results are presented as log fold change from sham 
±SEM. NT-Sz n=10, NT-NoSz n=9, HT-Sz n=12, HT-NoSz n=6. Data are presented as log fold 
change from sham ±SEM. Significant differences from sham are indicated by * (*p<0.05, **p<0.01, 
and ***p<0.001). Significant differences from NT are indicated by # (#p<0.05, ##p<0.01, ###p<0.001). 
5.4.7 THE EFFECT OF HYPOTHERMIA ON INFLAMMATION 
Inflammation is a major mediator of brain injury and BBB-disruption in neonatal HIE. We 
assessed a number of inflammatory cytokines and chemokines by qPCR to investigate the 
effect of HT on inflammation following HI. 
Parietal Cortex 
Alterations of the mRNA expression of transforming growth factor  (TGF), cyclooxygenase 
2 (COX2), tumour necrosis factor  (TNF), C-C chemokine receptor type 5 (CCR5), C-X-
C motif chemokine 10 (CXCL10), interleukin 1 (IL1), interleukin 6 (IL6), and interleukin 8 
(IL8) in the parietal cortex are presented in Figure 5.17. 
TGFmRNA expression was significantly upregulated in the NT group compared with the 
sham group (p<0.05), and HT attenuated this upregulation (HT cf. NT group p<0.01). There 
was no difference between HT and sham expression of TGF (Figure 5.17). Elevated 
expression of TGF was driven predominantly by seizures, with significantly higher 
TGFexpression in the NT-Sz group compared with both the sham group, and the NT-NoSz 
group (NT-Sz cf. sham p<0.01, NT-Sz cf. NT-NoSz p<0.05). HT attenuated this upregulation 
and the HT-Sz group had significantly lower expression of TGF (toward sham) compared 
with the NT-Sz group (p<0.001) (Figure 5.18A). There was no difference between sham 
and either HI-NoSz group. 
COX2 was significantly upregulated in the HT group compared with the NT group (p<0.001). 
While neither HT nor NT groups were significant altered from sham, COX2 mRNA 
expression did appear differentially regulated by treatment – HI animals with NT appeared 
downregulated from sham, and HT treated animals appeared upregulated (Figure 5.17). 
Animals with seizure treated with HT appeared to be driving this effect. HT-Sz animals had 
significantly higher expression of COX2 compared with both sham (p<0.05), and NT-Sz 
groups (p<0.001). There was no difference between NT-Sz and the sham group (Figure 
5.18B). There was no difference in the NoSz sub-group between sham and the HI-NoSz 
groups, or between NT-NoSz and HT-NoSz groups (Figure 5.18B). 
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TNF was upregulated in both NT and HT groups compared with the sham group (p<0.001), 
but expression was not different between NT and HT groups (Figure 5.17). This effect was 
maintained following sub-grouping analysis with all HI groups upregulated compared with 
the sham group (p<0.01) (Figure 5.18C). There was no difference between NT-Sz and HT-
Sz groups, or between NT-NoSz and HT-NoSz groups. There was, however a significant 
difference between NT-Sz and NT-NoSz animals with NT-Sz significantly more upregulated 
than NT-NoSz animals (p<0.05). 
CCR5 and CXCL10 expression was not altered from sham levels in either NT or HT treated 
groups (Figure 5.17). There was no significant difference found following sub-group analysis 
in either CCR5 mRNA expression (Figure 5.18D), or CXCL10 mRNA expression (Figure 
5.18E). 
IL1 was significantly upregulated in the HT group compared with both sham and NT groups 
(p<0.001). There was no difference between NT and sham groups (Figure 5.17). However, 
following seizure sub-grouping, both NT-Sz and HT-Sz groups were significantly 
upregulated from sham expression (p<0.01) (Figure 5.18F). In the NoSz sub-groups, HT-
NoSz animals had significantly higher IL1 mRNA expression than both sham and NT-NoSz 
animals (p<0.001), but the NT-NoSz group was not significantly different from sham group 
(Figure 5.18F). 
IL6 was significantly higher in both NT and HT groups compared with the sham group 
(p<0.001) (Figure 5.17). This effect was maintained following sub-group analysis with all HI 
sub-groups significant elevated from the sham group (p<0.01) (Figure 5.18G). There was 
no difference between NT-Sz and HT-Sz groups, or between NT-NoSz and HT-NoSz 
groups. 
IL8 mRNA expression was upregulated in both NT and HT groups compared with the sham 
group, but this was not statistically significant. NT and HT groups were not significantly 
different from each other (Figure 5.17). There did, however, appear to be an effect of seizure 
with both HT and NT animals with seizure having upregulated IL8. This was significant in 
the NT-Sz group compared with the sham group (p<0.05). This increase in IL8 expression 
was greatest in the NT-Sz group and there was a significant difference between NT-Sz and 
NT-NoSz groups (p<0.01). This increase in the seizure animals appeared to be reduced in 
HT-Sz animals. IL8 expression in NoSz groups was not altered from sham (Figure 5.18H). 
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Figure 5.17: mRNA expression of inflammatory markers in the parietal cortex of sham (n=5), and 
hypoxic-ischaemic animals treated with normothermia (NT) (n=19) or hypothermia (HT) (n=18). Data 
are presented as log fold change from sham ±SEM. Significantly different from sham is indicated by 
*, significantly different from NT is indicated by # (*p<0.05, **p<0.01, *** p<0.001). Abbreviations: 
transforming growth factor beta (TGF), cyclooxygenase 2 (COX2), tumour necrosis factor alpha 
(TNF), C-C chemokine receptor type 5 (CCR5), C-X-C motif chemokine 10 (CXCL10), interleukin 
1 beta (IL1), interleukin 6 (IL6), interleukin 8 (IL8). 
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Figure 5.18: mRNA expression changes to inflammatory markers in the parietal cortex of sham, and 
hypoxic-ischaemic animals treated with normothermia (NT) (n=19) or hypothermia (HT) (n=18) and 
sub-grouped into seizure and no seizure animals. NT-Sz n=10, NT-NoSz n=9, HT-Sz n=12, HT-
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NoSz n=6. Data are presented as log fold change from sham ±SEM. Significantly different from sham 
is indicated by *, significantly different from NT is indicated by #. Significantly different from no seizure 
is indicated by + (*p<0.05, **p<0.01, *** p<0.001). Abbreviations: normothermia treated animals with 
seizure (NT-Sz), hypothermia treated animals with seizure (HT-Sz), normothermia treated animals 
without seizure (NT-NoSz), hypothermia treated animals without seizure (HT-NoSz), transforming 
growth factor beta (TGF), cyclooxygenase 2 (COX2), tumour necrosis factor alpha (TNF), C-C 
chemokine receptor type 5 (CCR5), C-X-C motif chemokine 10 (CXCL10), interleukin 1 beta (IL1), 
interleukin 6 (IL6), interleukin 8 (IL8). 
 
Hippocampus 
TGF mRNA in the hippocampus of the HT group was significantly downregulated 
compared with the NT group (p<0.001). However, there was no difference in expression 
between HT and sham groups, or between NT and sham groups (Figure 5.19). Alterations 
to mRNA for the inflammatory markers in sub-grouped analysis of Sz and NoSz animals are 
presented in Figure 5.20. Within the seizure sub-group, the NT-Sz group was significantly 
upregulated compared with the sham group (p<0.05), and the HT-Sz group was significantly 
downregulated compared with the NT-Sz group (p<0.001). There was no difference between 
HT-NoSz and sham groups (Figure 5.20A). There was no difference between sham and 
NT-NoSz groups, sham and HT-NoSz groups, or between NT-NoSz and HT-NoSz groups. 
COX2 expression was significantly higher in the HT group compared with both sham 
(p<0.01), and NT groups (p<0.05). While the NT group did appear upregulated compared 
with sham, this was not significantly different (Figure 5.19). Following sub-group analysis 
there appeared to be a significant effect of seizure. Both NT-Sz and HT-Sz groups were 
significantly upregulated compared with the sham group (NT p<0.05, HT p<0.001). In 
addition, the HT-Sz group was significantly upregulated compared with the HT-NoSz group 
(p<0.05). However, there was no difference between NT-Sz and HT-Sz animals, nor 
between NT-NoSz and HT-NoSz groups (Figure 5.20B). 
TNF was upregulated in both HT and NT groups compared with the sham group (p<0.001) 
(5.19). This effect was maintained following sub-group analysis with seizure and no seizure 
animals in both treatment groups upregulated compared with the sham group (p<0.05) 
(Figure 5.20C). There did not appear to be an effect of HT, there were no differences 
between HT and NT in either seizure or no seizure sub-groups. 
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Animals in the HT group had significantly lower expression of CCR5 (toward sham levels) 
compared with the NT group (p<0.05). There was no difference between HT and sham 
groups, or between NT and sham groups (Figure 5.19). Following sub-group analysis there 
did appear to be an upregulation of CCR5 in the NT-Sz sub-group, and this appeared to be 
attenuated in the HT-Sz sub-group but this was not significant. There was no difference in 
CCR expression between the no seizure sub-groups and the sham group (Figure 5.20D).  
There was no difference in CXCL10 mRNA expression between sham and NT groups, sham 
and HT groups, or between NT and HT groups (Figure 5.19). Additionally, there was no 
difference between any group in the Sz and NoSz sub-group analysis (Figure 5.20E). 
Il1 was found to be significantly upregulated in the NT group compared with the sham group 
(p<0.05). The HT group also appeared to be upregulated compared with sham but this was 
not statistically different. There was no difference found between the NT and HT groups 
(Figure 5.19). This effect was similar in after sub-grouping. The NT-Sz sub-group had 
significantly upregulated expression of IL-1 compared with the sham group. NT-Sz animals 
had significantly upregulated IL1 compared with the NT-NoSz group (p<0.05) which HT 
appeared to attenuate. Sham and HT-Sz groups were not significantly different from each 
other (Figure 5.20F). There was no difference between the sham group and either HI NoSz 
groups, or between NT and HT NoSz groups. 
IL6 was not significantly altered in the NT group compared with the sham group, in the HT 
group compared with the sham group, or between NT and HT groups (Figure 5.19). 
However, in the Sz sub-group analysis IL6 expression was particularly upregulated in the 
NT-Sz group compared with the sham group (p<0.05) and the HT-Sz group had significantly 
lower IL6 expression (toward sham levels) compared with the NT-Sz group (p<0.05). There 
was no difference between HT-Sz and sham groups (Figure 5.20G). There was no 
difference in the NT-NoSz group compared with the sham group, no difference between the 
HT-NoSz group compared with the sham group, and no difference between HT-NoSz and 
NT-NoSz groups. 
IL8 mRNA expression was not altered from sham in either NT or HT groups. There was also 
no difference between NT and HT groups (Figure 5.19). There was, however, a significant 
upregulation in both NT-Sz and HT-Sz groups compared with the sham group (p<0.001, and 
p<0.01 respectively). There was also a significant upregulation in the NT-Sz group 
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compared with the NT-NoSz group. There was no difference between NT-Sz and HT-Sz 
groups (Figure 5.20H). There was no difference in IL8 mRNA expression between any of 
the groups in the NoSz sub-group analysis. 
 
Figure 5.19: mRNA expression of inflammatory markers in the hippocampus of sham (n=5), and 
hypoxic-ischaemic animals treated with normothermia (NT) (n=19) or hypothermia (HT) (n=18). Data 
are presented as log fold change from sham ±SEM. Significantly different from sham is indicated by 
*, significantly different from NT is indicated by # (*p<0.05, **p<0.01, *** p<0.001). Abbreviations: 
transforming growth factor beta (TGF), cyclooxygenase 2 (COX2), tumour necrosis factor alpha 
(TNF), C-C chemokine receptor type 5 (CCR5), C-X-C motif chemokine 10 (CXCL10), interleukin 
1 beta (IL1), interleukin 6 (IL6), interleukin 8 (IL8). 
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Figure 5.20: mRNA expression of inflammatory markers in the hippocampus of sham, and hypoxic-
ischaemic animals treated with normothermia (NT) (n=19) or hypothermia (HT) (n=18) and sub-
grouped into seizure and no seizure animals. NT-Sz n=10, NT-NoSz n=9, HT Sz n=12, HT-NoSz 
n=6. Data are presented as log fold change from sham ±SEM. Significantly different from sham is 
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indicated by *, significantly different from NT is indicated by #, significantly different from no seizure 
sub-group is indicated by + (*p<0.05, **p<0.01, *** p<0.001). Abbreviations: : normothermia treated 
animals with seizure (NT-Sz), hypothermia treated animals with seizure (HT-Sz), normothermia 
treated animals without seizure (NT-NoSz), hypothermia treated animals without seizure (HT-NoSz), 
transforming growth factor beta (TGF), cyclooxygenase 2 (COX2), tumour necrosis factor alpha 
(TNF), C-C chemokine receptor type 5 (CCR5), C-X-C motif chemokine 10 (CXCL10), interleukin 
1 beta (IL1), interleukin 6 (IL6), interleukin 8 (IL8). 
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5.5 Discussion 
To the best of my knowledge of the current literature, there has been no investigation of how 
HT affects BBB-disruption following neonatal HIE. This chapter aimed to address that gap 
in knowledge by examining whether HT alters the permeability of the BBB to serum protein, 
alters tight junction protein level and mRNA expression, or alters pathological processes 
that are known to impact the BBB.  
5.5.1 EFFICACY OF THERAPEUTIC HT 
The efficacy of therapeutic HT in reducing brain injury, and improving short and long term 
outcomes has been substantially evaluated in the human HIE newborn (Gluckman et al. 
2005, Shankaran et al. 2005, Azzopardi et al. 2009, Simbruner et al. 2010, Zhou et al. 2010, 
Jacobs et al. 2013). A number of studies using piglets have described neuroprotection 
following HT treatment which allowed the adoption of this therapy into the clinic. Alonso-
Alconada and colleagues (2015) found that cooling to 35 and 33.5°C in piglets (a 3.5 or 5°C 
decrease respectively) reduced cell death and microglial activation. Thoresen et al, (1995) 
showed in piglets that 12h of HT reduced secondary energy failure as measured by 
magnetic resonance spectroscopy. Tooley and colleagues (2003) found in their study using 
piglets cooled to 35°C for a period of 24h that HT improved neurological scores, reduced 
neuropathology scores, and reduced both number and total duration of seizures. 
However, our study failed to identify any difference between HT and NT animals in terms of 
our outcome measures (aEEG background pattern, neurobehavioural score, and 
histopathology). There are a number of reasons that could explain this divergent result. It is 
possible that our measures of neuroprotection were not sensitive enough to detect 
differences between our groups. Other studies have found the most significant results in 
sensitive measures such as total cell counts for degenerating cells or microglial activation 
(Alconada et al. 2015), or in MRS measures (Thoresen et al. 1995). Additionally, HT has 
been found to be most protective in neonates with mild to moderate aEEG abnormalities 
(Gluckman et al. 2005). In this study we had several animals with severe injury as 
determined by aEEG score and histopathology score, however, we had insufficient numbers 
to sub-group and analyse the effectiveness of our HT treatment only in mild and moderately 
injured animals and we cannot exclude the possibility that our HT treated group was too 
severe to identify changes in our measures of outcome. 
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However, in this study we only utilised 24h of cooling, as opposed to the current standard of 
care which is 72h. This was primarily due to prohibitive cost and time reasons because of 
the intensive nature of the piglet experiments. Our protocol was originally based off seminal 
studies which suggested that 24h of cooling to this degree was sufficient to produce 
neuroprotective effects (Thoresen et al. 1995, Tooley et al. 2003, Alonso-Alconada et al. 
2015). Since then, studies have shown that the length of cooling does have a significant 
effect on neuroprotection, at least in the short term (Clark et al. 2009, Rocha-Ferreira et al. 
2018), with cooling showing benefit in various animal models from 12-72h post-HI, whereas 
when extended to 96h in sheep there appeared to be a small reduction in neuronal survival 
(Davidson et al. 2015). 
We should note that the depth of cooling in this instance is slightly greater than the human 
equivalent as the normal body temperature of a piglet is ~39°C, rather than 37°C (both 
cooled to 33.5°C). Depth of cooling may also be associated with alterations in 
neuroprotection – a reduction in temperature of 3.5°C in a piglet model found 
neuroprotection (Thoresen et al. 1995), however a reduction of 8.5°C showed an increase 
in cell death (Alonso-Alconada et al. 2015).  Despite this, 24h has been found previously in 
a piglet HI model to produce neuroprotective effects, and it is not entirely clear why we could 
not replicate this effect (Tooley et al, 2003, Alonso-Alconada et al, 2015, Iwata et al, 2005). 
In the future we should trial utilising longer hypothermia times, return depth of cooling to 
more clinically relevant values, and include more sensitive measures of neuroprotection 
such as MRI or total cell counts. 
Although there is strong evidence that HT is neuroprotective the number needed to treat to 
prevent one case of death or major disability is between 5 and 10 (Azzopardi et al. 2009, 
Jacobs et al. 2013). Following HT treatment, approximately 40-50% of treated neonates still 
die or have significant neuropathology (Shankaran et al. 2005, Jacobs et al. 2011). 
Therefore, there is room for improvement in our strategies to treat HIE neonates. The focus 
currently is to find therapies that work synergistically with HT to improve outcomes. To do 
this effectively we first need to understand the pathological processes that occur following 
neonatal HIE and how HT affects them. 
5.5.2 IMPACT OF HYPOTHERMIA ON SEIZURES 
There is some debate in the field regarding the efficacy of HT to reduce seizures in neonates 
with HIE. While the seizure incidence in neonates treated with HT are not different from the 
190 
 
pre-hypothermic era, seizure burden has been reported to be significantly reduced (Wusthoff 
et al. 2011, Boylan et al. 2015). Both sheep and piglet models of HIE have demonstrated 
that HT does reduce seizure; a reduction in seizure amplitude was shown in sheep, and a 
reduction in total seizure number and total time spent in seizure in piglets (Tooley et al. 
2002, Bennet et al. 2007). In humans, much of the evidence suggests that HT-treated 
neonates have a lower seizure burden than non-treated neonates. An observational study 
published by Low and colleagues (2012) demonstrated that HT-treated neonates had a 
significantly lower seizure burden than non-cooled neonates. However, this effect was only 
evident in neonates with moderate HIE, which supports previous observations that HT is 
most effective in moderately injured neonates (Gluckman et al. 2005, Low et al. 2012). 
Another study of cooled neonates with HIE corroborated the above results – indicating that 
HT does reduce seizure burden compared with non-cooled neonates. However, again this 
effect was only evident in neonates with moderate HIE (Srinivasakumar et al. 2013). 
Similarly, Guidotti et al, (2016) showed that cooled neonates with HIE has significantly fewer 
seizures, shorter mean seizure duration, were administered fewer antiepileptic drugs, and 
had a lower seizure burden than uncooled neonates with HIE. 
Given the relationship between BBB-disruption and seizures described in Chapter 4, one of 
the ways HT may be reducing BBB-disruption is by reducing seizure. There did seem to be 
an effect of HT on reducing seizures in terms of total number of seizures and total duration 
of seizures– however this was not significant. Again, we demonstrated that IgG protein level 
in the parietal cortex of both HT and NT animals with seizure was significantly correlated 
with seizure burden. An interesting observation is that HT appeared to prevent the onset of 
seizures – the mean seizure start time was 31h in HT treated animals versus 23h in NT 
animals – and the temporal data shows that animals rarely have seizures while they are 
being treated with HT. This may also be a mechanism of neuroprotection. It was proposed 
that a reduction of seizure activity by HT during secondary energy failure may be 
neuroprotective of less severely injured brain regions via a reduction in energy metabolism 
(as seizures are high energy). However, we postulate that HT reducing seizures also has 
an impact of HI injury because of the close relationship between the BBB and seizures and 
thus is reducing brain injury via a subsequent reduction in injurious inflammatory and 
oxidative stress mechanisms. This is partially supported by evidence that HT is not 
neuroprotective if it is started after the onset of seizures (Gunn et al. 1999). However, we 
must take into account that the effect of HT appearing to reduce the number of seizures may 
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be due to a delay in the onset of seizures and a capped experimental time – perhaps those 
animals may have gone on to suffer similar numbers of seizures as the NT animals if we 
had extended the period of observation – resulting in a subsequent increase in BBB-
disruption. However, a study that investigated temporal differences between neonates with 
HIE that had been cooled or untreated did find that even with a longer window of observation, 
neonates treated with hypothermia did still have a lower seizure burden (Low et al. 2012). 
5.5.3 HYPOTHERMIA ALTERS THE BLOOD-BRAIN BARRIER 
BBB permeability to IgG 
While there is little to no evidence for HT efficacy in reducing BBB disruption in neonates, 
experimental studies in adult animal models suggests that BBB permeability is reduced 
following HT treatment; an adult rodent stroke model using middle cerebral artery occlusion 
(MCAO) found that HT reduces BBB permeability as assessed by Evans blue extravasation 
(Tang et al. 2013). Another MCAO adult stroke model found that HT induced by isoflurane 
anaesthesia prevented Evans blue extravasation (Liu et al. 2017). An adult rodent model of 
traumatic brain injury (TBI) also demonstrated that moderate HT (30°C) can reduce albumin 
immunoreactivity, indicating reduced BBB permeability (Jiang et al. 1992). An adult rodent 
cortical impact model also found that HT prior to and after injury can reduce BBB 
permeability to Evans blue (Smith and Hall 1996). In addition, another adult rodent TBI 
model found mild HT (33°C for 4h) reduced BBB permeability to two different sized tracers 
(a small dextran and horseradish peroxidase) (Lotocki et al. 2009). A juvenile pig model (12-
24 week pigs) of cardiopulmonary resuscitation (CPR) found that mild hypothermia (33°C) 
reduced BBB permeability as assessed by Evans blue and oedema formation (Li et al. 
2017). 
Despite evidence in animal models that HT can reduce BBB permeability, we did not 
demonstrate that permeability to IgG was significantly different in the HT group compared 
with the NT group. However, there was a wider range of IgG extravasation in the NT group 
as assessed by western blot, which we chose to investigate further by sub-grouping the 
animals into seizure and no seizure sub-groups. Sub-group analysis of animals with and 
without seizure revealed that there was significant infiltration of IgG in animals with seizure 
compared with sham animals. Although it was not significant, there appeared to be a 
reduction of IgG in seizure animals treated with HT. Consistent with Chapter 4 findings, 
animals without seizures in both HT and NT groups had very little IgG extravasation as 
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demonstrated by western blot and IHC analysis. Despite this, both western and IHC analysis 
did seem to indicate that hypothermia treated animals without seizure had greater signs of 
IgG extravasation than the NT treated group. We postulate that it was not HT per se that 
was causing the observed slight increase in BBB permeability, but the fact that there was a 
greater proportion of severely injured animals in the HT NoSz group than the NT NoSz group 
as assessed by aEEG background pattern and histopathology. 
Tight junctions 
While we did not demonstrate any differences in mRNA expression of the tight junctions, we 
did show significant differences at the protein level. 
We did not identify any differences in CLDN5 expression in the parietal cortex. However, in 
the hippocampus CLDN5 protein was significantly reduced in the HT treated animals 
compared with the NT treated animals, and this effect was maintained in the seizure sub-
groups. This result differs from previous experiments in adult animal models which suggest 
that HI causes a loss of CLDN5 which is restored by HT treatment (Sun et al. 2013, Li et al. 
2017). An study using a juvenile pig model of CPR indicated that CLDN5 is reduced by HI 
events and restored to control levels following HT treatment (Li et al. 2017). In addition, an 
adult rat model of intracerebral haemorrhage found a similar effect of HT partially restoring 
CLDN5 protein toward control levels (Sun et al. 2013). Targeted CLDN5 suppression has 
been shown to reduce oedema and improve outcomes in an adult mouse model of TBI so it 
is possible that our observed reduction in CLDN5 following HT is restorative rather than 
pathological (Campbell et al. 2012). However, given the results in this thesis regarding 
changes to CLDN5 at the mRNA and protein level do not agree substantially with previous 
similar studies, and given the variability in the literature regarding CLDN5 and other tight 
junction proteins overall, it appears likely that CLDN5 is not a good marker for BBB-
disruption and therefore would not make a good target for future therapies. 
While CLDN5 is the only tight junction of the three investigated here that shows a selective 
increase in BBB permeability when CLDN5 is knocked-down (Nitta et al. 2003), alterations 
OCLN and ZO1 appear to be more closely correlated to BBB-alterations both in previous 
literature and in this thesis. OCLN loss has been demonstrated in cases of BBB-disruption 
previously (Jiao et al. 2011, Liu et al. 2012, Ek et al. 2015). Jiao and colleagues (2011) found 
in an adult rat MCAO model of stroke that OCLN protein and mRNA was lost at every time-
point between 3-120h post-insult and this loss correlated with increased BBB permeability. 
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Additionally, Ek and colleagues found that HI in P9 rats resulted in a loss of OCLN protein 
levels at 6h post-insult (Ek et al. 2015). A significant increase in OCLN protein were identified 
in the parietal cortex. We found a significant increase in OCLN protein following HT 
treatment compared with both sham and NT animals. After sub-group analysis it appeared 
that the seizure animals were driving this effect as the increase in OCLN was significant only 
in HT animals treated with seizure, however, the no seizure sub-group had the same trend. 
While we did not demonstrate a significant effect of HI on the total protein level of OCLN, 
the increase of OCLN in the HT group is consistent with previous literature that shows that 
HT in adult models of CPR can restore OCLN levels toward sham (Li et al. 2017). In addition 
there is evidence in an adult rodent model of intracerebral haemorrhage that 4h of HT can 
partially restore the loss of OCLN (Sun et al. 2013). However, we have not found literature 
that suggests HT can increase OCLN protein levels above sham as we have observed here.  
ZO1 is important for anchoring the transmembrane tight junctions into the cytoskeleton 
proteins of the endothelial cells and subsequent loss of ZO1 is associated with 
disorganisation of other tight junctions (Ballabh et al. 2004). As with the other tight junctions, 
ZO1 loss has been shown to be associated with BBB-disruption (Mark and Davis 2002, Jiao 
et al. 2011). Similar to the OCLN result described above, Jiao et al. (2011) demonstrated a 
significant loss of ZO1 in adult rats with MCAO. Initial observations of ZO1 protein in our 
study did not show any difference between treatment groups in either parietal cortex or 
hippocampus. However, there was a significant effect in animals with seizures having 
reduced ZO1 protein which is restored with HT treatment.  
The results from this chapter are similar to previous chapters in that the clearest results 
occur in OCLN and ZO1 changes; there is no clear change to CLDN5 mRNA or protein, 
however OCLN and ZO1 are restored toward sham levels in animals with seizure due to HT 
and this is consistent with the direction of IgG-extravasation improvement. These results 
suggest that HT can alter BBB permeability and tight junction protein at 3 days after HI injury 
in our neonatal model, however given the conflicting evidence in the literature and in this 
thesis about the changes in tight junctions not matching with alterations in BBB-permeability 
we believe future studies should investigate the BBB more holistically by investigating the 
entire neurovascular unit to infer disruption or permeability alterations, rather than relying 
solely on the tight junctions. 
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5.5.4 MEDIATORS OF HT INDUCED PROTECTION OF THE BBB 
There are several mechanisms that can contribute to BBB-disruption following HI. Many of 
the following have been shown to disrupt tight junctions. BBB-disruption has been linked to 
HIF1-mediated VEGF and inflammatory cytokine release, as well as activation of MMPs.  
Matrix metalloproteinase 2 
MMPs are enzymes that can degrade extracellular matrix and tight junction proteins, leading 
to BBB-disruption. We found that HI induced upregulations of MMP2 mRNA was reduced in 
both parietal cortex and hippocampus of animals treated with HT. This finding was 
particularly evident in animals with seizure. These data are consistent with findings in adult 
stroke models. For example, Lee et al, (2005) demonstrated that mild HT following adult rat 
MCAO resulted in a reduction in MMP2 protein level compared with animals maintained at 
normal body temperature. Hamann and colleagues (2004) also demonstrated a reduction in 
MMP2 following HT treatment compared to both NT animals and shams in an adult rat 
ischemic model. Furthermore, this reduction was associated with preserved microvascular 
integrity as indicated by presence of basal lamina proteins (Hamann et al. 2004). MMP2 
reduction may be one way that HT acts to modulate BBB-disruption. 
Vascular Endothelial Growth Factor A 
VEGFA is a protein that acts on endothelial cells and has a variety of effects, including 
modulation of vascular permeability, angiogenesis, vasculogenesis, and inhibition of 
apoptosis. VEGFA mRNA expression was significantly reduced in the parietal cortex of both 
NT and HT animals. However, while HI had an effect, the reductions in NT and HT treated 
animals were equal, indicating there was no treatment effect. Similarly, to other genes, 
seizure appeared to drive significant changes in expression.  
Sweetman et al, (2017) showed decreased levels of VEGFA in perinatal asphyxic newborns 
which was related to the severity of injury – neonates who had moderate to severe HIE and 
those that died had significantly lower serum levels of VEGF. The majority of infants with 
moderate to severe HIE also had seizures (71.7%). Part of the cohort investigated was 
cooled, however the authors haven’t shown data for cooled vs uncooled. In contrast, Roka 
et al, (2013) showed that HT increased levels of VEGFA in the serum of HIE neonates 
between 6 and 24h post-birth. Li et al, (2017) demonstrated that VEGF protein was 
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increased following brain injury in their pig CPR model and that treatment with 12h of mild 
HT reduced VEGF similar to that observed in sham animals. 
VEGF has been shown to have both detrimental and protective functions. VEGF drives 
angiogenesis and repair long-term following HI insults (Sun et al. 2003). However, VEGF 
has been shown to contribute to BBB disruption via the promotion of newer ‘leaky’ blood 
vessels and the breakdown of tight junction proteins (Argaw et al. 2009, Argaw et al. 2012, 
Chapouly et al. 2015). Indeed, astrocyte-driven reduction of VEGF in vitro is believed to be 
a compensatory mechanism in response to hypoxia to limit BBB-disruption and oedema 
(Fischer et al. 2000). Therefore, it is unclear what functional impact the reduction in VEGFA 
we have demonstrated may have following neonatal HIE and treatment with HT, and given 
the contradictory effects suppression of VEGFA may have we do not believe it is a good 
treatment target. 
Aquaporin 4 
AQP4 is a bi-directional water channel located predominantly on perivascular astrocyte end 
feet and is essential for maintaining water homeostasis across the BBB. Previous studies in 
models of HIE have shown both up- and downregulations of APQ4 (Meng et al. 2004, Badaut 
et al. 2007, Ferrari et al. 2010, Wang et al. 2013).  
We showed that AQP4 is downregulated following HI (although not significantly different 
from shams) but is further downregulated following HT treatment. Seizures again appeared 
to contribute to this change, with AQP4 expression exacerbated by HT treatment. Changes 
to AQP4 gene expression were only noted in the parietal cortex which may be related to the 
severity of oedema formation in the different brain regions. This result is in contrast to 
previous investigations which show that HT increases AQP4 protein in cultured astrocytes 
(Salman et al. 2017) and following thrombin induced oedema (Gao et al. 2015). However, 
this may be related to the time-point studied as AQP4 is expected to reach maximal 
expression early after injury (Szczygielski et al. 2018). 
Differential expression (both increases and decreases) of AQP4 have been demonstrated 
to be associated with oedema formation, swollen perivascular astrocytes and BBB 
permeability alterations (Higashida et al. 2011, Tourdias et al. 2011). Seizure-induced 
oedema formation has been demonstrated to be worse in APQ4 null mice (Lee et al. 2012). 
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However, AQP4 gene inhibition has been shown to alleviate oedema in a mouse model of 
meningitis (Papadopoulos and Verkman 2005).  
There is a small amount of evidence that HT can reduce oedema following HI events. In the 
neonate there is evidence that HT may reduce cytotoxic oedema (Bonifacio et al, 2012, 
Gunn et al, 1997). However, given our findings at 72h, it is possible that AQP4 is increased 
early in injury and reducing vasogenic oedema, which occurs in the early period following 
HI, and that a reduction in cytotoxic oedema is due to other mechanisms. 
Overall, HT did appear to have a mild effect on three of the above proteins in the parietal 
cortex which may contribute to the neuroprotective effect of HT, or may be related to the 
effect on seizure. However, these effects were small and a greater powered study that had 
longer HT treatment may be better equipped to investigate if these changes related to tight 
junction alterations and BBB-permeability. 
Inflammatory Cytokines 
Inflammation has profound effects on BBB-disruption. Inflammation in the form of increased 
pro-inflammatory cytokines, both in the brain and in the systemic blood supply, have been 
shown to alter BBB function in a variety of ways including alteration of tight junctions and 
enhanced peripheral immune cell migration. Therefore, we investigated the effect of HT on 
the mRNA expression of several inflammatory cytokines and chemokines that have been 
shown to influence BBB disruption. 
HT has been shown in both animal models and humans with HIE to affect inflammation. 
Although there is conflicting evidence regarding the direction and extent HT treatment 
impacts the expression of inflammatory cytokines. Serum levels of IL6, which has both pro 
and anti-inflammatory effects, were found to be lower in HT treated neonates during HT 
when compared with NT neonates with HIE, however, there was no difference in levels of 
IL1, IL4, or IL8 (Moon et al. 2016). 
Xiong and colleagues (2009) found that HT reduced TNF and IL6 mRNA in P7 rat brains 
following ischemia and these animals had lower infarct volumes and reduced astrogliosis. 
Truettner et al (2005) also showed that HT treatment reduced TGF toward sham levels, 
but not IL1 in a rat TBI model. However, another rat study found that HT did not reduce 
levels of IL1, IL-6, or TNF compared with NT animals (Park et al. 2015). Additionally, a 
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rat model of inflammation-sensitised neonatal HIE found that treatment with HT, while 
neuroprotective, was not associated with alterations to inflammatory makers (particularly 
IL1, TNF) (Chevin et al. 2016). 
This study did find that HT treatment reduced the upregulation of TGF seen in NT animals 
in both brain regions, and that IL6 was reduced by HT treatment toward sham levels in the 
hippocampus. However, many other cytokines were not altered by HT treatment. HT had no 
effect of the upregulation of TNFin either brain region and IL6 mRNA expression was 
unaltered in the parietal cortex. IL1 on the other hand was significantly upregulated in the 
parietal cortex which appeared to be a treatment effect of HT in the animals without seizure.  
There have been reports that rather than simply reducing inflammation, HT is altering the 
trajectory of the inflammatory response. Rocha-Ferreira et al, (2017) showed that HT treated 
piglets did not have significantly different ratios of pro/anti-inflammatory cytokines compared 
with NT animals at early time-points, but by 36h post HI, HT-treated animals actually had 
higher pro/anti-inflammatory cytokine ratios than NT animals – indicating greater 
inflammation. The authors speculated that the surge in inflammation was related to a 
delayed response which was initiated at the onset of rewarming. In addition, Jenkins et al, 
(2012) measured cytokines in serial serum samples in neonates with HIE and showed that 
HT significantly upregulated the expression of pro-inflammatory cytokines IL6, and IL8, and 
the anti-inflammatory IL10. Regardless of treatment group, higher IL6 levels overall were 
associated with mortality, however, a peak of IL6 or IL8 at 24h was associated with a better 
outcome. This data suggests that while HT may not reduce pro-inflammatory cytokines, HT-
induced alteration of pro-inflammatory cytokines may be associated with better outcomes. 
On the other hand, if HT is truly not having an effect on some of these pro-inflammatory 
markers (or even increasing them) we may be able target them to decrease BBB-disruption 
and neuropathology. Studies have demonstrated a synergistic effect of HT and anti-
inflammatory therapies previously. Lafuente and colleagues (2016) found that cannabidiol 
could reduce TNF expression more than HT alone and was neuroprotective. Additionally, 
Park and colleagues (2015) demonstrated that rats treated with both HT and mesenchymal 
stem cells had reduced IL1 and TNF than either HT or stem cells alone. To assist with 
this therapy research, an area of future research could establish the source of increased 
pro-inflammatory cytokines in brain tissue – while we know that neonates have less immune 
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cell extravasation following HI, cytokines can still be produced in large amounts peripherally 
and be transported across the BBB – disrupted or otherwise (Banks et al. 1995, Liu and 
McCullough 2013).  
5.5.5 CONCLUSIONS 
While we did describe differences to the BBB due to HT treatment, future studies may further 
this work by increasing the length of HT in order to make the findings even more clinically 
applicable. In addition, a temporal characterisation of BBB changes in HT treated animals 
would allow greater understanding of how HT protects the BBB. If HT does alter the temporal 
progression of BBB-disruption this would have consequences for synergistic therapies, and 
exploitation of increased BBB permeability to deliver drugs.  
While there is strong evidence that HT positively impacts the BBB in stroke, TBI, and CPR 
injury models, to the best of our knowledge this is the first investigation of the effect of 
therapeutic HT on BBB-disruption in a neonatal model of HIE. HT does not provide total 
neuroprotection for neonates with HIE and understanding of mechanisms of action may be 
important in order to develop novel neuroprotective strategies. 
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CHAPTER 6 - GENERAL DISCUSSION 
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The blood-brain barrier (BBB) is essential in maintaining a healthy environment required for 
correct brain function and disruption of the BBB can result in substantial pathogenesis in the 
central nervous system (CNS). Despite this role in injury progression following brain injury, 
there has been very little investigation on the integrity of the BBB following neonatal HIE. 
Neonatal HIE is a complex syndrome in which there are many pathways to injury. To date, 
the available therapies are incompletely effective. Therefore, understanding BBB-disruption 
in HIE may help us target therapies to reduce brain injury.  In this thesis I addressed several 
knowledge gaps regarding the evolution of BBB-disruption following neonatal HI, how BBB-
disruption is related to seizures in this syndrome, and if the current standard of care 
(hypothermia) is attenuating BBB-disruption all in a clinically relevant model of neonatal HIE. 
6.1 Novel findings 
6.1.1 NEONATAL HYPOXIA ISCHAEMIA AND BBB PERMEABILITY 
There have only been a small number of studies demonstrating the evolution of BBB-
disruption following neonatal HI insults; the majority of which have been performed in 
rodents. My study has several strengths including the use of a large animal model that 
reliably recapitulates the clinical situation, utilisation of two tracers (one endogenous and 
one exogenous), in-depth analysis of permeability patterns in two distinct brain regions, and 
multiple time-points from 2 to 24h, and then at 72h following hypoxia ischaemia (HI). This 
study evaluated tracer breaching the BBB, immunohistochemistry to gain an overarching 
view of IgG extravasation and gross patterns of vulnerability, as well as detailed investigation 
of labelling patterns using immunofluorescence in order to understand how serum proteins 
leak into brain tissue, and how this changes over time. 
Although there are only limited studies describing BBB-disruption following neonatal HI, 
there is general consensus that the BBB has an early peak of increased permeability (Lee 
et al. 2017). Studies in piglets, sheep, and mice indicate there is a period of increased BBB 
permeability between 30min to 6h post-HI (study dependant) (Mirro et al. 1991, Chen et al. 
2012, Ek et al. 2015). However, there is also evidence, predominantly in rats, that BBB-
disruption may also occur at 24h (Muramatsu et al. 1997, Qiao et al. 2001, Ek et al. 2015) 
(Chapter 1, table 1). Ek and colleagues (2015) in particular demonstrate that mice following 
a HI insult had increased BBB permeability as early as 2h, peaking at 6h, and resolution to 
24h and 7 days post-insult. This is in contrast to studies in adult animal models of stroke 
and TBI in which a number of studies have demonstrated that BBB-disruption occurs in a 
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clear biphasic pattern (Kuroiwa et al. 1985, Baskaya et al. 1997, Huang et al. 1999). 
However, studies demonstrating this biphasic pattern have been predominantly performed 
in rats and has been challenged in a more recent study in patients which shows that BBB-
disruption continues to worsen over time until 90h post-injury as measured by dynamic 
contrast enhanced magnetic resonance imaging (Merali et al. 2017). 
Our study utilised a pre-clinical model of neonatal HIE – the piglet. Piglets have been thought 
to be relatively resistant to BBB-disruption. A study in the early 1990’s found in a piglet model 
of hypoxia/hypercapnia that the BBB permeability to sodium and mannitol was not altered 
at the cessation of the insult or 24h post-insult (Stonestreet et al. 1992). However, another 
group demonstrated that ischaemia in piglets causes increased BBB permeability at 30min 
and 2h post-insult (Mirro et al. 1991). Here we have provided evidence that the BBB is 
compromised in our piglet model of neonatal HIE as we have shown clear extravasation of 
serum proteins into the brain tissue and changes to the tight junctions of the cerebrovascular 
endothelial cells. We did not, however, describe clear, time-related patterns of injury. There 
was variable evidence of increased BBB permeability at every-time point. We endeavoured 
to maintain a similar initial HI insult in all our piglets by manipulating inspired oxygen 
percentage to achieve similar end insult values of pH, arterial base excess, period of low 
amplitude EEG, and period of hypotension. Despite this, there was individual differences in 
the evolution of injury in our piglets with some recovering early in terms of their aEEG scores 
and some experiencing either delayed recovery or maintained poor EEG scores until 
euthanasia. This is similar to the human situation, where initial insult parameters such as pH 
and arterial base excess (while important for diagnosis) are poor indicators of longer term 
outcome (Aridas et al. 2014, Ahearne et al. 2016). This suggests that individual differences 
in the progression of injury play a more important role. In terms of BBB-disruption this results 
in the lack of a clear time where disruption occurs and peaks, however our evidence does 
indicate that it worsens over the first 24h post-insult, and is largely resolved by 72h, except 
in those animals with seizure. 
The results from chapter 4 show clearly that there is a relationship between seizures and 
increased BBB-permeability. In fact, animals with seizure in this study had by far the most 
amount of IgG extravasation than animals following HI at any other time-point (from 2-72h 
post insult). One of the complexities of the work in chapter 4 is that we cannot be certain 
when the BBB-disruption is occurring. As we only took one measurement at 72h post-insult, 
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the IgG could have leaked into the tissue as any time prior to then. However, if we 
incorporate the findings from chapter 3 we see that IgG leakage up to 24h post-HI was 
relatively mild, and the majority of IgG leakage is therefore occurring between 24 and 72h 
post-insult. While there was some degree of association between HI severity and BBB-
disruption in animals from chapter 3, it was not a strong relationship. Whereas in chapters 
4 and 5 with animals survived to 72h, BBB permeability was better related to outcome that 
initial insult severity. I therefore suggest the majority of protein leak is occurring in 
conjunction with seizure (maximal seizure burden between 24-48h post-HI in normothermic 
animals, and slightly delayed in hypothermic animals). If IgG leakage is indeed occurring 
with seizures, it appears the efflux mechanisms of IgG are impaired, or did not have sufficient 
time to clear the protein prior to the experiment’s end. These hypotheses could be 
investigated further by establishing if efflux is altered and tying in a measure of BBB-
disruption in live animals – such as a biomarker of BBB permeability. 
6.1.2 TIGHT JUNCTIONS OF THE CEREBROVASCULATURE 
One potential mechanism of increased BBB permeability is loss or alteration of the tight 
junctions which are primarily responsible for the restriction of paracellular movement 
between the blood and the brain. In this thesis, I investigated three important tight junction 
proteins – claudin 5, occludin, and zonula-occludens 1. Chapter 3 describes changes of 
mRNA expression, protein abundance, and localisation of these tight junctions, which may 
have resulted in increased BBB permeability. In chapter 3, CLDN5 mRNA is upregulated 
over time, and OCLN and ZO1 are downregulated (maximally ~4-8h). Whereas protein 
levels of OCLN were increased at 4h and ZO1 protein decreased at 8h. By 72h, in chapters 
4 and 5, there were no changes identified to tight junction mRNA expression, but I described 
loss of zonula-occludens 1 and occludin protein in seizure animals (Chapter 4) that is 
reversed by HT (Chapter 5). OCLN and ZO1 therefore are better describing the IgG results 
than CLDN5, though the relationship is far from perfect. IgG extravasation was most severe 
in seizure animals at 72h post-insult, however, this group of animals did not have the most 
severe alterations of the tight junctions. This suggests that tight junctions and paracellular 
restriction are not the sole determinants of serum protein extravasation.  
The BBB is not a static wall with fixed properties and there are a number of pathways from 
the blood to the brain, and vice versa. Other pathways into the brain include the paracellular 
aqueous pathway, transcellular lipophilic pathways, transport proteins, receptor mediated 
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transcytosis, and adsorptive transcytosis (Abbott et al. 2006). Hypoxic stress has been 
shown to increase BBB permeability via the transcellular route, including transcellular 
extravasation of albumin (Plateel et al. 1997, Cipolla et al. 2004). Hypoxia, epilepsy, and 
inflammation can also have a significant effect on the transporters at the BBB; breakdown 
of transporter function can lead to insufficient nutrient and water supply, or build-up of toxic 
products such as serum proteins in the brain (Shah and Abbruscato 2014, Makirdes et al. 
2017). For example, the neonatal FC receptor is responsible for the transport of IgG across 
the BBB and is mediated by inflammatory cytokine tumour necrosis factor alpha (TNF (Liu 
et al, 2007, Marroni et al, 2003, Roopenian & Akilesh, 2007, Zhang & Pardridge, 2001). In 
addition to mediating brain injury and other pathological processes, alterations to BBB 
transporters may also have an effect on drug delivery and therefore describing alterations 
to the transporters is an interesting avenue of future research. I suggest that future studies 
that investigate the role of the BBB in disease processes undertake a more holistic role by 
studying changes to the whole of the neurovascular unit (including transport mechanisms) 
to establish disruption or mechanisms of permeability alterations, rather than rely solely on 
the tight junctions as a surrogate marker of BBB opening. 
6.1.3 BLOOD BRAIN BARRIER DISRUPTION AND SEIZURES 
The result in this thesis that severe BBB-disruption occurring late following HI in neonates 
is tied to the occurrence of seizure is of critical importance and emphasises the need to 
study mechanisms of injury in a variety of models with different strengths and limitations. A 
strength of our model is that HI causes seizures in a subset of animals in a way that is similar 
to the clinical situation. Therefore, we are able to investigate possible mechanisms of seizure 
induced brain injury in a model that reliably mimics the human.  
Effective treatment of seizures is one of the most pressing issues in neonatal medicine. 
Status epilepticus (uncontrolled seizures) is particularly injurious for the neonatal brain 
resulting in unfavourable long term outcome, neuronal changes, adverse effects of brain 
development, and cognitive function (McBride et al. 2000, Miller et al. 2002, Glass et al. 
2009). Making matters worse, there have been reports that the currently utilised anti-
epileptic drugs are at best incompletely effective, and at worst having deleterious effects 
(Kim et al. 2007, Jansen 2018). A call for a greater understanding of the mechanisms driving 
and sustaining seizures in neonates has been made in order to identify novel therapies. 
Much of the research into seizures has been focused on neuronal origins, including 
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characterising the hyper-excitable environment that exists normally in early life and 
exacerbation of this excitability following HI events. Excitability is increased in neonates as 
a result of overexpressed glutamate receptors and complicated by increased excitation at 
this developmental stage due to the contribution of excitatory gamma aminobutyric acid 
(GABA) function (Leinekugel et al. 1999, Spitzer et al. 2002, Wu and Sun 2015, Miller et al. 
2017). HI can then further regulate excitatory systems and often results in excitotoxicity and 
seizures (Sanchez et al. 2001, Talos et al. 2006, Miller et al. 2016). 
There is clear and substantial evidence of neuronal origins of seizure, however, compromise 
of the BBB has also been found to contribute to seizure generation and exacerbation in 
adults and animal models (Oby and Janigro 2006, Marchi et al. 2007, Marchi et al. 2012, 
Salar et al. 2014). Evidence from this thesis contributes to the literature by describing the 
association between seizures and BBB-disruption in a neonatal model of HIE. Therefore, 
the BBB and the cerebrovasculature are novel targets for treatment of injurious seizures in 
the neonate. 
Though this work has been designed to allow maximal clinical relatability, one of the 
complications of this thesis is that it is difficult to untangle the direction of the relationship 
between seizures, BBB-disruption, and outcome. Previous mechanistic studies have 
attempted to elucidate the mechanism by demonstrating that osmotic BBB-disruption can 
directly lead to seizures (Marchi et al. 2007). BBB-disruption can result in increased 
inflammation, and altered pH, calcium, glutamate, and potassium concentrations; such 
changes to the brain microenvironment can contribute to increased excitation, leading to a 
decreased seizure threshold, seizure initiation, exacerbation, and recurrence. However, 
there is also evidence that seizures can contribute to BBB-disruption through stimulating the 
release of pro-inflammatory cytokines, and other effector molecules such as vascular 
endothelial growth factor and the matrix metalloproteinases (MMPs). 
Given the evidence of a reciprocal relationship between seizures and BBB-disruption, it is 
likely that seizures and BBB-disruption worsen each other, and brain injury as a result, which 
may lead to poorer long-term outcomes. However, researchers have previously proposed a 
BBB-centric hypothesis for this phenomena (Marchi et al. 2011). Such that HI events, 
disease, or injury result initially in BBB-disruption which then pre-disposes the patient (or 
animal) toward developing seizures which results in worsened BBB-disruption (Marchi et al. 
2011). If we look at evidence from this thesis in the BBB-centric context we might conclude 
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that: BBB-disruption occurs early in animals to varying degrees which results in increased 
serum protein extravasation into brain tissue and inflammation, which may predispose 
animals to seizure or worsen seizure. Seizures then exacerbate BBB-disruption and results 
in a negative, injurious feedback loop. 
While we did demonstrate a degree of BBB-disruption in animals in the first 2-24h post-HI 
(prior to the typical onset of seizures) (chapter 3), and a more severe degree of BBB-
disruption in animals with seizures at 72h (chapters 4 and 5), we have not shown that early 
BBB-disruption leads to increased seizure propensity or severity. However, given previous 
research has shown BBB-disruption is linked to the likelihood to seize, and given the 
variability of BBB-disruption in animals from early time-points, an interesting question may 
be whether degree of early BBB-disruption could explain why some animals (or neonates) 
and not others develop seizures. A candidate for mediation of the relationship between 
seizures and BBB-disruption is inflammation – which we know occurs early in response to 
HI and is related to both seizure and BBB-disruption onset and severity. The variability in 
the initial BBB-disruption as demonstrated in Chapter 3 may help account for the long-
debated reason some animals (or neonates) develop seizures and some do not. There were 
3 animals in chapter 3 that had the most severe IgG extravasation and pro-inflammatory 
response – one of these animals had seizures, one had epileptiform activity which can 
evolve into seizures, and one did not, but had substantial EEG abnormalities – is it possible 
these animals would have developed seizures (or worsened seizures)? Strategies for 
studies to investigate this hypothesis are outlined below in the future directions section. 
6.1.4 INFLAMMATION AND BBB-DISRUPTION 
Inflammation is critically important in the reciprocal relationship between seizures and BBB-
disruption, and we therefore investigated inflammatory cytokines and chemokines that have 
been shown to be related to BBB-disruption. Significant, substantial inflammation occurred 
rapidly following the HI insult, was worse in animals with seizure, and affected by HT. In 
particular, TGF, TNF, CXCL10, IL1b, IL6, and IL8 were substantially upregulated from 2h 
post-HI (Chapter 3), these were also upregulated at 72h in animals with seizure – with only 
TNF and IL6 that maintained upregulated state in no seizure animals, whereas HT 
appeared to alter TGF, COX2, and IL1.  While previous reports have suggested that one 
of HT’s actions is to attenuate inflammation (Leon 2004, Perrone et al. 2018). However, HT 
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did not decrease inflammation uniformly, and in some cases actually appeared to increase 
pro-inflammatory cytokines at the time-point investigated (72h).  
It has been suggested that large animal models of perinatal brain injury are required to 
develop cytokine profiles that can be utilised for diagnostics and clinical application of 
treatments (McAdams and Juul 2012). The inflammatory profile we investigated is a first 
step in untangling the contribution of pro-inflammatory cytokines and chemokines in BBB-
disruption following neonatal HIE. I must note; gene expression was only evaluated in brain 
tissue, we did not investigate protein and we did not investigate peripheral levels of 
inflammation. This research was simply designed to track how some inflammatory mediators 
evolve following neonatal HIE in the hope to better inform studies in the future that might 
seek to alter them to impact outcome or BBB-disruption. 
Chapter 1 outlines the effects several inflammatory cytokines and chemokines have at the 
BBB. Inflammation directly and indirectly modulates BBB-disruption via alteration of tight 
junction expression, apoptosis of endothelial cells, enhancing peripheral immune cell 
infiltration, increasing release of VEGF and MMPs, and exacerbation of the inflammatory 
pathway through glial activation (de Vries et al. 1996, Desai et al. 2002, Stolp et al. 2005, 
Candelario-Jalil et al. 2007, Sprague and Khalil 2009, Sumi et al. 2010, Wang et al. 2010, 
Brochu et al. 2011, Shen et al. 2011, Cohen et al. 2013). Therefore, inflammation is likely 
an attractive drug target for the reduction of BBB-disruption.  
Indeed, there has already been research investigating treatment of inflammation on the 
permeability of the BBB. For example, in rodents treated with the immune-stimulating agent, 
lipopolysaccharide, mesenchymal stem cells have been shown to reduce BBB permeability 
to Evans blue via a reduction in inflammatory astrocyte and microglial activation and VEGFA 
signalling (Park et al. 2015). Additionally, antibody therapies that target pro-inflammatory 
cytokines have been shown to effectively protect the BBB (Wilson et al. 2009, Chen et al. 
2015, Zhang et al. 2015). For example, treatment with anti-TNF in a radiotherapy mouse 
model resulted in lowered BBB permeability to a dextran tracer molecule, reduced leukocyte 
adhesion, and lowered astrogliosis (Wilson et al. 2009). Similarly, a rodent model of 
ischaemia found that treatment with anti-interleukin 1 beta (IL1), and anti-interleukin 6 (IL6) 
resulted in decreased BBB permeability and in the case of anti-IL6, had an effect on the 
protein level of several tight junctions (Chen et al. 2015, Zhang et al. 2015). 
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Inflammation is also a major target to reduce HI-induced brain injury (Disdier et al. 2018). A 
number of drugs that have anti-inflammatory effects are being trialled in neonates with HIE 
and neonatal models of HIE. These include erythropoietin (Sun et al. 2005, Zhu et al. 2009, 
Wu et al. 2016), melatonin (Reiter et al. 2000, Kaur et al. 2008), and stem cell therapy 
(Cotten et al. 2014, Archambault et al. 2017, Nabetani et al. 2018, Nair and Kumar 2018). A 
number of these also have protective effects on the BBB (Jiang et al. 2007, Horie et al. 2011, 
Menge et al. 2012, Chen et al. 2015, Moretti et al. 2015, Dende et al. 2017). For example, 
curcumin has been shown to reduce BBB-disruption in an adult rat model of cerebral 
ischaemia via a reduction in oxidative stress (Jiang et al. 2007). Whereas stem cells have 
been shown to protect BBB integrity and reduce BBB permeability via regulation of VEGF 
and pro-inflammatory cytokines (Horie et al. 2011, Menge et al. 2012, Chen et al. 2015).  
However, inflammation is a complicated process, not the least because it is a normal 
response to injury that becomes pathological due to excessive release of pro-inflammatory 
cytokines (Ziemka-Nalecz et al. 2017). It is therefore difficult to target a specific cytokine (IL6 
for example has both pro- and anti-inflammatory effects) for injury reduction without some 
unintended consequences. Additionally, with the exception of the antibodies that specifically 
inhibit certain cytokines, many of the drugs shown to attenuate HI brain injury and BBB-
disruption have effects on processes other than inflammation. It is therefore it is difficult to 
be certain a reduction in inflammation is driving the protective effects. With these 
considerations in mind, we propose that a therapy that targets several mechanisms of BBB-
disruption following neonatal HI may be most effective. As hypothermia is standard of care 
any new therapies will likely need to work synergistically with hypothermia, and at the very 
least not reduce its neuroprotective effects. In the search for protective treatments at the 
BBB the results here suggest they will need to interact with hypothermia (which we see is 
not completely protective of BBB-disruption), will need to affect seizures, and inflammation.  
6.2 The animal model 
We utilised a newborn piglet model of neonatal HIE for several reasons. In pigs, the main 
brain growth spurt occurs in the late prenatal to early postnatal period, equivalently timed 
with the human (Dobbing and Sands, 1979). This is in comparison to the sheep and rhesus 
monkey in which the brain growth spurt occurs prenatally. Whereas rodent brains are more 
similar to term human brains at postnatal day 7 to 10 (Dobbing and Sands 1979, Conrad 
and Johnson 2015). Pig brain development is also similar to the human in terms of 
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neurotransmitter development at birth – particularly GABAergic, dopaminergic and 
serotonergic systems (Niblock et al. 2005, Miller et al. 2017). 
Aside from development, piglets are similar to the human newborn in terms of general size 
(newborn piglets in this study weighed approximately 1.5-2kg, opposed to the human 
newborn at approximately 3.3kg). Size similarities are useful for instrumentation in the same 
manner as the human neonate. Indeed, our laboratory utilises neonatal intensive care unit 
equipment such as specialised neonatal ventilators, heaters, cooling mattresses for HT 
treatment, and physiological monitoring devices. Additionally, as a post-natal model of HIE, 
newborn piglets can be recovered following the HI insult to allow neurobehavioural testing 
which does not occur in the fetal sheep model. 
A novel finding to this thesis is that seizures are associated with BBB-disruption in this 
model. Seizures in the piglet occur following HI without chemical or electrical intervention as 
is required in other models. It therefore better recapitulates the human situation where 
seizures arise “spontaneously” following HI and can be very difficult to predict. Seizures in 
the piglet also occur at a similar time to the human neonate; a study by Lynch and colleagues 
demonstrated that the median age at the first recorded electrographic seizure was ~17h 
(Lynch et al. 2012) – in our study the average time to seizure onset in animals not treated 
with HT was ~23h. This is in contrast with some rodent models where HI-induced seizures 
occur either during HI or rapidly following the insult (Cuaycong et al. 2011, Sampath et al. 
2014). 
However, as with all models of human disease, there are limitations to the piglet model of 
neonatal HIE. As mentioned above, the piglet’s brain development is similar to a term 
human. While this has advantages, it also means that the HI insult occurs ex utero – which 
is dissimilar to the majority of acute neonatal HI cases in which HI occurs prior to, or during 
birth. It is technically feasible to perform surgery on the pregnant sow just prior to birth in a 
similar procedure to the fetal sheep model of HI. This would require surgery to externalise 
and instrument the piglet, followed by the HI event, then recovering the piglet after the HI 
insult ex utero. However, this does raise ethical and financial issues. Unlike the sheep, the 
pig has large litters (in our experience approximately 11/litter) most of which could not be 
recovered following the surgery due to technical feasibility issues such as the amount of 
staff and equipment required to recover even 1-2 piglets. In addition, the current model 
doesn’t require surgery on the sow and negates the loss of the animal after the experiment. 
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Another limitation of the model is that our laboratory can only run two piglets in our intensive 
HI protocol at a time. This means the model is far lower throughput and more expensive 
than rodent models of HI. This limitation contributed to the low numbers of animals per group 
in Chapter 3. A final consideration when utilising a piglet model of neonatal HIE is the impact 
of stress due to the experimental protocol and maternal separation on the animal. Previous 
studies have demonstrated that stress can play a major role in the recovery of animals from 
insults such as HI. HT has been found not to be neuroprotective in unanaethetised piglets 
which was proposed to be due to stress (Thoresen et al. 2001, Tooley et al. 2003). This is 
in contrast to the fetal sheep model of HIE in which sedation is not required in order to 
achieve neuroprotection following HT treatment (Gunn et al. 1997). Of course it is possible 
that HT is not as stressful in the in utero environment compared with postnatal survival 
models like the piglet, or selective head cooling which is utilised predominantly in the sheep 
model is less stressful than whole body cooling (Tooley et al. 2003). 
 
6.3 Future Directions 
6.3.1 UNTANGLING THE RELATIONSHIP BETWEEN SEIZURES AND BBB-DISRUPTION 
If we look at evidence from this thesis in the BBB-centric context we might conclude that: 
BBB-disruption occurs early in animals to varying degrees which results in increased serum 
protein extravasation into brain tissue and inflammation, which may predispose animals to 
seizure or worsen seizure. Seizures then exacerbate BBB-disruption and results in a 
negative, injurious feedback loop. However, we must keep in mind there are other possible 
explanations for the results of this thesis: BBB-disruption may not be a primary driver of 
seizure initiation in neonatal HI. Seizures can arise due to other, well-established processes 
following injury and seizure occurrence in some animals or patients and not others may be 
unrelated to BBB-disruption. Once seizures are established they may have contributed to 
BBB-disruption in the later stages of HIE. Or, BBB-disruption and seizure are not directly 
related but driven by a common factor (increased vulnerability in some neonates due to 
some as yet unknown cause).  
Future directions may involve characterising whether BBB-disruption is a seizure-inducing 
factor in neonatal HIE. One way to investigate this is with an in vivo measure of BBB-
disruption (such as gadolinium-enhanced magnetic resonance imaging) in order to track 
210 
 
whether animals that have BBB-disruption early or to a greater extent are more likely to 
develop seizures. This method could also help us evaluate future treatments for protecting 
the BBB and what effect they might have on reducing seizure burden. 
6.3.2 BIOMARKERS OF INJURY 
Throughout this thesis I have focused on the impact of IgG and NaFlsc from the blood 
entering the brain at higher concentrations due to a more permeable BBB. However, the 
reverse can also be true – substances normally found predominantly in the brain can more 
easily cross a disrupted BBB to be found in the blood supply. This effect needs to be taken 
into consideration during development of biomarkers of injury in neonatal HIE. For example, 
UCHL1 and S100 are markers of neuronal and glial damage following HIE and are 
reasonable predictors of short and long term outcome (Kecskes et al. 2005, Douglas-
Escobar et al. 2010, Liu et al. 2010, Ringger et al. 2011, Douglas-Escobar et al. 2014). 
However, they have also been shown to be good indicators of BBB-disruption (Larsson et 
al. 2005, Blyth et al. 2011, Steinacker et al. 2013). This adds a layer of complexity to their 
interpretation as these biomarkers may be increased due to injury and therefore crossing 
the BBB at a higher rate, or they may be found at higher concentrations in blood due to BBB-
disruption, or a combination of both. Due to the relationship between BBB-disruption and 
outcome this relationship may be difficult to untangle. In addition to biomarkers of injury and 
predictors of outcome, there is ongoing work to identify markers of BBB-disruption. Pan and 
colleagues (2017) recently described detection of circulating occludin as a marker of BBB-
disruption. Given the results of this thesis indicate BBB-disruption and seizure are 
associated, it is possible that a biomarker of BBB-disruption could be utilised to predict the 
likelihood of seizure occurrence. Prediction of seizure would be a valuable tool in the clinic 
as neonatal seizure signs can be subtle and ongoing EEG recordings are not universally 
available, and often difficult to interpret by untrained staff. Additionally, neonates who are 
deemed more at risk of developing seizure may be able to receive prophylactic anti-epileptic 
drug treatment, which has been shown to control seizures more reliably in this population 
(Hall et al. 1998, Singh et al. 2005). 
6.3.3 EXPLOITING THE BBB 
The BBB not only restricts the movement of neurotoxic substances from blood to brain, but 
also hinders the delivery of drugs to the brain. This limits the therapeutic options and effects 
of drugs in disorders like HIE. Therefore, better understanding of BBB-disruption and periods 
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of increased permeability may allow the opening of the BBB to be exploited for drug delivery. 
Osmotic opening of the BBB has been found to enhance delivery of therapeutics to the brain 
(Rapoport 2000, Marchi et al. 2007). Previous evidence has shown that brain concentrations 
of some drugs increase following BBB opening (Zylber-Katz et al. 2000, Wei et al. 2013). 
However, there is also evidence to suggest that the concurrent increase in serum 
extravasation into brain tissue following BBB-disruption has a buffering effect – particularly 
on lipophilic drugs such as commonly used anti-epileptic drugs - which have been shown to 
have lowered penetrations in regions of BBB-disruption and therefore may have a reduced 
therapeutic effect (Marchi et al. 2009). Therefore, enhanced drug delivery across an 
impaired BBB is not straightforward and further research is needed before clinicians can 
take full advantage of BBB-disruption that occurs following brain injury. 
6.3.4 NOVEL THERAPIES FOR HIE 
HIE is a complex syndrome with numerous pathological processes that can individually 
contribute to neuronal damage and exacerbate other processes. Therefore, in order to treat 
newborns with this disorder effectively we need to understand the mechanisms of injury. 
There have been several studies investigating novel therapeutics that either treat BBB-
disruption as their main action or have a protective effect on the BBB indirectly by attenuating 
other pathological processes that also impact the BBB. For example, omega 3 
polyunsaturated fatty acids preserves BBB integrity in a rat HI model through reduction of 
MMPs (Zhang et al, 2016). Whereas Vitexin (hypoxia inducible factor 1 alpha inhibitor) has 
been shown to reduce both HI-induced brain injury, seizures, and BBB-disruption via a 
VEGFA mediated mechanism, and through reducing excitotoxicity via modulation of a 
sodium-potassium co-transporter (NKCC1) important for GABA function (Luo et al, 2018, 
Min et al, 2015). Other therapies have shown protective effects of the BBB in neonatal HI 
models; Osetopontin appears to reduce BBB permeability to Evans blue and ameliorates 
oedema (Dixon et al, 2016). Whereas plasminogen activator inhibitor reduces BBB 
disruption and prevents brain tissue loss and inflammation via suppression of nuclear factor 
kappa light chain enhancer of activated B cells (Yang et al, 2009, Yang et al, 2013a, Yang 
et al, 2013b). Additionally treatment with human umbilical vein endothelial cells resulted in 
lower BBB permeability to IgG, less vessel damage, and fewer apoptotic neurons (Wu et al, 
2013). Therefore, treatments that are effective in reducing BBB-disruption have been shown 
to improve neuroprotection as well as reducing seizures and this is an exciting avenue of 
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future research. Melatonin has been shown to protect the BBB (possibly via modulation of 
inflammation and oxidative stress), work well in combination with hypothermia, is 
neuroprotective and may have anti-seizure effects (Robertson et al. 2012, Goldberg-Stern 
et al. 2012, Alluri et al. 2016). 
6.4 Conclusion 
The BBB is a vital component of the functioning central nervous system and disruption of 
the BBB can play a significant role in exacerbating brain injury. BBB-disruption can 
contribute to cell death and long-term outcome both directly by altering the micro-
environment of the brain required for healthy cell function, and indirectly through 
exacerbation of pathological processes such as seizure, inflammation, or oedema. This 
thesis adds to the knowledge base by describing the extent of increased BBB permeability 
over time, the relationship with two key pathological processes that are affected by and 
affect the BBB – seizures and inflammation, and how therapeutic HT affects BBB-disruption. 
I aimed to describe alterations to the BBB in a model of neonatal HIE in the hope that it 
assists the development of novel therapeutics to treat HI-induced brain injury in neonates. 
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“The brain is a world consisting of a number of unexplored continents and great stretches 
of unknown territory” – Santiago Ramόn y Cajal 
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Appendix 1: Hypoxia ischaemia insult parameters for the entire cohort of animals. 
 
 2h HI 4h HI 8h HI 12h HI 24h HI Sham NT No Sz NT Sz HT 
Hours of 
anaesthesia 
4.22 (0.21) 6.25 (0.19) 10.15 (0.13) 14.23 (0.13) 26.12 (0.07) 38.24 (0.24) 37.94 (0.69) 38.25 (0.19) 38.1 (0.12) 
Number of 
animals with 
seizures 
0 0 1* 1 0 0 14 0 12 
MABP Before 
insult (mmHg) 
39.67 (3.21) 39.5 (6.95) 39.5 (5.32) 40.5 (11.03) 40.5 (3.51) 46.4 (±4.5) 42.9 (±6.8) 46.1 (±7.7) 39.8 (6.48) 
MABP end 
insult (mmHg) 
19 (8.72) 18 (7.87) 22.25 (9.54) 20.5 (7.23) 14.5 (2.65) 45.4 (±4.9) 19.1 (±10.9) 19.4 (±4.5) 17.33 (7.52) 
Time 
hypotensive 
during insult 
11.17 (7.97) 16.90 (7.31) 13.67 (8.42) 14.63 
(12.58) 
15.94 (5.41) 0 14.49 (±9.1) 11.92(±6.6) 16.13 (7.69) 
pH before 
insult 
7.42 (0.04) 7.43 (0.11) 7.46 (0.03) 7.44 (0.05) 7.42 (0.02) 7.42 (±0.04) 7.48 (±0.04) 7.47 (±0.05) 7.51 (0.05) 
pH end insult 7.01 (0.08) 7.09 (0.03) 7.04 (0.06) 7.04 (0.03) 7.06 (0.05) 7.41 (±0.05) 7.08 (±0.07) 7.02 (±0.08) 7.05 (0.09) 
ABE before 
insult (mmol/L) 
2.77 (3.35) 2.13 (6.60) 4.2 (0.25) 1.1 (2.64) 1.6 (0.59) 1.32 (±2.0) 6.1 (±2.7) 5.31 (±1.9) 5.69 (2.52) 
ABE end insult 
(mmol/L) 
-18.17 
(5.49) 
-15.58 
(2.52) 
-15.63 
(3.35) 
-17.3 (4.25) -17.35 
(1.69) 
2.5 (±2.97) -14.99 
(±4.4) 
-18.0 (±2.8) -17.20 
(3.78) 
pCO2 before 
insult (mmHg) 
38.33 (4.83) 39.85 (2.60) 39.85 (4.09) 37.2 (2.18) 41.14 (3.72) 39.97 (±3.9) 40.33 (±4.2) 39.71 
(±5.82) 
36.34 (6.68) 
pCO2 end 
insult (mmHg) 
48.23 
(11.58) 
46.3 (11.2) 54.98 (6.29) 47.78 
(13.70) 
42.98 (1.92) 43.6 (±5.7) 49.56 
(±16.0) 
49.16 (±9.0) 45.24 
(11.12) 
pO2 before 
insult (mmHg) 
104.8 (22.1) 109.9 (26.8) 131.8 (2.3) 100.7 (13.0) 96.1 (1.78) 97.23 
(±23.5) 
99.1 (±20.2) 96.94 
(±14.7) 
91.5 (15.2) 
pO2 end insult 
(mmHg) 
15.7 (2) 22.2 (8.4) 36.8 (13) 19.4 (8.1) 20.6 (4.8) 97.72 
(±21.6) 
26.0 (±14.9) 23.1 (±10.3) 19.7 (6.2) 
Total insult 
duration 
29.01 (2.83) 32.30 (6.18) 29.83 (4.55) 30.93 (3.14) 31.48 (2.87) 30.00 32.95 
(±03.85) 
29.53 
(±03.04) 
31.30 (3.21) 
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Abbreviations: hypoxia ischaemia (HI), mean arterial blood pressure (MABP), minutes (min), millimetres of mercury (mmHg), arterial base excess 
(ABE), partial pressure carbon dioxide (PaCO2), low amplitude electroencephalography (LAEEG), seizures (Sz), normothermia (NT), 
hypothermia (HT). Data are presented as mean±SD
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Appendix 2: Animal ethics certificate UQCCR/565/09/NHMRC  
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  Appendix 3: Animal ethics certificate UQCCR/566/09 
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Appendix 4: Animal ethics certificate UQCCR/576/12 
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Appendix 5: Animal ethics certificate UQCCR/426/14/NHMRC 
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